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Transcription factors play demonstrably critical roles in development. The 
transcription factor Gata2 is required for the proliferation of hematopoietic progenitors 
and proper urogenital development. Gata2 null mutant mice die at embryonic day 10.5 
from a complete failure of primitive and definitive hematopoiesis; hematopoietic-
rescued compound mutant animals succumb to hydroureteronephrosis shortly after birth. 
The Gata2 null mutant background deficiencies were successfully rescued using a 413-
kilobase pair  (kbp) linked-Bacterial Artificial Transgene (BAC) containing both the 5’ 
hematopoietic and 3’ urogenital enhancers. Rescued transgenic mice are both viable and 
fertile, indicating that the endpoints of this linked-BAC define the functional boundaries 
of the Gata2 locus. A 290-bp endothelial enhancer of Gata2, termed VE (vascular 
enhancer), was localized within Gata2 intron 4 and characterized in detail, revealing a 
requirement for an E box binding site for proper expression from this element. To 
determine whether GATA-2 is required for the differentiation of definitive 
hemangioblasts, presumptive common progenitors of both the endothelial and 
hematopoietic lineages, mice carrying the Gata2 VE element driving cre expression 
(TgVE-Cre) were generated in order to conditionally ablate Gata2 in this precursor cell 
type. Through lineage tracing studies in TgVE-Cre:Rosa26RlacZ mice, we provide evidence 
that precursor cells from the mesoderm give rise to at least a subset of definitive, 
lineage-restricted hematopoietic cells and endothelial cells. Through understanding of 
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the cis regulatory elements and trans-acting factors that govern Gata2 expression and its 
role in these developmental processes, our comprehension of the functional networks 













The development of a living organism is an intricate and complex process.  The 
complete blueprint resides within every individual cell, and yet throughout development 
each cell becomes ever more highly restricted to carrying out specific tasks. This is made 
possible through the process of differentiation.  While each cell contains every gene 
necessary for life, a specialized group of proteins called transcription factors decide 
which genes are activated or repressed in any given cell.  
 Purified eukaryotic RNA polymerase II is incapable of initiating transcription in 
vitro, unlike bacterial RNA polymerase. This finding led to the discovery of 
supplementary factors that are necessary for initiating transcription. These general 
transcription factors bind to DNA and allow RNA polymerase to function.  While these 
factors are necessary for initiation of all gene transcription, other transcription factors 
have evolved more specific functions.  
 Eukaryotic DNA contains regulatory sequences with the ability to promote, 
enhance, or silence gene transcription.  Transcription factors have evolved the ability to 
bind to these regulatory elements (Mitchell and Tjian, 1989), allowing for the unique 
expression of a subset of genes in any given cell. With multiple transcription factors 
working in concert to regulate which genes are activated or repressed in a given cell, the 
complex pattern of differentiation is unveiled throughout development.  
 Regulatory transcription factors can be divided into two major categories: 
developmental transcription factors and signal-dependent transcription factors. Signal-
dependent transcription factors function precisely as their name implies, through 
activation by one of three main extrinsic stimuli: steroid hormones, small intracellular 
signaling molecules, or cell-surface receptors (Brivanlou and Darnell, 2002). 
Developmental transcription factors enter the nucleus directly without requiring 
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posttranslational modifications. However, their production is regulated, often depending 
upon specific intracellular or extracellular signals. Various developmental transcription 
factors work in concert to influence cell determination and differentiation (Brivanlou and 
Darnell, 2002). Understanding how these factors are regulated, and what in turn they 
regulate, will help elucidate the control mechanisms underlying development. This 
information becomes exceptionally useful when the transcriptional machinery becomes 
corrupted and leads to disease, such as in the setting of human congenital or acquired 
deficiencies (e.g. cancer).  
  This dissertation focuses on the developmental transcription factor GATA-2, 
which has been found to regulate a number of independent developmental pathways. It is 
expressed in discrete tissue types, and displays distinct functions in these various 
physiological domains. Understanding the mechanism(s) that regulate these processes 
will help to elucidate one or more of the pathways by which developmental progression 
proceeds.  
 
The GATA Family of Transcription Factors 
The first GATA factor to be discovered, originally named Eryf1, was found in 
chicken erythroid cells while studying the regulation of the β-globin gene (Evans et al., 
1988). Eryf1, also called GF-1 in the mouse, was found to contain two zinc fingers 
(Evans and Felsenfeld, 1989; Tsai et al., 1989) and bind to a consensus 
(A/T)GATA(A/G) sequence (Ko and Engel, 1993; Merika and Orkin, 1993), from which 
the factor obtained its modern namesake. Using a murine GATA-1 probe, two additional 
GATA transcription factors (GATA-2 and GATA-3) were discovered in chickens 
(Yamamoto et al., 1990), and then in all other vertebrates. The discovery of these two 
additional family members was followed some years later by the cloning of GATA-4, 
which was identified in an embryonic day 6.5 (e6.5) mouse embryo library (Arceci et al., 
1993). This was followed soon thereafter by the cloning of GATA-5 (Kelley et al., 1993; 
Laverriere et al., 1994; Morrisey et al., 1997) and GATA-6 (Laverriere et al., 1994; 
Morrisey et al., 1996; Suzuki et al., 1996). All six of these vertebrate family members 
bind to the same consensus GATA sequence and contain two zinc fingers.  
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 By the beginning of the third millennium AD, ninety-three proteins, ranging from 
cellular slime mold to plants to humans, have been discovered that contain at least one 
GATA-type zinc finger (Lowry and Atchley, 2000).  Five GATA factors have been 
discovered in Drosophila (Gillis et al., 2008), some of which retain more similar 
functions to their vertebrate counterparts (Brown and Castelli-Gair Hombría, 2000; 
Fossett and Schulz, 2001; Lebestky et al., 2000) than others (Gillis et al., 2008). Eleven 
GATA factors have been discovered in Caenorhabditis elegans, which also appear to 
have overlapping as well as unique activities (Patient and McGhee, 2002).  Fungal 
GATA factors regulate distinctly invertebrate processes including nitrogen metabolism, 
mating-type switching, and chromatin rearrangement (Scazzocchio, 2000). Clearly, while 
GATA factors have taken on unique roles in different phyla, their function is 
evolutionarily critical.  
 Focusing on the vertebrate GATA factors, the amino-terminus functions as a 
transcriptional activator (Martin and Orkin, 1990; Yang and Evans, 1992). The GATA 
factors contain two zinc fingers, which contain four cysteine residues that chelate a single 
zinc ion (Teakle and Gilmartin, 1998), but are functionally distinct. The amino finger can 
specify and stabilize DNA binding (Trainor et al., 1996), can bind weakly to a GATC 
consensus sequence (Newton et al., 2001), and also contains key residues that allow 
specific binding to cofactor proteins such as FOG1 (Fox et al., 1998; Tsang et al., 1997). 
The carboxyl finger directly binds the consensus GATA recognition sequence on DNA 
(Martin and Orkin, 1990; Yang and Evans, 1992), but also is capable of physically 
interacting with other transcription factors, including Sp1 and PU.1 (Merika and Orkin, 
1995; Rekhtman et al., 1999). The C-terminus of the GATA factors contain basic motifs 
and augment DNA binding (Yang and Evans, 1992).   
 In keeping with the strong conservation of the GATA factor family, all but one of 
the GATA genes has been found to contain two distinct promoters and alternate first 
exons capable of independently regulating gene expression in distinct tissues or cell 
lineages. The alternative promoter for GATA-1 directs expression in Sertoli cells of the 
testis (Ito et al., 1993; Yomogida et al., 1994).  GATA-2’s alternative promoter directs 
expression to hematopoietic progenitor cells and the midbrain (Minegishi et al., 1998; 
Pan et al., 2000). An alternative GATA-3 promoter directs expression in the brain and in 
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T lymphocytes (Asnagli et al., 2002). The alternative promoter for GATA-5 creates an 
isoform that splices to exon three, creating a protein that contains only a single zinc 
finger (MacNeill et al., 1997), though its function remains to be determined.  Finally, the 
alternative promoter of GATA-6 creates an isoform that is expressed in the same tissue-
specific and developmental stage-specific pattern as the more abundantly transcribed 
promoter, although the longer protein appears to have a more robust transactivation 
activity (Brewer et al., 1999). 
 The GATA family can be functionally divided into two subgroups. GATA-1/2/3 
are primarily involved in hematopoietic lineage development (Ness and Engel, 1994), 
while GATA-4/5/6 are primarily involved in mesoderm- and endoderm-derived tissue 
development including the gonad, gut, heart, liver, and lung (Molkentin, 2000).  
 
GATA-1 
The founding and best characterized member of the GATA family of transcription 
factors (likely because its expression pattern is far simpler than the other factors), GATA-
1, was discovered in erythroid cells bound to two sites in the chicken β-globin enhancer 
(Evans et al., 1988), and was discovered soon thereafter in mice (Tsai et al., 1989). 
GATA-1 can activate erythroid-specific genes (Evans and Felsenfeld, 1989; Mignotte et 
al., 1989), including β-globin (Evans et al., 1988; Talbot and Grosveld, 1991), and is 
induced by erythropoietin in response to tissue hypoxia (Krantz, 1991). GATA-1 is 
important for the characteristic chromatin structure of the β-globin locus by creating a 
hypersensitive site in the locus control region (Stamatoyannopoulos et al., 1995), but 
requires other erythroid factors to function in an additive fashion (Boyes and Felsenfeld, 
1996). Recently, Ikaros has been found to interact with GATA-1 to impair the β-globin 
locus control region from being in close proximity to the human γ-globin genes, 
potentially augmenting the switch from γ to β-globin (Bottardi et al., 2009). 
By disrupting GATA-1 in embryonic stem cells, it was shown that erythroid 
differentiation is blocked in the absence of this factor in chimeric mice (Pevny et al., 
1991) at the proerythroblast stage (Pevny et al., 1995; Weiss et al., 1994). This was also 
found to be true in conditional knockout mice in which the erythroid promoter of GATA-
1 was ablated (Takahashi et al., 1997).  These mice could be fully rescued by transgenic 
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GATA-1 cDNA expression, but only partially by transgenes expressing GATA-2 or 
GATA-3, indicating that the hematopoietic GATA factor proteins are not functionally 
equivalent (Takahashi et al., 2000).  
GATA-1 was also found to suppress apoptosis in maturing erythroid cells (Weiss 
and Orkin, 1995), a process that can be regulated by steroid hormones (Blobel et al., 
1998). Caspase-mediated cleavage of GATA-1 functions as a negative feedback loop of 
erythropoiesis (De Maria et al., 1999).  
 GATA-1 is also expressed in other myeloid lineages, including megakaryocytes 
(Martin et al., 1990; Romeo et al., 1990), mast cells (Martin et al., 1990), and eosinophils 
(Hirasawa et al., 2002; Zon et al., 1993). GATA-1 was shown to induce megakaryocyte 
differentiation when forcibly expressed in an early mouse myeloid cell line (Visvader et 
al., 1992). In chicken myeloblasts, GATA-1 induces the generation of erythroblasts, 
eosinophils, and megakaryocytes (thromboblasts) (Kulessa et al., 1995).  Megakaryocyte 
lineage-specific knockout of Gata1 in mice resulted in impaired maturation of 
megakaryocytes and quantifiably fewer platelets (Shivdasani et al., 1997), though 
complete maturation was possible (Pevny et al., 1995). Mutations of GATA1 resulting in 
premature stop codons preceed the generation of acute megakaryoblastic leukemia in 
Downs syndrome children (Wechsler et al., 2002). GATA-1 has recently been shown to 
interact with the positive transcriptional elongation factor P-TEFb for megakaryocyte 
differentiation (Elagib et al., 2008). Inhibition of cyclin-dependent kinase 9, part of the P-
TEFb complex, produces a megakaryoblastic disorder similar to Downs syndrome 
(Elagib et al., 2008).   
 Eosinophil differentiation relies on the carboxy-terminal finger of GATA-1 
(Hirasawa et al., 2002), as well as a double GATA motif in the erythroid promoter of 
GATA-1 (Yu et al., 2002). Interestingly, the double GATA motif appears to be 
dispensable for erythroid, megakaryocyte, mast cell, or other early hematopoietic 
precursors (Yu et al., 2002).  
 Gata1 has a separate promoter upstream from the erythroid promoter (Ito et al., 
1993). This was discovered through expression of GATA-1 in the seminiferous tubules of 
the testes (Ito et al., 1993).  GATA-1 expression initiates concurrently in Sertoli cells 
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with the first wave of spermatogenesis, but is turned off in maturing germ cells 
(Yomogida et al., 1994).  
 The zinc fingers of GATA-1 can bind the histone acetyltransferase CBP (Ogryzko 
et al., 1996) to augment gene expression and differentiation (Blobel et al., 1998).  
Acetylation of GATA-1 allows for a more open chromatin structure enhancing the ability 
of GATA-1 to function as a transcription factor (Boyes et al., 1998), though the presence 
of GATA-1 alone is inadequate to create an open chromatin state (Yamamoto et al., 
1997).  Interestingly, the N-finger of GATA-1 is critical for erythroid differentiation in 
vitro, even though it is dispensable for binding most GATA motifs (Weiss et al., 1997). 
When tested in vivo, the N-finger was found to be critical for definitive erythropoiesis, 
but dispensable for primitive erythropoiesis (Shimizu et al., 2001). The N-terminal 
transactivation domain was found to be important for definitive erythropoiesis, but not 
absolutely required (Shimizu et al., 2001). Furthermore, primitive erythroid cells only 
require a 5’ enhancer of Gata1 for expression, while definitive erythroid cells require 
both the 5’ enhancer as well as an element in the first intron (Nishimura et al., 2000; 
Onodera et al., 1997).  
 Using yeast two-hybrid assays, the zinc finger protein Friend of GATA-1 
(FOG1), was found to bind to the N-finger of Gata1 and synergistically activate 
transcription during erythroid and megakaryocyte differentiation (Tsang et al., 1997). 
FOG1 knockout mice demonstrated that GATA-1 requires FOG1 for erythroid 
maturation, and that FOG1 appears to have a GATA-independent role in the earliest 
stages of megakaryocyte differentiation (Tsang et al., 1998). Mutation of the binding site 
for FOG1 on the amino-finger of Gata1 results in x-linked dyserythropoietic anaemia and 
thrombocytopenia (Nichols et al., 2000). However, GATA-1 appears to regulate mast cell 
differentiation in a FOG1-independent matter by binding to PU.1; in fact, if FOG1 is 
forcibly expressed, PU.1 binding to GATA-1 is disrupted and converts earlier progenitors 
into neutrophils, erythroid, megakaryocytic and granulocytic lineages instead (Cantor et 
al., 2008; Sugiyama et al., 2008).   
 Another FOG protein, FOG2, also binds to the N-finger of Gata1 (Tevosian et al., 
1999). FOG2 functionally complements FOG1 in at least some aspects (even though the 
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primary sequence is quite divergent) as FOG2 can rescue terminal erythroid 
differentiation in Fog1-/- hematopoietic cells (Tevosian et al., 1999). 
 Similar to GATA-1, the basic helix-loop-helix protein Stem Cell Leukemia (SCL) 
is necessary for proper maturation of erythroid and megakaryocytic precursors (Porcher 
et al., 1999). SCL also binds as a complex with LMO2 and its interacting protein GATA-
1 on composite E-box-GATA DNA binding sites (Wadman et al., 1997). SCL, LMO2, 
and GATA-1 together induce the erythroid program in naïve ectoderm of Xenopus 
embryos (Mead et al., 2001). This was also shown in hematopoietic cells where SCL acts 
to assemble this complex and GATA-1 functions as a DNA tether to activate the 
transcription of the erythroid marker glycophorin A (Lahlil et al., 2004). Interestingly, a 
recent study has shown that SCL is bound to GATA-1 when it functions to activate 
transcription, yet is depleted when GATA-1 functions as a transcriptional repressor 
(Tripic et al., 2009).  
 
GATA-3 
Using a mouse GATA-1 cDNA as a probe, GATA-2 and GATA-3 cDNAs were 
discovered as homologues in the chicken (Yamamoto et al., 1990), mouse and human 
(Ko et al. 1991) genomes. GATA-3 is highly conserved across species and functions 
most clearly to regulate T-cell differentiation (Ko et al., 1991). However, GATA-3 
expression is also observed in the placenta, definitive erythrocytes, kidney, adrenal gland, 
central and peripheral nervous systems, the embryonic liver, the skin, in hair follicles and 
in breast epithelial cells as well as in T-lymphocytes, and in several cases has been shown 
to be required for specific aspects of their organogenesis (George et al., 1994; 
Kornhauser et al., 1994; Yamamoto et al., 1990). GATA-3 is capable of binding to 
GATA sites in an enhancer of CD8, potentially augmenting the formation of DNase I 
hypersensitive sites (Landry et al., 1993). GATA-3 also has broader DNA recognition 
properties than GATA-1, due in part to its ability to bind GATC sequences as well as 
GATA (Ko and Engel, 1993). Distinct regulatory elements of Gata3 have been 
discovered for early muscle mass, a subset of PNS neurons, the genital tubercle, branchial 
arches, and endocardium, which helps to explain the ability of GATA factors to 
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contribute to distinct temporal and spatial patterns of cellular differentiation 
(Lakshmanan et al., 1999; Lieuw et al., 1997).  
 Gata3 heterozygous mutant mice are normal, but null mutants die between e11 
and e12 from hemorrhage, growth retardation, brain and spinal cord deformities, and 
irregularities in fetal liver hematopoiesis (Pandolfi et al., 1995).  The specific cause of 
mortality was found to be a neuroendocrine deficiency, with reduced levels of tyrosine 
hydroxylase and dopamine β-hydroxylase in the sympathetic nervous system. Feeding 
catechol intermediates to pregnant dams was able to significantly prolong the life of 
Gata3 null animals, revealing new deficits including renal hypoplasia and defects in 
cephalic neural crest cell contributions (Lim et al., 2000). However, the 
pharmacologically rescued mutants still succumbed to embyronic lethality, most likely 
from cardiac developmental abnormalities (Lim et al., 2000). Specific transgenic GATA-
3 expression in sympathoadrenal (SA) lineages was also capable of rescuing SA cells, 
with induced expression of Mash1, Hand2, and Phox2b, which are believed to create a 
mutually reinforcing transcriptional network (Moriguchi et al., 2006). GATA-3 haplo-
insufficiency has also been found to be the causal mutation in human HDR syndrome 
(Hypoparathyroidism, sensorineural Deafness, and Renal dysplasia). Both nonsense 
mutations and intragenic deletions of GATA-3 have resulted in this DiGeorge-like 
syndrome, resulting in hypoparathyroidism, deafness, renal and craniofacial 
abnormalities (Van Esch et al., 2000).  
 Within the kidney, the loss of GATA-3 results in a failure of the nephric duct to 
extend into or augment the differentiation of the metanephric mesenchyme (Lim et al., 
2000). An enhancer directing GATA-3 in the kidney was isolated and used to create 
transgenic mice, which were then used to complement the Gata3 null mutation. From 
these studies, it was found that at least 50% of endogenous GATA-3 protein abundance is 
required for normal nephrogenesis. Less than 50% results in localized kidney defects 
similar to those encountered in HDR syndrome (Hasegawa et al., 2007).  Recently, a 
piece of the genetic cascade regulating these events has been resolved. β-catenin appears 
to regulate GATA-3 to prevent premature cell differentiation in the nephric duct. 
Independent of this activity, GATA-3 also positively regulates Ret expression. 
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Conditional knockout of GATA-3 specifically in nephric duct cells reduces Ret 
expression and results in ectopic ureter budding (Grote et al., 2008).  
 Within hematopoietic lineages, GATA-3 is primarily restricted to thymocytes and 
T cells. GATA-3 binding sites in multiple T cell specific genes have been functionally 
identified (Hambor et al., 1993; Ho et al., 1991; Ko et al., 1991; Marine and Winoto, 
1991). Mutation of Gata3 in embryonic stem cells has revealed that T cells are blocked at 
or before the formation of double negative (CD4-/CD8-) thymocytes, indicating that 
GATA-3 is required for early thymocyte development (Ting et al., 1996), including the 
expansion of T cell progenitors (Hendriks et al., 1999). Further characterization of 
GATA-3’s role in the thymus has found that it is necessary for β selection and single 
CD4-positive thymocyte development (Pai et al., 2003). Finally, GATA-3 is required for 
the development and maintenance of T helper type 2 (Th2) cells, but not Th1 cells (Pai et 
al., 2004; Zhang et al., 1997). This occurs through two mechanisms: reduced Th1 
development through IL-12 receptor repression and positive GATA-3 feedback 
autoregulation (Zhou and Ouyang, 2003). A signal transducer of the transforming growth 
factor β (TGFβ) family, phosphorylated Smad3 can bind GATA-3 to cooperatively 
activate both IL-5 and IL-10 (Blokzijl et al., 2002). This is one of the first studies to 
demonstrate the process by which extracellular signals can affect nuclear programming. 
Acetylation of GATA-3 is also critical for its function, as a hypo-acetylated mutant 
results in prolonged survival after activation and defective T cell homing to systemic 
lymph nodes (Yamagata et al., 2000).  
 Similar to GATA-1 expression in the testis, GATA-3 contains an alternative 
promoter that regulates expression specifically in the brain (Asnagli et al., 2002). These 
two GATA-3 isoforms have also been shown to have differential activity through 
different stages of Th2 development, indicating a potentially unique role for each isoform 
in this process (Asnagli et al., 2002). In the developing brain, GATA-3 is critical for the 
development and locomotor function of serotonergic neurons (van Doorninck et al., 
1999). GATA-3 is also downstream of GATA-2 and Hoxb1 in ventral rhombomere 4 
supporting the migration of facial branchiomotor neurons and projection of contralateral 
vestibuloacoustic (CVA) efferent neurons (Pata et al., 1999).   
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 Recently, GATA-3 has also been implicated in the maintenance of luminal 
epithelial differentiation in the adult mammary gland. Gata3, when conditionally deleted 
specifically from mammary cells in mice, fails to properly form terminal end buds 
resulting in mammary developmental defects (Kouros-Mehr et al., 2006). Loss of Gata3 
results in early breast cancer carcinoma progression along with tumor propagation 
(Kouros-Mehr et al., 2008).  
   
GATA-4 
Discovered through an embryonic mouse library screen using a probe to the 
highly conserved Gata1 zinc finger domain, GATA-4 is expressed in the heart, intestinal 
epithelium, primitive endoderm, and gonads (Arceci et al., 1993; Kelley et al., 1993). 
GATA-4’s role in cardiac development was enhanced through regulation of cardiac 
muscle-specific troponin C (cTnC) (Ip et al., 1994), cardiac actin (Jiang and Evans, 
1996), atrial natriuretic factor (Grépin et al., 1994; Morin et al., 2001), brain natriuretic 
factor (Grépin et al., 1994; Thuerauf et al., 1994), myosin heavy chain α (Jiang and 
Evans, 1996; Molkentin et al., 1994), and Nkx2.5 (Lien et al., 1999). A role for GATA-4 
in heart development was further verified through a chromosomal deletion containing the 
Gata4 gene that results in congenital heart disease (Bhatia et al., 1999; Pehlivan et al., 
1999). A missense mutation in the Gata4 gene, preempting GATA-4 binding with the T-
box protein TBX5, implicated GATA-4 in cardiac septal defects (Garg et al., 2003).  
 Gata4 null mutant mice die between e7.0 and e10.5 (Kuo et al., 1997; Molkentin 
et al., 1997). These mice develop partially outside of the yolk sac, suffer from cardia 
bifida, and contain disorganized foregut and anterior intestinal portal. These deformities 
indicate a role for GATA-4 in the caudal and ventral folding of the embryo (Kuo et al., 
1997; Molkentin et al., 1997). In embryonic stem cells, forced expression of GATA-4 can 
induce differentiation of extraembryonic endoderm (Fujikura et al., 2002).  
 The zinc finger protein FOG-2 has been found to interact with GATA-4 to cause 
both synergistic activation and repression of GATA-dependent promoters depending on 
the target and cell type involved (Lu et al., 1999). Fog2 null mice lack coronary 
vasculature, though cross regulation is not expected, as GATA-4 expression is normal in 
these mice (Tevosian et al., 2000). FOG-2 and GATA-4 are also required for normal 
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gonadal differentiation. Without the physical interaction between FOG-2 and GATA-4, 
testis cords fail to develop and genes required for Sertoli cell function, Sox 9, Mis and 
Dhh, are not expressed, indicating a role for both FOG-2 and GATA-4 in sex 
determination (Tevosian et al., 2002). Recently, developmental defects in ovarian 
development were also found to rely on the interaction of GATA-4 to FOG-2 (Manuylov 
et al., 2008).  
 GATA-4 also interacts with the GTPase RhoA to induce sarcomere reorganization 
(Charron et al., 2001). During myocardial cell hypertrophy, the kinase ROCK-1 is 
involved in GATA-4-dependent ET-1 transcription, which is abrogated in the absence of 
ROCK-1 (Yanazume et al., 2002). Recently, a nonclassical nuclear localization signal of 
GATA-4 has been discovered that can actively transport GATA-4 to the nucleus of 
cardiac myocytes. Importin β interacts with four arginine residues in this region to 
mediate transport. These residues were also found to be important for DNA binding and 
cardiac-specific gene activation of GATA-4 (Philips et al., 2007). 
 Bone Morphogenetic Proteins (BMPs) regulate the septum transversum 
mesenchyme to induce liver genes and exclude a pancreatic fate in the endoderm, at least 
partially through elevating the protein levels of GATA-4 (Nemer and Nemer, 2003; Rossi 
et al., 2001). GATA-4 binds an enhancer of the albumin gene, seemingly even within 
compacted chromatin, indicating that early transcription factors are capable of accessing 
and opening local chromatin structures (Cirillo et al., 2002). GATA-4 also binds to the 
erythropoietin promoter in hepatocytes, with RNAi of GATA-4 resulting in reduced Epo 
transcription in Hep3B cells (Dame et al., 2004). Epo expression transitions from the fetal 
liver to the adult kidney during development. While GATA-4 is highly expressed in 
hepatocytes of the fetal liver, it is low in the adult liver, indicating a potential role for 
GATA-4 in the transition of Epo from the fetal liver to the adult kidney (Dame et al., 
2004).  
 GATA-4 expression has also recently been reported in the developing adrenal 
gland, more specifically in the less differentiated proliferating cells of the fetal cortex 
(Parviainen et al., 2007). GATA-4 has also been shown to regulate the expression of 
genes associated with normal adrenal function, namely inhibin-α and steroidogenic 
factor-1 (Tremblay and Viger, 2003). Gonadotropin dependent mouse adrenocortical 
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tumors also contain higher levels of GATA-4 than does wild type cortex. It has been 
shown that gonadotropins augment the expression of GATA-4 (Looyenga and Hammer, 
2006), which in turn transactivates luteinizing hormone receptor (Rahman et al., 2004).   
 
GATA-5 
GATA-5 was originally discovered in Xenopus (Kelley et al., 1993). It is 
expressed in the cardiac crescent before the heart tube is formed (Laverriere et al., 1994). 
GATA-5 is then expressed in lateral plate derivatives, including the endocardium and 
myocardium. It is also found in the primitive embryonic gut, and at later stages in 
specific regions of gastrointestinal epithelia, along with the spleen (Laverriere et al., 
1994). Murine GATA-5 is expressed in the precardiac mesoderm of the primitive streak, 
and is found early in heart development. GATA-5 is expressed in both atrial and 
ventricular chambers at e9.5, just the atrial endocardium by e12.5, and not at all at later 
stages (Morrisey et al., 1997). GATA-5 is also uniquely expressed in the pulmonary 
mesenchyme and restricted subsets of smooth muscle cells in the bladder (Morrisey et al., 
1997).  
 GATA-5 is required for myocardial precursors to expand properly (Reiter et al., 
1999). Cardiac primordial migration to the embryonic midline and morphogenesis of the 
endoderm also requires proper GATA-5 expression (Reiter et al., 1999). This occurs at 
least in part through GATA-5 regulation of the cardiac-specific factor Nkx2.5 (Reiter et 
al., 1999). Endodermal patterning has been found to require nodal signaling, which 
induces GATA-5 expression along with the homeobox transcription factor Mixer, in turn 
regulating a Sox-like factor to stimulate endodermal genes (Patient and McGhee, 2002). 
 GATA-5 is the only GATA family transcription factor not absolutely required for 
embryonic development, as null mutations in all other family members incorporated into 
the germ line of mice result in embryonic lethality.  Gata5 null mutant mice are viable 
and fertile. Female Gata5 null mice contained vaginal and uterine defects, along with 
hypospadias, whereas males showed no genitourinary abnormalities.  The female 
urogenital developmental deficiency was determined to be a defect in partitioning of the 
urogenital sinus (Molkentin et al., 2000).  




A cDNA clone originally identified in chickens denoted GATA-6 was identified 
and found to be distinct from other GATA factor members (Laverriere et al., 1994). This 
protein is highly expressed in liver, lung, stomach, and ovary, and to a lesser extent in the 
intestines and heart (Laverriere et al., 1994). The murine homologue binds to the cardiac-
specific troponin C gene (cTnC). It is expressed in the precardiac mesoderm, the 
embryonic heart tube, the primitive gut, the developing bronchi, arterial smooth muscle 
cells, and the urogenital ridge and bladder (Morrisey et al., 1996). The human homologue 
has a similar expression profile (Suzuki et al., 1996).  
 GATA-6 has a broader DNA binding sequence specificity than other GATA 
family members (except GATA-3), with the consensus GATA sequence still being the 
highest affinity, followed by GATT and then GATC; the core motif is (A/T)GATA(A/G), 
but GATA-6 binds the tightest when flanked on both sides by adenines (Sakai et al., 
1998).   
 GATA-6 is the GATA family member that is required first in embryonic 
development, as Gata6 null mutant mice die between e6.5 and e7.5 from defects in the 
differentiation of visceral endoderm; expression of a number of endodermal markers, 
including α-fetoprotein, GATA-4, HNF3β, and HNF4 were all greatly reduced or 
altogether absent in Gata6 null mutants (Koutsourakis et al., 1999; Morrisey et al., 1998). 
Analysis of chimeras revealed that GATA-6 is only required for the branching and 
differentiation of epithelial cells, not the process of endoderm specification itself (Keijzer 
et al., 2001).  
 GATA-6 is upregulated by tumor necrosis factor-α, which enhances binding and 
transcriptional activation of vascular cell adhesion molecule-1, which functions in 
inflammatory response (Umetani et al., 2001). Furthermore, NKX3.2, serum response 
factor, and GATA-6 form a complex to transactivate the smooth muscle genes α1 
integrin, SM22α, and caldesmon (Nishida et al., 2002); this process appears to be at least 
partially activated by statins (Wada et al., 2008). GATA-6 also plays a role in 
maintaining vascular smooth muscle quiescence (Perlman et al., 1998); it is down 
regulated upon arterial injury to promote vessel lesion formation (Mano et al., 1999). 
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Further clarification of a role for GATA-6 in vascular smooth muscle differentiation 
showed that it could displace myocardin from the serum-response factor to repress 
telokin promoter activity; at the same time, GATA-6 activates smooth muscle myosin 
heavy chain and smooth muscle actin alpha-actin promoters (Yin and Herring, 2005).  
 The adrenal gland also appears to require the expression of GATA-6 (Kiiveri et 
al., 2002), particularly for developmental changes and corticosteroid production in the 
zona fasciculata (Nakamura et al., 2007). Interestingly, Gata6 appears to be dispensable 
for early stages of megakaryocyte differentiation, but is specifically up regulated in late 
stage megakaryocytes, potentially cooperating with Elf-1 to induce expression of 
megakaryocyte-specific genes (Dumon et al., 2006). 
 Given its early role in extraembryonic endoderm development, it has been 
difficult to study later roles of GATA-6 in vivo; to circumvent this problem, a conditional 
knockout of Gata6 has been created with LoxP sites flanking exon 2 of the Gata6 gene 
(Sodhi et al., 2006). The efficacy of these conditional mice was tested through a cross to 
mice expressing Cre from the Villin promoter, which is specifically expressed in the 
intestine. The homozygous conditional mice had significantly reduced levels of GATA-6, 
indicating that this conditional knock-out mouse should prove to be a valuable tool in 
addressing the role of GATA-6 during later developmental stages (Sodhi et al., 2006).   
 
GATA-2 
Gata2, the principal focus of these studies, was originally isolated as a chicken 
cDNA clone by virtue of its homology to Gata1 (Yamamoto et al., 1990). GATA-2 
expression was found in all developmental stage erythroid cells, along with embryonic 
brain, liver, cardiac muscle, adult kidney and fibroblasts (Yamamoto et al., 1990). The 
human homologue was discovered soon thereafter and found to regulate endothelin-1 
(Kawana et al., 1995; Lee et al., 2001). Other early studies found GATA-2 to be 
important for regulation of endothelial cells (Dorfman et al., 1992; Lee et al., 2001), in 
early – but not mature – erythroid cells (Leonard et al., 1993), mast cells (Zon et al., 
1991), megakaryocytes (Visvader and Adams, 1993), eosinophils (Zon et al., 1993), 
basophils (Zon et al., 1993), neutrophils (Zon et al., 1993), hematopoietic stem cells 
(Orlic et al., 1995) in the AGM region of the developing embryo (Minegishi et al., 1999), 
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placental trophoblasts (Ma et al., 1997; Ng et al., 1994), gonadotropes and thyrotropes of 
the pituitary gland (Charles et al., 2006; Dasen et al., 1999), urogenital development 
(Zhou et al., 1998), adipocyte differentiation (Okitsu et al., 2007; Tong et al., 2005), V2 
interneurons (Zhou et al., 2000), the central nervous system (Nardelli et al., 1999), 
vascular endothelium (Wozniak et al., 2007), and serotonergic neurons of the hindbrain 
(Craven et al., 2004; Krueger and Deneris, 2008). 
 Gata2 null mutant embryos die at e10.5 from a failure of primitive and definitive 
hematopoiesis (Tsai et al., 1994). In vitro studies have shown that GATA-2 is required 
for survival and proliferation of hematopoietic progenitors (Briegel et al., 1993), possibly 
through regulation by Evi-1 and repression of TGF-β signaling (Sato et al., 2008). 
GATA-2 is also required for the production of mast cells; however, it is not required for 
the terminal differentiation of macrophages or erythroid cells (Tsai and Orkin, 1997). 
Gata2 haploinsufficiency studies reveal that GATA-2 is required for the production and 
proliferation of hematopoietic stem cells (HSC) in the aorta-gonad-mesonephros region 
of the embryo, as well as propagation of HSCs in adult bone marrow (Ling et al., 2004). 
BMP-4 stimulates GATA-2 expression in the ventral mesoderm (Maeno et al., 1996). 
The threshold of GATA-2 expression plays a role in self-renewal versus differentiation of 
hematopoietic progenitors (Heyworth et al., 1999; Persons et al., 1999). This threshold 
appears to be at least partially regulated by Notch1, which maintains GATA-2 expression 
allowing it to sustain the undifferentiated state of hematopoietic progenitors (Kumano et 
al., 2001; Minegishi et al., 2003). GATA-2 can maintain quiescence by inhibiting the cell 
cycle of these progenitors (Tipping et al., 2009).  
 The ability of GATA-2 to undergo a broader array of regulatory functions than 
GATA-1 may stem at least partially from its ability to bind to a consensus GATC 
sequence (Ko and Engel, 1993). This binding may occur through the N-terminal finger, 
as opposed to the traditional binding by the C-terminal finger; this binding is stabilized 
by two basic regions on either side of the amino finger, one of which is lacking in 
GATA-1 (Pedone et al., 1997).   
 GATA-2 transcription, like almost all GATA factor family members, is regulated 
by alternate promoters (Minegishi et al., 1998). The downstream 1G (general) promoter 
sequence is similar to the promoters described for Xenopus and human, but the upstream 
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1S (specific) promoter shows unique expression in hematopoietic progenitor cells and 
neural tissues (Minegishi et al., 1998; Pan et al., 2000). A knock-in reporter driving GFP 
expression from the Gata2 1S promoter was used to evaluate hematopoietic stem cell 
function in the bone marrow (Suzuki et al., 2006). From these studies HSCs appear to be 
solitary and maintain intimate contact with osteoblasts that characterize the HSC niche 
(Suzuki et al., 2006). Another interesting observation is that, even though GATA-2 
expression driven from the 1S promoter marks putative hematopoietic/endothelial 
precursor cells (Kobayashi-Osaki et al., 2005), no hematopoietic deficiency was observed 
when 1S promoter activity was abrogated, indicating that transcription from the 1G 
promoter can fully complement deficient 1S activity (Suzuki et al., 2006).  
 GATA-2 is required in neurogenesis for the generation of V2 interneurons (Zhou 
et al., 2000). This expression was localized to an enhancer in intron 5 of the Gata2 locus 
(Zhou et al., 2000). GATA-2 is necessary for the proper expression of GATA-3 in the 
central nervous system (Nardelli et al., 1999; Pata et al., 1999). A developmental cascade 
involving GATA-2 has also recently been deduced for the differentiation of serotonergic 
neurons in the hindbrain. Sonic hedgehog activates the homeodomain proteins Nkx2.2 
and Nkx6.1. These proteins then cooperate to activate GATA-2, which goes on to 
stimulate the expression of the transcription factors Lmx1b, Pet1, and Gata3. This 
process induces serotonergic neuron production within rhombomere 1 of the hindbrain 
(Craven et al., 2004). GATA-2 also regulates the ETS transcription factor fifth Ewing 
variant (FEV) in serotonergic neurons (Krueger and Deneris, 2008).  
 In attempting to rescue Gata2 null embryonic lethality, a YAC transgene was 
found that encompasses two hematopoietic enhancers located 100 to 150 kilobase pairs 
upstream of the Gata2 structural gene. Expression of the YAC in a Gata2 null mutant 
background was able to rescue hematopoiesis; however, these mice then die perinatally 
from complications in urogenital development including hydroureternephrosis (Zhou et 
al., 1998). Following the development of a novel BAC-mapping strategy, two distinct 
urogenital enhancers were identified (Khandekar et al., 2004). One enhancer is expressed 
specifically in the mesenchyme surrounding the nephric duct along with the mesonephric 
mesenchyme; the second regulates Gata2 expression in the mesenchyme around the 
ureteric bud along with the urogenital sinus (Khandekar et al., 2004). A third urogenital 
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enhancer was deduced to exist, but not specifically localized, as the Gata2-GFP reporter 
mice showed expression in the ureteric epithelium, but neither of the isolated urogenital 
enhancers conveyed expression in this tissue (Khandekar et al., 2004). A piece of this 
transcriptional pathway has recently been resolved: a GATA-2 hypomorph reduces the 
expression level of BMP-4 resulting in abnormalities resembling human congenital 
anomalies of the kidney and urinary tract (CAKUT) (Hoshino et al., 2008).  
 GATA-2 only binds to a small subset of the composite GATA sequence elements 
that are available in the genome. Recently, a set of unique molecular hallmarks 
demarcating these sites from unoccupied sites has been elucidated, including a distinct 
epigenetic signature, specific neighboring cis elements, and binding by the transcription 
factor SCL (Wozniak et al., 2008). 
 Deregulation of GATA-2 has been linked to acute myeloid leukemia through 
analysis of 3q21 aberrations (Wieser et al., 2000). Concurrently, GATA-2 has been 
shown to complex with promyelocytic leukemia protein to modify the transactivation 
capacity of GATA-2 (Tsuzuki and Enver, 2002; Tsuzuki et al., 2000). Recently, GATA-2 
has also been implicated in atherosclerosis (Seo et al., 2004), early-onset coronary artery 
disease (Connelly 2006), chronic myelogenous leukemia (Zhang et al., 2008), and 
Parkinson’s disease (Scherzer et al., 2008).  
 
Interplay between GATA Factors 
While each of the GATA factor family members play distinct roles in embryonic 
development, they also interact and functionally complement each other in multiple 
developmental processes. GATA-1 was proposed to repress GATA-2 in erythroid 
maturation soon after their discovery (Weiss et al., 1994). Given their role in 
hematopoiesis, one of the first combinatorial studies focused on elucidating the 
phenotype of GATA-1/2 double knockouts. Double heterozygote mice die at mid-
gestation from anemia. In the double knockout, the yolk sac vascular network appeared to 
be intact, but no circulating cells were observed. This severe phenotype indicates that 
GATA-1 and GATA-2 functionally overlap at the earliest stages of primitive 
hematopoiesis; the Gata2 null phenotype predominates in definitive hematopoiesis, as the 
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phenotype of the double knockout resembles that of the Gata2 null (Fujiwara et al., 
2004).  
 GATA-2 appears to positively autoregulate the Gata2 gene during hematopoietic 
development specifically through an enhancer located 2.8 kbp upstream of the Gata2 1S 
promoter, even though there are dozens of other GATA consensus sites in the region 
(Grass et al., 2003). GATA-1 then displaces GATA-2 specifically at this enhancer, 
resulting in reduced acetylation to generate a repressive chromatin state (Grass et al., 
2003). This process has been termed a “GATA switch” (Grass et al., 2003), and appears 
to require the coregulator Friend of GATA-1 (FOG-1) for the GATA switch to occur by 
facilitating chromatin occupancy with GATA-1 (Pal et al., 2004a). A similar GATA 
switch occurs at other locations in the Gata2 locus (Grass et al., 2006; Martowicz et al., 
2005), the α-globin promoter (Anguita et al., 2004), and neurokinin-B promoter (Pal et 
al., 2004b).  
 Interestingly, GATA-1 requires FOG-1 to displace GATA-2 in the Gata2 -2.8 kbp 
enhancer to promote erythroid differentiation, but GATA-1 must act independently of 
FOG-1 to promote mast cell maturation (Cantor et al., 2008). Forced expression of FOG-
1 in mast cell progenitors actually redirects them to other hematopoietic lineages, 
implicating FOG-1 as a negative regulator of the mast cell fate (Cantor et al., 2008). 
GATA-1 has also been shown to enhance histone acetylation in other settings, together 
with CBP (Letting et al., 2003), indicating that GATA factor function relies on specific 
cofactor binding to elicit the desired chromatin state. 
 Recently, a similar GATA switch has been reported between GATA-2 and 
GATA-3. GATA-3, in association with FOG-1, directly represses Gata2 in 
undifferentiated trophoblast cells. GATA-2 then displaces GATA-3 and FOG-1 at two 
separate regions of the mouse Gata2 locus (-3.9 and +9.5 kbp) to initiate trophoblast 
giant-cell specific differentiation (Ray et al., 2009). It is also interesting that regulatory 
elements at -1.8, -2.8, and -77 kbp, known to be important for hematopoietic regulation, 
are not occupied by GATA factors in trophoblast cells, presumably through sequestration 
in repressed chromatin structure (Ray et al., 2009).  
  GATA-4 and GATA-6 have a similar relationship to GATA-1 and GATA-2. 
While they overlap or synergize expression in some tissues, such as cardiac myocytes 
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(Charron et al., 1999; Kuo et al., 1997; Molkentin et al., 1997), it has been proposed that 
GATA-6 confers positive regulation on GATA-4, while GATA-4 acts in a negative 
feedback manner (Morrisey et al., 1998). The abundance of each transcription factor has 
also been shown to be important for multiple processes. An interesting study recently 
found that while mice heterozygous for a Gata4 or Gata6 null allele are phenotypically 
normal, compound heterozygotes are embryonic lethal from an array of cardiovascular 
defects (Xin et al., 2006). In contrast, in the mouse pancreas GATA-4 expression seems 
to be restricted to exocrine pancreatic differentiation, while GATA-6 is directed to the 
endocrine pancreas (Ketola et al., 2004). It will be interesting to uncover the mechanism 
behind their restricted expression domains, and if it mimics the GATA switch of the 
hematopoietic factors.  
  
Hemangioblasts, Hematopoiesis, and Vasculogenesis 
A hypothesis put forth at the beginning of the 20th century was that since 
endothelial and hematopoietic lineages arise from the same location at the same time, 
they might arise from a common progenitor -- a cell termed the “hemangioblast” 
(Murray, 1932; Sabin, 1920). More recent evidence to support this idea is the 
identification of proteins that are expressed in both of these cell types, including CD34 
(Young et al., 1995), Flk-1 (Kabrun et al., 1997; Millauer et al., 1993; Yamaguchi et al., 
1993), Flt-1 (Fong et al., 1996), TIE-2 (Takakura et al., 1998), SCL (Kallianpur et al., 
1994), GATA-2 (Orkin, 1992), and PECAM-1 (Watt et al., 1995). Since then, a few of 
these proteins have been shown to play physiologically important roles in both 
hematopoietic and endothelial cell development, including cloche (Stainier et al., 1995), 
Flk-1 (Eichmann et al., 1997; Shalaby et al., 1995), and SCL (Visvader et al., 1998).  
 Embryonic stem cell derived embryoid bodies have the capacity to produce both 
hematopoietic as well as endothelial cells. Mixing studies demonstrate that both of these 
cell types arise from the same cell – termed the blast colony-forming cell (BL-CFC) 
(Choi et al., 1998). This BL-CFC is believed to be the in vitro equivalent of the 
hemangioblast. A cell with similar properties has been isolated from the primitive streak 
of e7.0 mouse embryos (Huber et al., 2004).  
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 The site of origin for the primitive hemangioblast was found to be the embryonic 
blood islands of the yolk sac (Sabin, 1920). Peripheral endothelial precursors (ie – 
angioblasts) surround hematopoietic precursors (Risau and Flamme, 1995). For some 
time, hematopoietic stem cells arising from these yolk sac blood islands were thought to 
colonize hematopoietic organ rudiments including the fetal liver, spleen, and bone 
marrow (Moore and Owen, 1965). Quail/chick grafting experiments showed that while 
the yolk sac was capable of generating a transient wave of hematopoiesis, the 
hematopoietic organs were seeded principally by embryo-derived hematopoietic stem 
cells (Beaupain et al., 1979; Dieterlen-Lievre, 1975; Martin et al., 1978). However, recent 
lineage tracing studies have found that yolk sac hematopoiesis may still contribute a 
small percentage of hematopoietic stem cells to hematopoietic organ rudiments 
(Samokhvalov et al., 2007).  
 Vasculogenesis is defined as the differentiation of angioblasts from the mesoderm 
and the subsequent amassing of these angioblasts into blood vessels (Risau and Flamme, 
1995). The first intraembryonic angioblasts arise adjacent to the endoderm (Coffin and 
Poole, 1988). Some angioblasts then fuse with other angioblasts in situ to form vessels; 
others migrate as single cells or clusters and incorporate into developing vessels or form 
new vessels at remote locations (Coffin and Poole, 1988; Poole and Coffin, 1989). 
Capillaries then sprout off of these primary vessels in a process termed angiogenesis to 
form the mature vasculature (Folkman and Shing, 1992). The first known molecular 
marker expressed on angioblasts is Flk-1 (Millauer et al., 1993). Flk1 null mutant mice 
can form some endothelial precursors cells, but they never aggregate into mature vessels 
(Shalaby et al., 1995). Intraembryonic vasculogenesis originates in the embryo proper at 
e7.3, where Flk1 is already strongly expressed (Drake and Fleming, 2000). By e9.0, the 
dorsal aorta, intersomitic vessels and the intervertebral arteries are already formed (Drake 
and Fleming, 2000).  
 The origin of definitive hematopoietic stem cells must reside within the embryo 
proper, possibly arising from a definitive form of the hemangioblast. Early studies noted 
that putative hematopoietic cells have been seen lining the ventral wall of the dorsal aorta 
endothelium (Jordan, 1917). These cells take up basophilic stain and express 
hematopoietic markers (Dieterlen-Lièvre and Martin, 1981; Jaffredo et al., 1998; 
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Pardanaud et al., 1987). Further studies demonstrated that the aorta-gonad-mesonephros 
(AGM) region of the developing mouse embryo is the site of definitive hematopoietic 
progenitor generation (Cormier, 1993; Godin et al., 1993; Medvinsky et al., 1993). 
Hematopoietic stem cells (HSC) first emerge from the AGM at e10.5 of development 
(Medvinsky and Dzierzak, 1996) along with contributions from the vitelline and 
umbilical arteries (de Bruijn et al., 2000). Definitive HSCs can be found in the yolk sac 
one day later at e11.5 (Medvinsky and Dzierzak, 1996; Müller et al., 1994).  
 Since HSCs are first generated in the AGM, the next question is whether they are 
derived directly from hemangioblasts, from “hemogenic endothelium”, or from some 
other undefined mesodermal progenitor (Dzierzak et al., 1998; Orkin, 2000). Hemogenic 
endothelium is defined as specified endothelial cells that can give rise to hematopoietic 
cells (Jaffredo et al., 2005). Based on the expression of a Sca1-directed GFP reporter 
gene in mice, HSCs do not appear in the mesenchyme, but rather localize specifically to 
the endothelium lining the floor of the dorsal aorta (de Bruijn et al., 2002). Accordingly, 
DiI-conjugated acetylated low-density lipoprotein (LDL) tagged endothelial cells were 
able to give rise to DiI labeled circulating erythroid cells (Sugiyama et al., 2003). Mice 
haploinsufficient for Runx1, a transcription factor that is required for definitive HSC 
generation, labeled HSCs in the hematopoietic clusters, the endothelium, and in the 
underlying mesenchymal cell population, indicating that HSC precursors may reside in 
the mesenchyme in an undifferentiated state (North et al., 2002). Recent studies may have 
reconciled these events, as the primary support for a direct hemangioblast model came 
from BL-CFC’s in vitro directly giving rise to hematopoietic and endothelial cells. 
Lancrin et al have recently shown that BL-CFC’s actually give rise to a transiently 
adherent cell population, the hemogenic endothelium equivalent, before quickly 
differentiating into distinct hematopoietic and endothelial populations (Lancrin et al., 
2009). Also, separate labelling of the endothelium versus its underlying mesenchyme has 
shown that hematopoietic cells specifically and uniquely arise from the endothelial 
population (Zovein et al., 2008).  
 Hematopoietic clusters are generally localized to the ventral floor of the dorsal 
aorta (Jaffredo, 1999). A potential explanation for this has been elucidated through 
grafting experiments in avian embryos. The roof and walls of the dorsal aorta are derived 
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from paraxial mesoderm, while the floor is derived from the splanchnopleural mesoderm 
(Pardanaud et al., 1996). These splanchnopleural cells are capable of giving rise to 
hematopoietic cells, but only in the proper microenvironment (Pardanaud et al., 1996). 
While one factor, Glypican-1, has recently been shown to support hematopoietic 
development (Nagao et al., 2008), three hematopoietic transcription factors in particular 
have been shown to play crucial roles in hematopoietic stem cell formation – SCL, 
GATA-2, and RUNX1 (Jaffredo et al., 2005). GATA-2’s role in hematopoietic 
development has been described above. 
SCL (also known as TAL-1) is a helix-loop-helix protein that was originally 
identified through its participation in a chromosomal translocation that results in stem cell 
leukemia, from which the protein garners its name (Begley et al., 1989). Scl null mutant 
mice suffer from hematopoietic failure and die around e9.5 (Robb et al., 1995). Studies of 
Scl mutant embryonic stem cells in chimeric mice show that SCL is required for the 
development of all hematopoietic lineages (Porcher et al., 1996). An enhancer of Scl was 
uncovered that was found to bind GATA-2, Fli-1, and Elf-1 in vivo, uncovering part of 
the regulatory network in hematopoietic development (Göttgens et al., 2002). Expression 
of Flk-1 and SCL enrich the hemangioblast population in cell culture studies (Chung et 
al., 2002). GATA-2 appears to stimulate the regulation of SCL, inducing Flk-1 positive 
mesoderm to become Flk1+SCL+ hemangioblasts, and then rapidly differentiate into 
hematopoietic or endothelial cells (Lugus et al., 2007). SCL has been found to be 
necessary for angiogenic remodeling of the capillary network of the yolk sac (Visvader et 
al., 1998), and is expressed at sites of neovascularization and lymphangiogenesis (Tang et 
al., 2006).  
Runx1 (also known as Cbfa2 and Aml1), a member of the core binding factor 
family, was originally discovered from a translocation resulting in acute myeloid 
leukemia (Miyoshi et al., 1991). Runx1 null mutant animals die around e12.5 from 
hemorrhaging in the central nervous system (Wang et al., 1996) and a failure to initiate 
definitive hematopoiesis (Okuda et al., 1996). While definitive hematopoiesis is 
abrogated, primitive hematopoiesis is not affected (Lacaud et al., 2002; Okuda et al., 
1996). RUNX1 protein expression is restricted to the ventral aspect of the dorsal aorta 
and intra-aortic hematopoietic clusters are not formed in its absence (North et al., 1999). 
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Haploinsufficiency of Runx1 results in alteration of the temporal and spatial emergence 
of hematopoietic stem cells (Cai et al., 2000; Lacaud et al., 2004). Therefore, it is 
believed that RUNX1 functions during the transition from hemogenic endothelium to 
hematopoietic stem cells (North et al., 1999; Yokomizo et al., 2001). Part of the 
mechanism behind this transition may involve the downregulation of Flk1 through direct 
repression by Runx1, as demonstrated in embryonic stem cell differentiation cultures 
(Hirai et al., 2005). Runx1 contains an enhancer that binds GATA-2, Ets proteins, and 
SCL to initiate the generation of hematopoietic stem cells (Nottingham et al., 2007). 
Recent conditional deletion studies have shown that RUNX1 is required for the 
differentiation of hematopoietic cells from the endothelium, but is not required once these 
cells express Vav1 – an early HSC specific pan-hematopoietic gene (Chen et al., 2009). 
Another study has proposed that the hemogenic endothelium is Tie2hic-kit+CD41-, and 
cannot reach this stage without functional SCL; differentiation of hemogenic endothelium 
to HSCs then requires RUNX1 repression of Tie2, allowing CD41, another early 
hematopoietic marker, expression to increase (Lancrin et al., 2009).  
While a distinct process from the epithelial-to-mesenchymal cell transition 
(EMT), the budding of hematopoietic cells from the dorsal aorta is a similar progression, 
which may implicate a number of other factors in this development process as well. Key 
inducers of EMT include the bHLH transcription factor Twist along with members of the 
Snail superfamily, which function as transcriptional repressors of E-cadherin and 
components of tight junctions (Moreno-Bueno et al., 2008). 
 
The Role of GATA-2 in Development 
The developmental role and patterning of the GATA family of transcription 
factors are quite diverse. Numerous individual enhancer elements have been localized for 
Gata2 alone, including two hematopoietic (Zhou et al., 1998), one endothelial (Chapter 2; 
(Wozniak et al., 2007), two central nervous system (Zhou et al., 2000), and three 
urogenital enhancers (Khandekar et al., 2004), as well as the two Gata2 promoters 
(Minegishi et al., 1998). This is without the other regulatory elements that deductively 
must exist given the involvement of GATA-2 in many other developmental events, such 
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as the generation of placental trophoblasts, adipose tissue, and pituitary specification 
(Dasen et al., 1999; Ma et al., 1997; Tong et al., 2000).  
 In this work, I have sought to elucidate mechanisms that regulate Gata2 and to 
determine the role that GATA-2 plays in specific aspects of mammalian development. 
Chapter 2 describes the isolation and characterization of an endothelial enhancer that was 
first localized within Gata2 intron 4.  In Chapter 3, we intended to generate and then test 
whether a linked BAC would encompass all of the necessary regulatory elements 
required for embryonic viability in the Gata2 locus, or to hypothetically reveal new 
essential roles for GATA-2 in development.  In Chapter 4, I describe my most recent 
studies examining the role of GATA-2 in the differentiation of the definitive 
hemangioblast and hemogenic endothelium. Through understanding the cis regulatory 
elements and trans acting factors governing Gata2 expression and its role in various 
developmental processes, we can begin to understand the functional networks governing 
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 The early murine blood vasculature develops from angioblasts associated with 
blood islands of the yolk sac. This process, known as vasculogenesis, results in the 
formation of the initial vascular network (Pardanaud et al., 1987), which consists of 
paired dorsal aortae, the cardinal veins, the vitelline artery and vein, and the endocardial 
tubes. The primordial differentiation of this network then proceeds based on the 
mesodermal germ layer involved.  Paraxial mesoderm gives rise to angioblasts capable of 
colonizing the endothelial lining of vessels, including the roof and sides of the dorsal 
aorta.  Splanchnopleural mesoderm, while also contributing to the endothelial lining of 
vessels, can invade visceral organs and contribute to the floor of the dorsal aorta 
(Pardanaud et al., 1996), where definitive hematopoietic precursors first become evident 
(de Bruijn et al., 2002).   
New endothelial cells and vessels are generated later via a process called 
angiogenesis, which proceeds via two distinct mechanisms: sprouting and non-sprouting 
angiogenesis (Risau, 1997).  Sprouting angiogenesis involves the extension of pre-
existing vessels. The extracellular matrix is removed via proteolytic degradation. 
Endothelial cells then proliferate, form a new lumen and mature into a functional 
endothelium.  This is the primary method of vascularization of the brain.  Non-sprouting 
angiogenesis, or intussusception, is when pre-existing vessels split via transcapillary 
pillars or posts of extracellular matrix. This is the primary method of vascularization in 
the embryonic lung.  Multiple organs develop through concurrent utilization of both 
methods of angiogenesis.  Superfluous branches are then pruned or remodeled, resulting 
in the formation of the mature vascular network (Risau, 1997).  
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Throughout development, hematopoietic and endothelial progenitors originate in 
the same locales. In the yolk sac, the blood islands contain primitive erythrocytes 
surrounded by a thin layer of angioblasts.  In the aorta-gonad-mesonephros region of the 
embryo proper, which is the initial site of definitive hematopoiesis, hematopoietic stem 
cells can be detected budding from the endothelium of the dorsal aorta (de Bruijn et al., 
2002). Given the close physical proximity of the very earliest hematopoietic and 
endothelial cells, it has been speculated that they originate from a common progenitor 
cell, which has been termed the hemangioblast (Murray, 1932). A number of 
transcription factors have been shown to play a role in the development of both cell 
lineages: for example, cloche is required for the formation of endothelial and 
hematopoietic progenitors in zebrafish (Stainier et al., 1995) and Scl (also known as Tal1 
– Mouse Genome Informatics), which encodes a basic helix-loop-helix transcription 
factor, was initially shown to be required for hematopoietic development in mice (Robb 
et al., 1995; Shivdasani et al., 1995). Subsequent transgenic rescue of the hematopoietic 
defect in Scl-null embryos revealed a requirement for SCL in the remodeling of the yolk 
sac vasculature (Visvader et al., 1998), and it has since been shown to play a role in 
vasculogenesis (Patterson et al., 2005), as well as in the migration and morphogenesis of 
endothelial cells (Lazrak et al., 2004).  Transgenic expression of SCL is able to rescue the 
phenotypic consequences of cloche mutation in the zebrafish, suggesting that Scl 
functions downstream of cloche (Liao et al., 1998). LMO2, a member of the LIM domain 
family, is required for primitive erythropoiesis in the embryo; Lmo2 ablation results in 
death at embryonic day (E) 9.75 secondary to hematopoietic failure (Warren et al., 1994). 
Analysis of chimeric mice bearing contributions from Lmo2–/– embryonic stem (ES) cells 
revealed that angiogenic remodeling of blood vessels requires Lmo2 (Yamada et al., 
2000).  Similarly, targeted disruption of the receptor tyrosine kinase Flk1 results in 
embryonic lethality around 8.5 days post-coitum (dpc) from a lack of organized blood 
vessels and a severely reduced number of hematopoietic progenitors (Shalaby et al., 
1995). 
Embryonic stem cell-derived embryoid bodies, in response to vascular endothelial 
growth factor (the ligand of Flk1), give rise to blast colony-forming cells, which in turn 
can directly differentiate to hematopoietic and endothelial precursors in vitro (Choi et al., 
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1998).  Moreover, single-cell-resolution fate maps in zebrafish have now shown in vivo 
that individual cells along the ventral mesoderm can contribute to both lineages (Vogeli 
et al., 2006).  
Given the dual requirement for many hematopoietic transcription factors in 
angiogenesis, and the fact that expression of GATA factors had been reported in several 
endothelial cell lines (Dorfman et al., 1992; Umetani et al., 2001), it seemed reasonable 
that GATA family members might share a similar role in development.  GATA factors 
belong to an evolutionarily conserved family of C4 zinc-finger transcription factors that 
play demonstrably crucial roles in development. There are six GATA family members in 
vertebrates, which have historically been subdivided into two subfamilies. GATA-1, 
GATA-2 and GATA-3 are important for hematopoietic determination and differentiation, 
participating respectively in erythroid, hematopoietic progenitor and T-lymphoid 
development, among other activities (Pandolfi et al., 1995; Pevny et al., 1995; Tsai et al., 
1994).  Similarly, GATA-4, GATA-5 and GATA-6 have been shown to be involved in 
cardiac, genitourinary and multiple endodermal developmental events (Molkentin, 2000; 
Molkentin et al., 1997; Molkentin et al., 2000; Morrisey et al., 1998).  
GATA-2 was originally cloned from a chicken reticulocyte cDNA library 
(Yamamoto et al., 1990).  It is expressed in a wide variety of tissues, including 
hematopoietic, neuronal and endothelial cells. Gata2-null mutant embryos die at mid-
gestation due to a block in primitive hematopoiesis (Tsai et al., 1994). Further 
examination of Gata2 gain-of-function and in vitro differentiation of Gata2 null ES cells 
showed that GATA-2 plays a key role in the proliferation of very early hematopoietic 
progenitors (Briegel et al., 1993; Kitajima et al., 2002; Tsai and Orkin, 1997), 
accentuating the conclusions from the initial loss-of-function experiments.  
Given that many genes involved in hematopoiesis also participate in vascular 
development and that GATA-2 is strongly expressed in endothelial cell lines, it was 
originally believed that loss of GATA-2 function would result in vascular defects. 
Adding further to this expectation was early evidence that many genes that appeared to be 
crucial for endothelial development and function are regulated via GATA-binding sites 
(Dorfman et al., 1992). For example, GATA sites have been implicated in the regulation 
of the endothelium-specific genes preproendothelin (immature form of EDN1) (Dorfman 
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et al., 1992; Yamashita et al., 2001), Pecam1 (Gumina et al., 1997), Flk1 (Kappel et al., 
2000; Minami et al., 2004), eNOS (also known as Nos3 – Mouse Genome Informatics) 
(German et al., 2000) and Icam2 (Cowan et al., 1998). Mutation of a GATA-binding site 
in the Flk1 endothelium-specific enhancer completely abolished its activity in transgenic 
reporter assays, indicating that Flk1 expression is dependent on GATA activity in vivo 
(Kappel et al., 2000). Surprisingly, however, the analysis of Gata2-null embryos failed to 
reveal any obvious defects in the vasculature at the time of their early embryonic demise 
(~e10) (Tsai et al., 1994), leaving the role for GATA-2 in endothelial function undefined.  
To begin to investigate the role of GATA-2 in endothelial function, GFP 
expression in the developing vasculature of Gata2-GFP knock-in embryos was examined 
systematically during embryogenesis (Khandekar et al., 2007).  It was found that GFP 
was expressed in cells lining arterial and venous vessels formed during vasculogenesis 
and angiogenesis, and that its expression continued postnatally.  A 1.2-kbp region of 
Gata2 was then functionally identified in intron 4 that could regulate the expression of a 
cis-linked reporter transgene in cardiovascular and lymphatic endothelial cells. 
Additionally, using site-specific mutagenesis, it was found that the potency of the 
minimal endothelium-specific enhancer is crucially dependent on an E-box (CANNTG) 
motif. By contrast, disruption of three ETS-binding sites quantitatively reduced, but did 
not abolish, enhancer activity (Khandekar et al., 2007).  These studies also demonstrated 
that the vascular enhancer can be dissected into a core 167 base pair (bp) element capable 
of recapitulating vascular expression autonomously everywhere except in the 
endocardium; a 155-bp element, which is dependent on the 167-bp element, resides 
immediately upstream of the core enhancer and confers expression in the endocardium.  
We also showed that SCL is able to bind the critical E-box motif in the core enhancer in 
vitro. 
 
Materials and Methods 
 
Transgenic mice 
Wild-type CD1 mice were mated with Gata2-GFP knock-in heterozygous mice, which 
had GFP inserted (in frame) at the translation initiation codon in Gata2 exon 2 (Suzuki et 
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al., 2006). Embryos were harvested at the times indicated in the text and figure legends as 
previously described (Khandekar et al., 2004). Digital images were recorded as 
previously described (Khandekar et al., 2004). 
For founder transgenic analyses, expression constructs were purified for 
microinjection into fertilized ova as previously described (Khandekar et al., 2004). At the 
indicated times, embryos from foster mothers or a Gata2 YAC d16Z transgenic line were 
harvested for X-gal staining and PCR genotyped as previously described (Zhou et al., 
1998). Transgenic embryos were photographed as whole-mount or cryosectioned 
specimens as described previously (Zhou et al., 1998). 
 
Expression-plasmid construction 
 Gata2 fragments examined here were cloned 3’ to the herpes simplex virus (HSV) 
thymidine kinase (TK) gene promoter in TKβ (Clontech) to mimic their natural position 
in the Gata2 locus. To generate TKBXβ, a 2.9-kbp BamHI-SalI fragment from plasmid 
GR22 was first subcloned into pBluescript II (Stratagene) and then excised with XbaI 
before re-cloning into XbaI-digested TKβ. To generate TKSXβ, TKBXβ was treated with 
SpeI-SfiI and T4 DNA polymerase before self-religation. To construct TKAAβ, a 460-bp 
AlwNI-ApaI fragment was excised from plasmid GR22 and treated with T4 DNA 
polymerase before being cloned into TKβ, which had been treated sequentially with XbaI 
and with Klenow polymerase. For microinjection, TKANβ was generated from TKAAβ 
by NcoI restriction-enzyme digestion. To delete the internal AlwNI-ApaI fragment, a 
plasmid subclone containing the 1.2-kbp SfiI-XbaI Gata2 intron 4 was treated with 
AlwNI-ApaI and T4 polymerase before self-religation. The resultant 0.8-kbp SfiI-XbaI 
fragment was cloned into TKβ to generate TKSXΔAAβ. To clone the vascular 
endothelium-specific (VE) enhancer into TKβ (thereby generating TKVEβ, Fig. 2.2B), 
primers Endocons(f) and Endocons(r) containing an engineered XbaI site (5’- 
ggtctagaCCATGGAGTCACCTATACTGTG-3’ and 5’-
ggtctagaACTGAGTCGAGGTGGCTCTG-3’, respectively) were used to generate a 167-
bp amplicon (defined by the arrows in Fig. 2.1A, Fig. 2.2A), which was verified by 
sequencing. 
To mutate the E-box in the VE enhancer, oligonucleotide-based PCR mutagenesis 
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was performed to introduce mutations (from 5’-CATCTG-3’ to 5’-CAcccG-3’; mutations 
are lowercase) that had been shown to eliminate SCL binding in gel shift assays (Kappel 
et al., 2000). Primers EcSCLmut(f) (5’-CGGACAcccGCAGCCG-3’) and Endocons(r) 
(shown above) were used to generate a 3’ fragment using GR22 plasmid as template in a 
PCR reaction. Similarly, EcSCLmut(r) (5’-CGGCTGCgggTGTCCG-3’) and Endocons(f) 
were used to generate a 5’ fragment. The resultant amplicons were gel-purified and 
pooled as templates in a PCR reaction using Endocons(f) and Endocons(r) as primers. 
The gel-purified PCR products were sequenced to verify incorporation of the mutation 
and were then digested with XbaI prior to cloning into the XbaI site of TKβ to generate 
TKVEβmScl (Fig. 2.2D).  
A similar strategy was used to introduce a mutation (5’-CGGA-3’ to 5’- CGcg-3’) 
that had been shown to eliminate ETS-factor binding (O'Reilly et al., 2003) into all three 
ETS-binding sites in the Gata2 VE enhancer. The primers Ecmets1(f) (5’-
CTCCTGCCGcgGTTTCCTAT-3’), Ecmets1(r) (5’-ATAGGAAACcgCGGCAGGAG-
3’), Ecmets2(f) (5’-TTCCTATCCGcgCATCTGCAG- 3’), Ecmets2(r) (5’-  
CTGCAGATGcgCGGATAGGAA- 3’), Ecmets3(f) (5’-TGTTTCCGcgCCGGCAA-3’) 
and Ecmets3(r) (5’-TTGCCGGcgCGGAAACA-3’) were used to mutagenize the VE 
enhancer, as described above, and the enhancer was then sequenced to verify 
incorporation of the desired mutations. Fragments containing mutations in either the first 
two or all three ETS-binding motifs were digested with XbaI and then cloned into the 
XbaI site of TKβ to generate TKVEβmEts1,2 (data not shown) or TKVEβmEts1,2,3 (Fig. 
2.2C), respectively. 
 
Electrophoretic mobility shift assay 
 Nuclear extracts were prepared as described previously (Tanimoto et al., 2000) 
from 293T human embryonic kidney cells that were either mock transfected or 
transfected with EF-1α promoter-directed SCL cDNA alone or with a CMV promoter-
directed E12 expression plasmid. Either no extract or nuclear extract (35 µg) was added 
to binding buffer containing 20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.5 mM DTT and 
37.5 ng/µl poly(dI-dC) at 4°C. Unlabeled oligonucleotides [20- or 200-fold molar excess; 
wild type (5’-TCCGGACATCTGCAGCCGGT-3’; E-box underlined) or mutant (5’- 
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TCCGGACAcccGCAGCCGGT-3’; E-box underlined, mutated nucleotides lowercase)] 
or antibodies (Rodriguez et al., 2005) were added as indicated in the legend to Fig. 2.3. 
After 1 hour of pre-incubation, 2 µl (2x105 cpm) of radiolabeled wild-type 
oligonucleotide probe was added to each sample and incubated for an additional 30 
minutes. All samples were fractionated by electrophoresis on neutral 6% 
TBE/polyacrylamide gels. After electrophoresis, the gels were dried and recorded using a 




Localization of a Gata2 endothelium-specific enhancer 
 Melin Khandekar, a former graduate student in the lab, was able to localize the 
endothelium-specific enhancer of Gata2 to a 1.2 kilobase pair (kbp) region in intron 4 
(Khandekar et al., 2007).  He next tested a series of smaller constructs (Fig. 2.1A) to 
establish the boundaries of a minimum enhancer element required to achieve the Gata2 
endothelium-specific expression pattern. Deletion of the 1.2-kbp SX fragment from only 
the 3’ end (in TKSRβ) or from both termini (in TKAAβ) did not alter the cardiovascular 
endothelium-specific expression in E10.5 transgenic embryos (Fig. 2.1B,C). By contrast, 
deletion of the internal AlwNI-ApaI (AA) 460-bp fragment from the SX enhancer 
fragment eliminated all endothelial enhancer activity (0/15; Fig. 2.1A,D). Thus, the 
minimal endothelium-specific enhancer as defined by the AA restriction fragment is 
sufficient for endothelium-specific Gata2 enhancer activity.  
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Figure 2.1 - Fine localization of the Gata2 endothelium-specific enhancer. (A) Schematic illustrations 
of transgenic constructs (TKSXβ, TKSRβ, TKAAβ, TKSXΔAAβ and TKANβ) used to functionally 
localize the Gata2 endothelium-specific enhancer element. Sub-fragments of Gata2 intron 4 were 
individually cis-linked to a TK promoter-lacZ reporter gene. The positions of relevant restriction enzyme 
sites (AlwNI, A; ApaI, Ap; NcoI, N; RsrII, R, SfiI, S; XbaI, X) and the restriction fragment lengths (in bp) 
are indicated. The numbers on the right indicate the number of embryos with cardiovascular β-gal 
staining/total number of transgene-positive embryos. The arrows represent the positions of the primer pairs 
used to amplify the 167-bp VE enhancer (see Fig. 2.2). (B-E) E10.5 embryos bearing TKSRβ (B) or 
TKAAβ (C) transgenes showed widespread endothelial β-gal staining, whereas the TKSXΔAAβ (D) and 
TKANβ (E) transgenic embryos were devoid of endothelial X-gal accumulation. In the latter embryos, only 
ectopic β-gal activity was observed. 
 
Identification of key regulatory motifs within the Gata2 minimal endothelium-
specific enhancer 
Regulatory elements are thought to diverge more slowly than sequences that surround 
them (Loots et al., 2000). Comparison of the mouse Gata2 460-bp endothelium-specific 
sequence to that of the human sequence demonstrated that a 355-bp region within the AA 
fragment displayed 92% sequence identity, as well as a nearby 58-bp region that harbored 
96% identity (data not shown). This extreme degree of evolutionary sequence 
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conservation strongly implies an associated functional significance. Analysis of the 460-
bp element using Matinspector 2.2 (Quandt et al., 1995), which uses the consensus 
transcription factor-binding motifs from the TRANSFAC database, identified a number 
of candidate regulatory molecules that might bind to this enhancer (Fig. 2.2A). A closer 
examination of this restriction fragment showed an unusual clustering of binding sites 
within a central 167-bp core region (as delineated by the two convergent arrows shown in 
Fig. 2.1A and Fig. 2.2A). Interestingly, the 3’ terminus of this region corresponded 
closely to the RsrII site that was identified previously as defining the 3’ functional 
boundary of endothelium-specific activity (Fig. 2.1A,B). 
The mouse 167-bp endothelium-specific fragment (called VE) bearing the highest 
human-mouse identity was cloned into TKβ to test its ability to recapitulate endothelial 
expression. Analysis of transgenic founders showed that TKVEβ was able to confer 
endothelial expression in a range of vascular tissue (14/17; Fig. 2.2B) that did not differ 
from the TKAAβ construct. Strikingly, however, none of these embryos (0/17) exhibited 
endocardium-specific β-gal staining (Fig. 2.2B, arrow). We surmise from these data, in 
conjunction with data presented earlier (Fig. 2.1), that the endothelium-specific activity is 
largely contained within the 290-bp AlwNI-RsrII fragment of Gata2 intron 4 and that the 
5’-most 155-bp of the AlwNI-RsrII fragment are required for Gata2 expression in the 
endocardium while the adjoining 3’ 167-bp can autonomously direct transgene 
expression in blood endothelia (Fig. 2.1A and Fig. 2.2A). Examination of the former 
sequences revealed the presence of consensus binding sites for the NFAT, Nkx2.5 (also 
known as Nkx2-5), SMAD, AP2 (also known as Tcfap2a) and MEF2C transcription 
factors, some of which have been shown previously to directly regulate endocardial 
enhancers and to be involved in regulating endocardial differentiation (Nemer and 
Nemer, 2002; Zhou et al., 2005). Whether or not these serve as bona fide binding motifs 
for any of these factors, and determination of the underlying mechanism via which they 
contribute to endocardial endothelial development, will require further investigation. 
To ascertain whether the 5’-most 155-bp fragment was sufficient for 
endocardium-specific reporter gene activation, we tested the AlwNI-NcoI fragment in the 
context of TKβ (Fig. 2.1A), and found that, of 11 recovered transgenic embryos, none 
displayed endocardial X-gal staining despite exhibiting variably ectopic X-gal staining 
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(Fig. 2.1A,E). We conclude that the 5’-most 155-bp of the endothelium-specific enhancer 
alone is incapable of independently directing Gata2 endocardium expression. 
The Ets family of transcription factors have been shown to play crucial roles in 
vascular development (Ayadi et al., 2001; Wang et al., 1997), and have also been 
reported to play prominent roles in endothelium-specific enhancer activity (Göttgens et 
al., 2002; Kappel et al., 2000). The existence of three ETS-binding sites within the 167-
bp Gata2 VE enhancer suggested that one or multiple Ets family members might 
modulate its activity. To directly address this hypothesis, the three ETS-binding sites 
were individually mutated from CGGA to CGcg, a mutation that was previously shown 
to eliminate ETS-factor binding (O'Reilly et al., 2003). Mutation of either two or all three 
ETS-binding sites reduced the overall number of embryos displaying weak, albeit 
endothelium-specific, staining (1/12 and 3/25, respectively; data not shown and Fig. 
2.2C). 
Next we determined whether the single E-box motif present in the 167-bp VE 
enhancer is important for its overall activity. A mutation (5’-CATCTG-3’ to 5’-CAcccG-
3’) that was previously shown to eliminate SCL binding (Kappel et al., 2000) was 
incorporated into the TKVEβ plasmid. Among the 24 recovered TKVEβmE-box 
transgenic embryos, none displayed endothelial β-gal staining (e.g. Fig. 2.2D). This lack 
of staining was presumably not due to the effect of the transgene integration site, because 
some of the transgenic embryos (9/24) exhibited ectopic staining in the spinal cord or 
head. These data demonstrate that the single Gata2 intron 4 E-box exerts a profound 
effect on the activity of the VE enhancer and, by extension, in the regulation of Gata2 
expression throughout the blood endothelium. 
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Figure 2.2 - Identification of a crucial E-box for Gata2 vascular endothelium enhancer activity. (A) 
Consensus binding motifs for candidate regulatory effectors within the evolutionarily conserved 460-bp 
AlwNI-ApaI endothelium-specific enhancer sequence are highlighted. The 167-bp minimal vascular 
endothelium-specific (VE) enhancer in TKVEβ (B) was generated using the PCR primer pairs indicated by 
the two convergent arrows. The italicized sequences correspond to the radiolabeled probe used for EMSA 
studies (see Fig. 2.3). (B) TKVEβ recapitulates widespread vascular (14/17), but not endocardial (0/17, 
arrow), endothelial lacZ expression in e10.5 transgenic embryos. (C) Simultaneous mutation of all three 
ETS1-binding consensus sites (A) in TKVEβmEts1,2,3 resulted in far fewer (3/25) transgenic embryos that 
displayed vascular endothelium-specific lacZ expression. (D) Disruption of the single SCL-binding site (A) 
in TKVEβmScl completely abrogated vascular endothelium-specific X-gal accumulation (0/24). (E-G) 
Transverse sections through the hearts of e10.5 embryos bearing TKSRβ (E; Fig. 2.1B), TKAAβ (F; Fig. 
2.1C) or TKVEβ (G; Fig. 2.2B) transgenes. Notice the conspicuous absence of X-gal staining in the 
endocardium of the ventricular chamber of the TKVEβ embryo. 
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An SCL-E12 heterodimer avidly binds to the E-box motif in the Gata2 VE enhancer 
 Because SCL had been shown previously to be essential for endothelial 
differentiation (Visvader et al., 1998), we wished to determine whether SCL could bind 
to the E-box in the VE fragment. To do so, we performed electrophoretic mobility shift 
assays (EMSAs) using nuclear extracts from 293T cells transfected with either SCL, or 
SCL plus E12, expression vectors. Incubation of radiolabeled E-box oligonucleotide 
probes with nuclear extracts containing SCL-E12, but not SCL alone, resulted in a low-
mobility complex (Fig. 2.3, lane 4), which could be specifically competed by the addition 
of an excess of unlabeled E-box oligonucleotide (Fig. 2.3, lanes 5,6), but not by mutant 
E-box oligonucleotide (Fig. 2.3, lanes 7,8). The binding specificity and protein identity 
were confirmed by showing that addition of an anti-SCL antibody (Fig. 2.3, lanes 9,10), 
but not control IgG (Fig. 2.3, lane 11), significantly reduced EMSA complex formation. 
Thus, the crucial E-box motif in the Gata2 VE enhancer can be strongly bound by the 
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Figure 2.3 - An SCL-E12 complex binds specifically to the Gata2 VE-enhancer E-box. No extract (lane 
1) or nuclear extracts from 293T cells, which were mock transfected (lane 2), transfected with SCL alone 
(lane 3) or with SCL plus E12 expression plasmids (lanes 4-11), were incubated with radiolabeled E-box 
oligonucleotide probe. To demonstrate binding specificity, unlabeled competitors (20- or 200-fold excess) 
containing wild-type (wt; lanes 5,6) or mutant (mut; lanes 7,8) E-box, anti-SCL antibody (1 or 3 µl; lanes 
9,10) or control mouse IgG (lane 11) were added to separate binding reactions. Formation of a lower-
mobility complex was observed only when both SCL and E12 were present in the extract and was 





 In summary, the data presented here delimit the boundaries of a functionally 
defined 460-bp Gata2 fourth intron endothelium-specific enhancer element that is 
capable of autonomously directing reporter gene expression in vivo in vascular and 
endocardial endothelial cells, thus precisely mimicking endogenous GATA-2 expression. 
Both ETS and E-box binding sites contribute to the potency of the VE enhancer, thus 
implicating Ets family member(s) and SCL as candidate regulatory effectors of Gata2 
vascular endothelial expression. 
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Identification of Gata2 pan-endothelium-specific enhancer 
 The existence of an endothelial enhancer for Gata2 raises several intriguing 
questions about its function. Earlier genetic data indicated that GATA-2 plays a crucial 
role in early hematopoietic development (Tsai et al., 1994) and is indeed capable of 
specifically marking hematopoietic stem cells (Suzuki et al., 2006). Given that the 
earliest hemangiogenic cells are closely related to the endothelial lineage (Choi et al., 
1998), one might speculate that this endothelial enhancer could also target a subset of 
hematopoietic cells that are generated from the aortic endothelium. Suggestively, we 
identified lacZ-positive cells that appear to be ‘budding’ from the aortic wall (data not 
shown). Whether these cells are bona fide hematopoietic cells or simply endothelial cells 
being sloughed into the aorta is yet to be determined (Khandekar et al., 2007). However, 
the existence of an endothelium-specific enhancer of Scl, which also marks hematopoietic 
progenitors (Göttgens et al., 2004), suggests that the Gata2 intron 4 enhancer identified 
here may play some role in the appropriate regulation of Gata2 in hematopoietic 
progenitors as well, particularly in light of the recent observation that this enhancer 
appears to be active in definitive erythroid cells (Grass et al., 2006) (see below). 
In the blood vasculature, the lack of any reported phenotype in Gata2–/– embryos 
led to the initial conclusion that functional redundancy of other GATA family members, 
including GATA-4 and GATA-6, may compensate for any lack of GATA-2 in the 
endothelium. Another equally plausible possibility is that Gata2 mutant embryos simply 
die too early (~e10) (Tsai et al., 1994) to generate a robust vascular phenotype. Based on 
the analysis of Gata3-lacZ knock-in mice, Gata3 expression in the endothelium does not 
appear to be widespread, but this closely related GATA family member does seem to be 
sporadically active (our unpublished data). Gata4, which plays a crucial role in heart 
development, does not appear to be expressed in mature endothelial cells (Umetani et al., 
2001), although it is expressed in endothelial progenitors (Hatzopoulos et al., 1998). 
Gata6 is expressed in both endothelial precursors as well as in mature endothelial cells 
(Hatzopoulos et al., 1998; Umetani et al., 2001), making GATA-6 a prime candidate for a 
possible Gata2-complementing endothelium activity. Whereas Gata4 and Gata6 
heterozygotes are normal, compound heterozygotes display cardiovascular defects (Xin et 
al., 2006). Notably, these embryos displayed a less intricate patterning, which was 
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disorganized, of the cranial and intersomitic vasculature, as well as hemorrhaging. The 
recent generation of a Gata6 conditional loss-of-function allele (Sodhi et al., 2006) 
should now permit exploration of cell autonomous GATA-6 involvement, if any, in 
endothelial development. 
 
Role of Ets family transcription factors in Gata2 endothelium-specific enhancer 
activity 
 Within an initial functionally defined restriction fragment describing the Gata2 
endothelial enhancer, we subsequently identified a 167-bp core enhancer that was 
sufficient to recapitulate vascular endothelial expression. The existence of three putative 
Ets family-member binding sites implicated a role for these factors in the control of this 
VE enhancer. The Ets family of transcription factors have been shown to play an 
important role in vascular development in vivo (Sumanas and Lin, 2006) and have been 
shown to be functionally important in the activation of a number of endothelial-specific 
enhancers, including Scl (Göttgens et al., 2004), Tie2 (also known as Tek) (Minami et al., 
2003) and Flk1 (also known as Kdr) (Elvert et al., 2003). Furthermore, disruption of Tel 
(also known as Etv6), an Ets family member, results in defective yolk sac angiogenesis 
(Wang et al., 1997), suggesting that TEL plays an important role in vascular remodeling. 
However, targeted mutation of other ETS factors has not revealed vascular deficiencies, 
suggesting that these factors may either play no role or may also be functionally 
redundant in endothelium development. 
In the Gata2 VE enhancer defined here, mutations predicted to disrupt ETS-
binding sites significantly attenuated enhancer activity, as indicated by the number of, 
and X-gal-staining intensity in, transgenic embryos displaying endothelial β-gal staining. 
However, the weak staining pattern detected in these embryos appeared to remain 
endothelium-specific, indicating that the ETS-binding sites are not essential for the tissue 
specificity of the enhancer, but rather may serve to augment its overall potency. Because 
this cis mutation has been shown in a similar assay to eliminate DNA binding for some 
members of the family (O'Reilly et al., 2003), we cannot rule out the possibility that the 
mutation does not abolish the binding of the multiple Ets family members that are 
expressed within the endothelium (Lelièvre et al., 2001). Additionally, the heterogeneity 
 65  
of ETS-binding sites suggests that some family members may be able to bind to other 
sequences within the enhancer, enabling endothelial activation despite mutations within 
canonical high affinity binding sites. 
 
An E-box binding factor is required for Gata2 endothelial enhancer activity 
 The transcription factor SCL has been shown to play crucial roles in both 
hematopoiesis (Shivdasani et al., 1995) and vascular development (Patterson et al., 2005; 
Visvader et al., 1998), leading to the speculation that SCL may be important for the 
ontogeny of the hemangioblast. A comprehensive analysis of the transcriptional 
regulation of Scl has identified several tissue specific enhancers that are required for its 
appropriate expression (Barton et al., 2001; Göttgens et al., 2002; Sinclair et al., 1999). 
Interestingly, the enhancer specific for hematopoietic progenitors has GATA sites that are 
crucial for Scl enhancer activity in vivo. The factor responsible for binding to these sites 
in hematopoietic cell lines appears to be GATA-2, suggesting that GATA-2 is 
responsible for activating Scl in early hematopoiesis. However, there is no GATA-
binding site in the endothelial enhancer of human SCL, although it remains possible that a 
GATA factor is acting without directly binding to DNA (Göttgens et al., 2004). The data 
presented here are consistent with the possibility that Gata2 and Scl encode reciprocally 
reinforcing activators in these developmentally related tissues, although other 
interpretations are clearly not excluded from the data presented. 
To assess the relationship between Scl and Gata2 in the endothelium, we mutated 
the single E-box present within the 167-bp Gata2 VE enhancer. Scl has previously been 
shown to be regulated by GATA factors in both the CNS (Sinclair et al., 1999) and 
hematopoietic progenitors (Göttgens et al., 2002), suggesting that the nature of the 
epistatic relationship between these two factors may be dependent on the specific tissue 
in question. However, these data also underscore the point that the functions of these two 
factors are often intimately intertwined during development. Lending further credence to 
this point is the evidence that Scl expression in the endothelium is crucially dependent on 
Ets-family activity (Göttgens et al., 2004). The endothelial enhancer of Scl contains five 
ETS-binding sites that are required for the activity of the enhancer in trans-activation 
assays. Given that both Scl and Gata2 appear to be regulated by ETS factors in the 
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endothelium, we surmise that ETS, SCL and GATA-2 together constitute a regulatory 
circuitry wherein, in the simplest scenario envisaged, ETS factors activate Scl, and ETS 
and SCL then cooperate to activate Gata2 in endothelial cells. Similarly, the data are also 
consistent with the possibility that Ets family members collaborate with GATA-2 to 
reinforce Scl expression in a positive feedback loop. 
The similarities between the regulation of Scl and Gata2 are also underscored by 
the similarity of their functions in the hematopoietic system. Targeted mutation of both 
genes results in defects in both primitive and definitive hematopoiesis, resulting in mid-
gestational lethality (Shivdasani et al., 1995; Tsai et al., 1994). This phenotypic similarity 
has not been demonstrated in the vascular system, where SCL has been shown to play a 
prominent role in vascular remodeling, whereas GATA-2 has not. However, because the 
vascular defects in Scl-null mutants were only revealed after selective rescue of 
hematopoiesis, it seems likely that the early lethality of Gata2-null mice precludes a more 
precise analysis of the function of GATA-2 in the vascular system. Experiments are 
underway to circumvent the embryonic hematopoietic lethality and explore possible 
functions of GATA-2 in the vasculature (Chapter 4).  
The presence of multiple GATA-binding motifs within the VE enhancer also 
raises the issue of whether this enhancer might be auto-regulated by GATA-2, or even by 
another GATA factor. Of specific interest here, Grass et al. recently identified this same 
element through its evolutionary sequence conservation during an analysis of GATA-1 
regulation of the Gata2 gene in erythroid cells (Grass et al., 2006). In that study, the 
authors demonstrated that sequences overlapping the VE element exhibited robust 
activity in transfected erythroid cells and that elimination of the GATA sites abrogated 
the erythroid enhancer activity. Here, we show that the VE element is at least equally as 
active and as specific for endothelial cells in a rigorous in vivo assay. Whether the 
activity identified by Grass et al. and the activity we defined here represents an 
endothelial-enhancer activity that can simply be surreptitiously activated in erythroid 
cells or whether the element represents one that can be a bona fide target for GATA-
factor activation in both hematopoietic and endothelial cells (as one might imagine for a 
hemangioblast-responsive element) awaits resolution following further investigation 
(Chapter 4). 




Melin Khandekar, a former graduate student in the lab, initiated this work.  He examined 
expression of Gata2 in the endothelium, and he refined the position of the element and 
analyzed its expression, including all of the founder analysis except for TKANβ, which 
was performed by Kim Chew-Lim.  Melin also performed all of the analysis of the 
conserved regions and putative regulatory elements.  I analyzed the endocardial sequence 
for potential binding partners, and analyzed the transverse sections through the 
endocardium of the founders.  I also performed the EMSA study, and helped write and 
prepare the manuscript and figures for publication. The whole article can be found in 




















 68  
Bibliography 
 
Ayadi, A., Zheng, H., Sobieszczuk, P., Buchwalter, G., Moerman, P., Alitalo, K. and 
Wasylyk, B. (2001). Net-targeted mutant mice develop a vascular phenotype and up-
regulate egr-1. EMBO J 20, 5139-52. 
 
Barton, L. M., Gottgens, B., Gering, M., Gilbert, J. G., Grafham, D., Rogers, J., 
Bentley, D., Patient, R. and Green, A. R. (2001). Regulation of the stem cell 
leukemia (SCL) gene: a tale of two fishes. Proc Natl Acad Sci USA 98, 6747-52. 
 
Briegel, K., Lim, K. C., Plank, C., Beug, H., Engel, J. D. and Zenke, M. (1993). 
Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests 
erythroid differentiation in a hormone-dependent manner. Genes Dev 7, 1097-109. 
 
Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. and Keller, G. (1998). A 
common precursor for hematopoietic and endothelial cells. Development 125, 725-32. 
 
Cowan, P. J., Tsang, D., Pedic, C. M., Abbott, L. R., Shinkel, T. A., d'Apice, A. J. 
and Pearse, M. J. (1998). The human ICAM-2 promoter is endothelial cell-specific 
in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem 
273, 11737-44. 
 
de Bruijn, M. F., Ma, X., Robin, C., Ottersbach, K., Sanchez, M. J. and Dzierzak, E. 
(2002). Hematopoietic stem cells localize to the endothelial cell layer in the 
midgestation mouse aorta. Immunity 16, 673-83. 
 
Dorfman, D. M., Wilson, D. B., Bruns, G. A. and Orkin, S. H. (1992). Human 
transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene 
expression in endothelial cells. J Biol Chem 267, 1279-85. 
 
Elvert, G., Kappel, A., Heidenreich, R., Englmeier, U., Lanz, S., Acker, T., Rauter, 
M., Plate, K., Sieweke, M., Breier, G. et al. (2003). Cooperative interaction of 
hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional 
activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278, 
7520-30. 
 
German, Z., Chambliss, K. L., Pace, M. C., Arnet, U. A., Lowenstein, C. J. and 
Shaul, P. W. (2000). Molecular basis of cell-specific endothelial nitric-oxide 
synthase expression in airway epithelium. J Biol Chem 275, 8183-9. 
 
Göttgens, B., Broccardo, C., Sanchez, M. J., Deveaux, S., Murphy, G., Göthert, J. 
R., Kotsopoulou, E., Kinston, S., Delaney, L., Piltz, S. et al. (2004). The scl +18/19 
stem cell enhancer is not required for hematopoiesis: identification of a 5' 
bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell 
Biol 24, 1870-83. 
 69  
 
Göttgens, B., Nastos, A., Kinston, S., Piltz, S., Delabesse, E. C., Stanley, M., Sanchez, 
M. J., Ciau-Uitz, A., Patient, R. and Green, A. R. (2002). Establishing the 
transcriptional programme for blood: the SCL stem cell enhancer is regulated by a 
multiprotein complex containing Ets and GATA factors. EMBO J 21, 3039-50. 
 
Grass, J. A., Jing, H., Kim, S. I., Martowicz, M. L., Pal, S., Blobel, G. A. and 
Bresnick, E. H. (2006). Distinct functions of dispersed GATA factor complexes at an 
endogenous gene locus. Mol Cell Biol 26, 7056-67. 
 
Gumina, R. J., Kirschbaum, N. E., Piotrowski, K. and Newman, P. J. (1997). 
Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: 
identification of a GATA-2 binding element required for optimal transcriptional 
activity. Blood 89, 1260-9. 
 
Hatzopoulos, A. K., Folkman, J., Vasile, E., Eiselen, G. K. and Rosenberg, R. D. 
(1998). Isolation and characterization of endothelial progenitor cells from mouse 
embryos. Development 125, 1457-68. 
 
Kappel, A., Schlaeger, T. M., Flamme, I., Orkin, S. H., Risau, W. and Breier, G. 
(2000). Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the 
regulation of flk-1 expression during murine vascular development. Blood 96, 3078-
85. 
 
Khandekar, M., Brandt, W., Zhou, Y., Dagenais, S., Glover, T. W., Suzuki, N., 
Shimizu, R., Yamamoto, M., Lim, K. C. and Engel, J. D. (2007). A Gata2 intronic 
enhancer confers its pan-endothelia-specific regulation. Development 134, 1703-12. 
 
Khandekar, M., Suzuki, N., Lewton, J., Yamamoto, M. and Engel, J. D. (2004). 
Multiple, distant Gata2 enhancers specify temporally and tissue-specific patterning in 
the developing urogenital system. Mol Cell Biol 24, 10263-76. 
 
Kitajima, K., Masuhara, M., Era, T., Enver, T. and Nakano, T. (2002). GATA-2 and 
GATA-2/ER display opposing activities in the development and differentiation of 
blood progenitors. EMBO J 21, 3060-9. 
 
Lazrak, M., Deleuze, V., Noel, D., Haouzi, D., Chalhoub, E., Dohet, C., Robbins, I. 
and Mathieu, D. (2004). The bHLH TAL-1/SCL regulates endothelial cell migration 
and morphogenesis. J Cell Sci 117, 1161-71. 
 
Lelièvre, E., Lionneton, F., Soncin, F. and Vandenbunder, B. (2001). The Ets family 
contains transcriptional activators and repressors involved in angiogenesis. Int J 
Biochem Cell Biol 33, 391-407. 
 
 70  
Liao, E. C., Paw, B. H., Oates, A. C., Pratt, S. J., Postlethwait, J. H. and Zon, L. I. 
(1998). SCL/Tal-1 transcription factor acts downstream of cloche to specify 
hematopoietic and vascular progenitors in zebrafish. Genes Dev 12, 621-6. 
 
 
Loots, G. G., Locksley, R. M., Blankespoor, C. M., Wang, Z. E., Miller, W., Rubin, 
E. M. and Frazer, K. A. (2000). Identification of a coordinate regulator of 
interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288, 136-
40. 
 
Minami, T., Kuivenhoven, J. A., Evans, V., Kodama, T., Rosenberg, R. D. and Aird, 
W. C. (2003). Ets motifs are necessary for endothelial cell-specific expression of a 
723-bp Tie-2 promoter/enhancer in Hprt targeted transgenic mice. Arterioscler 
Thromb Vasc Biol 23, 2041-7. 
 
Minami, T., Murakami, T., Horiuchi, K., Miura, M., Noguchi, T., Miyazaki, J., 
Hamakubo, T., Aird, W. C. and Kodama, T. (2004). Interaction between hex and 
GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated 
vascular endothelial growth factor signaling. J Biol Chem 279, 20626-35. 
 
Molkentin, J. D. (2000). The zinc finger-containing transcription factors GATA-4, -5, 
and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol 
Chem 275, 38949-52. 
 
Molkentin, J. D., Lin, Q., Duncan, S. A. and Olson, E. N. (1997). Requirement of the 
transcription factor GATA4 for heart tube formation and ventral morphogenesis. 
Genes Dev 11, 1061-72. 
 
Molkentin, J. D., Tymitz, K. M., Richardson, J. A. and Olson, E. N. (2000). 
Abnormalities of the genitourinary tract in female mice lacking GATA5. Mol Cell 
Biol 20, 5256-60. 
 
Morrisey, E. E., Tang, Z., Sigrist, K., Lu, M. M., Jiang, F., Ip, H. S. and Parmacek, 
M. S. (1998). GATA6 regulates HNF4 and is required for differentiation of visceral 
endoderm in the mouse embryo. Genes Dev 12, 3579-90. 
 
Murray. (1932). The development in vitro of blood of early chick embryo. Proc R Soc 
London Biol Sci 111, 497-521. 
 
Nemer, G. and Nemer, M. (2002). Cooperative interaction between GATA5 and NF-
ATc regulates endothelial-endocardial differentiation of cardiogenic cells. 
Development 129, 4045-55. 
 
O'Reilly, D., Quinn, C. M., El-Shanawany, T., Gordon, S. and Greaves, D. R. (2003). 
Multiple Ets factors and interferon regulatory factor-4 modulate CD68 expression in a 
cell type-specific manner. J Biol Chem 278, 21909-19. 
 71  
 
Pandolfi, P. P., Roth, M. E., Karis, A., Leonard, M. W., Dzierzak, E., Grosveld, F. 
G., Engel, J. D. and Lindenbaum, M. H. (1995). Targeted disruption of the GATA3 
gene causes severe abnormalities in the nervous system and in fetal liver 
haematopoiesis. Nat Genet 11, 40-4. 
 
Pardanaud, L., Altmann, C., Kitos, P., Dieterlen-Lievre, F. and Buck, C. A. (1987). 
Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody 
recognizing endothelial cells. Development 100, 339-49. 
 
Pardanaud, L., Luton, D., Prigent, M., Bourcheix, L. M., Catala, M. and Dieterlen-
Lievre, F. (1996). Two distinct endothelial lineages in ontogeny, one of them related 
to hemopoiesis. Development 122, 1363-71. 
 
Patterson, L. J., Gering, M. and Patient, R. (2005). Scl is required for dorsal aorta as 
well as blood formation in zebrafish embryos. Blood 105, 3502-11. 
 
Pevny, L., Lin, C. S., D'Agati, V., Simon, M. C., Orkin, S. H. and Costantini, F. 
(1995). Development of hematopoietic cells lacking transcription factor GATA-1. 
Development 121, 163-72. 
 
Quandt, K., Frech, K., Karas, H., Wingender, E. and Werner, T. (1995). MatInd and 
MatInspector: new fast and versatile tools for detection of consensus matches in 
nucleotide sequence data. Nucleic Acids Res 23, 4878-84. 
 
Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-4. 
 
Robb, L., Lyons, I., Li, R., Hartley, L., Köntgen, F., Harvey, R. P., Metcalf, D. and 
Begley, C. G. (1995). Absence of yolk sac hematopoiesis from mice with a targeted 
disruption of the scl gene. Proc Natl Acad Sci USA 92, 7075-9. 
 
Rodriguez, P., Bonte, E., Krijgsveld, J., Kolodziej, K. E., Guyot, B., Heck, A. J., 
Vyas, P., de Boer, E., Grosveld, F. and Strouboulis, J. (2005). GATA-1 forms 
distinct activating and repressive complexes in erythroid cells. EMBO J 24, 2354-66. 
 
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, 
M. L. and Schuh, A. C. (1995). Failure of blood-island formation and 
vasculogenesis in Flk-1-deficient mice. Nature 376, 62-6. 
 
Shivdasani, R. A., Mayer, E. L. and Orkin, S. H. (1995). Absence of blood formation 
in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373, 432-4. 
 
Sinclair, A. M., Göttgens, B., Barton, L. M., Stanley, M. L., Pardanaud, L., Klaine, 
M., Gering, M., Bahn, S., Sanchez, M., Bench, A. J. et al. (1999). Distinct 5' SCL 
enhancers direct transcription to developing brain, spinal cord, and endothelium: 
neural expression is mediated by GATA factor binding sites. Dev Biol 209, 128-42. 
 72  
 
Sodhi, C., Li, J. and Duncan, S. (2006). Generation of mice harbouring a conditional 
loss-of-function allele of Gata6. BMC Dev Biol 6, 19. 
 
 
Stainier, D. Y., Weinstein, B. M., Detrich, H. W., Zon, L. I. and Fishman, M. C. 
(1995). Cloche, an early acting zebrafish gene, is required by both the endothelial and 
hematopoietic lineages. Development 121, 3141-50. 
 
Sumanas, S. and Lin, S. (2006). Ets1-related protein is a key regulator of vasculogenesis 
in zebrafish. Plos Biol 4, e10. 
 
Suzuki, N., Ohneda, O., Minegishi, N., Nishikawa, M., Ohta, T., Takahashi, S., 
Engel, J. D. and Yamamoto, M. (2006). Combinatorial Gata2 and Sca1 expression 
defines hematopoietic stem cells in the bone marrow niche. Proc Natl Acad Sci USA 
103, 2202-7. 
 
Tanimoto, K., Liu, Q., Grosveld, F., Bungert, J. and Engel, J. D. (2000). Context-
dependent EKLF responsiveness defines the developmental specificity of the human 
epsilon-globin gene in erythroid cells of YAC transgenic mice. Genes Dev 14, 2778-
94. 
 
Tsai, F. Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F. W. 
and Orkin, S. H. (1994). An early haematopoietic defect in mice lacking the 
transcription factor GATA-2. Nature 371, 221-6. 
 
Tsai, F. Y. and Orkin, S. H. (1997). Transcription factor GATA-2 is required for 
proliferation/survival of early hematopoietic cells and mast cell formation, but not for 
erythroid and myeloid terminal differentiation. Blood 89, 3636-43. 
 
Umetani, M., Mataki, C., Minegishi, N., Yamamoto, M., Hamakubo, T. and 
Kodama, T. (2001). Function of GATA transcription factors in induction of 
endothelial vascular cell adhesion molecule-1 by tumor necrosis factor-alpha. 
Arterioscler Thromb Vasc Biol 21, 917-22. 
 
Visvader, J. E., Fujiwara, Y. and Orkin, S. H. (1998). Unsuspected role for the T-cell 
leukemia protein SCL/tal-1 in vascular development. Genes Dev 12, 473-9. 
 
Vogeli, K. M., Jin, S. W., Martin, G. R. and Stainier, D. Y. (2006). A common 
progenitor for haematopoietic and endothelial lineages in the zebrafish gastrula. 
Nature 443, 337-9. 
 
Wang, L. C., Kuo, F., Fujiwara, Y., Gilliland, D. G., Golub, T. R. and Orkin, S. H. 
(1997). Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the 
Ets-related factor TEL. EMBO J 16, 4374-83. 
 
 73  
Warren, A. J., Colledge, W. H., Carlton, M. B., Evans, M. J., Smith, A. J. and 
Rabbitts, T. H. (1994). The oncogenic cysteine-rich LIM domain protein rbtn2 is 
essential for erythroid development. Cell 78, 45-57. 
 
Xin, M., Davis, C. A., Molkentin, J. D., Lien, C. L., Duncan, S., Richardson, J. A. 
and Olson, E. N. (2006). A threshold of GATA4 and GATA6 expression is required 
for cardiovascular development. Proc Natl Acad Sci USA 103, 11189-94. 
 
Yamada, Y., Pannell, R., Forster, A. and Rabbitts, T. H. (2000). The oncogenic LIM-
only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. 
Proc Natl Acad Sci USA 97, 320-4. 
 
Yamamoto, M., Ko, L. J., Leonard, M. W., Beug, H., Orkin, S. H. and Engel, J. D. 
(1990). Activity and tissue-specific expression of the transcription factor NF-E1 
multigene family. Genes Dev 4, 1650-62. 
 
Yamashita, K., Discher, D. J., Hu, J., Bishopric, N. H. and Webster, K. A. (2001). 
Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-
inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276, 
12645-53. 
 
Zhou, B., Wu, B., Tompkins, K. L., Boyer, K. L., Grindley, J. C. and Baldwin, H. S. 
(2005). Characterization of Nfatc1 regulation identifies an enhancer required for gene 
expression that is specific to pro-valve endocardial cells in the developing heart. 
Development 132, 1137-46. 
 
Zhou, Y., Lim, K. C., Onodera, K., Takahashi, S., Ohta, J., Minegishi, N., Tsai, F. 
Y., Orkin, S. H., Yamamoto, M. and Engel, J. D. (1998). Rescue of the embryonic 
lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital 












Defining the Functional Boundaries of the Gata2 Locus by Rescue with a Linked 




The transcription factor GATA-2 is exemplary of a vital developmental factor 
whose regulation reveals many of the intricacies of the controlling apparatus that is 
required for proper temporal and tissue-specific expression of a gene in many different 
tissues and organs that are critical for mammalian development. The evolutionarily 
conserved C4 zinc finger GATA transcription factors play demonstrably crucial roles in 
embryogenesis. GATA-2, originally cloned from a chicken cDNA library (Yamamoto et 
al., 1990), was shown to be essential for the proliferation and/or differentiation of early 
hematopoietic progenitors, as Gata2 null mutant mice die around mid-gestation from a 
block in primitive hematopoiesis (Tsai et al., 1994). Further examination of Gata2 gain-
of-function mice and in vitro differentiation of Gata2 null mutant ES cells underscored 
the fundamental conclusions from the initial loss of function experiments, and showed 
that GATA-2 plays a pivotal role in the proliferation of very early hematopoietic 
progenitors (Briegel et al., 1993; Kitajima et al., 2002; Tsai and Orkin, 1997). 
We showed several years ago that Gata2 null mutant embryonic lethality could be 
rescued by complementation with a 247 kilobase pair (kbp) transgenic yeast artificial 
chromosome (YAC) bearing sequences from -174 to +73 kbp (revised endpoints relative 
to the Gata2 translational initiation site); the YAC contains all of the regulatory 
information required to rescue Gata2 function in primitive and definitive hematopoiesis 
(Zhou et al., 1998). We subsequently found that Gata2 hematopoietic regulatory activity 
is conferred by at least two distinct cooperative cis elements, one lying about 170 kbp 5’ 
to the gene and another lying somewhere between 40 and 100 kbp 5’ (Suwabe and Engel, 
unpublished observations). However, compound mutant mice bearing this YAC, but 
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lacking endogenous Gata2, expired perinatally of kidney failure and uretero-vesicular 
obstruction, because the YAC-rescued Gata2 null mutant mice failed to develop a patent 
connection between the ureters and the bladder, causing the mice to develop cystic, non-
functional kidneys and megaureters (Zhou et al., 1998). Because the rescuing YAC was 
not expressed in the urogenital system, while endogenous GATA-2 is prominently 
expressed there, we speculated that the development of hydroureters and cystic kidneys 
was due to the absence of tissue-specific enhancers that were responsible for directing 
proper Gata2-mediated patterning of the developing urogenital system in the YAC 
transgene. 
Several years ago, we devised a BAC transgenic founder mapping strategy (BAC-
traps) that ultimately revealed the positions of the regulatory elements that control Gata2 
expression in the developing urogenital system (Khandekar et al., 2004). One cis element, 
responsible for Gata2 activation in the ureteric epithelium, was not specifically localized, 
but was predicted to lie very far, either upstream or downstream, from the structural gene. 
However, two enhancers that were finely localized are responsible for mesenchymal 
expression: one (UG2, located +113 kbp 3’ to the translational initiation site) controls 
Gata2 activation in the rostral metanephric mesenchyme, whereas a second (UG4, 
centered at +75 kbp) is responsible for Gata2 activation in the caudal periureteric 
mesenchyme and urogenital sinus. 
We have now regionally or precisely localized about a dozen individual cis 
elements that are required for Gata2 expression, including two hematopoietic (Zhou et 
al., 1998), two central nervous system (Zhou et al., 2000), one endothelial (Khandekar et 
al., 2007), and three urogenital enhancers (Khandekar et al., 2004), as well as the two 
Gata2 promoters (Minegishi et al., 1998); these individual elements are scattered over 
400 kbp 5’ and 3’ to (as well as within) the Gata2 structural gene. However, dozens of 
other elements must deductively exist, because Gata2 is involved in many other quite 
diverse organotypic developmental events (e.g. for the generation of placental 
trophoblasts, fat, and pituitary subtype specification (Dasen et al., 1999; Ma et al., 1997; 
Tong et al., 2000)), and indeed, our initial BAC-trap surveys demonstrated that other 
Gata2 enhancers lie even further away (e.g. a whisker follicle enhancer that maps to 
between +560 and +787 kbp 3’ to Gata2 (Khandekar et al., 2004)). 
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To determine whether the Gata2 urogenital enhancers that were identified in the 
initial BAC-trap survey defined the required functional domains of gene activity that are 
responsible for proper ureter/bladder morphogenesis, in this study we created a transgene 
that would recapitulate the expression of Gata2 in both the hematopoietic as well as the 
urogenital compartments. Although YACs have been generated that contain genomic 
inserts of the size required, numerous technical problems with YACs have also come to 
light, including chimerism (Larionov et al., 1994; Zhou et al., 1998) and innate 
replicative instability (Kouprina et al., 1999). BACs, while surmounting many of the 
problems encountered with YACs, posed a different problem, because the average 
genomic DNA insert size in BACs is only ~200 kbp (Osoegawa et al., 2000), which is 
insufficient in this case to span the interval between the most distant Gata2 hematopoietic 
(-170 kbp) and urogenital (+113 kbp) enhancers. 
To circumvent the size limitation of BACs, we devised a new general strategy to 
precisely link two BACs together to generate a single recombinant that contained a very 
large but stable genomic DNA fragment. Generation of mice bearing this BAC were 
predicted to create a transgene spanning the entire interval between the distant enhancer 
elements that were either known (hematopoietic) or suspected (urogenital) of being 
required for Gata2 function. Following breeding between Gata2 BAC transgenic mice 
and Gata2 germ line null mutant mice, we were able to formally test whether 
complementation of both the hematopoietic and urogenital functions would fully rescue 
Gata2 null mutants. Alternatively, complementation with the linked BAC might only 
partially rescue, and thereby reveal novel Gata2 mutant phenotypes due to as yet 
undiscovered enhancers that lie beyond the boundaries of the linked BAC. 
The present experiment revealed that rescue of the Gata2 null mutant phenotype 
with a 413-kbp linked BAC was complete using either of two independent rescuing BAC 
transgenic lines. Both lines allowed animals to survive to adulthood, and the rescued 
mice exhibited no obvious behavioral or reproductive anomalies. Therefore, we can place 
outer boundaries on the size of the Gata2 locus, including all sequences that are required 
to fulfill its most vital developmental functions. These data suggest that documented 
enhancers that lie outside these boundaries are either unnecessary for vital GATA-2-
mediated physiological functions in some tissues where that factor is expressed, or that 
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those functions are fully complemented by other molecules. 
 
Materials and Methods 
 
Bacterial Artificial Chromosomes 
BACs spanning the mouse Gata2 locus were identified (Osoegawa et al., 2000), 
purified (Marra et al., 1997), and modified (Khandekar et al., 2004) as previously 
described. 
 
Construction of Specialized Recombineering Plasmids 
plox514Neo: Two loxP514 sites (Siegel et al., 2001) with convenient cloning sites 
were created. lox514nx oligonucleotides (Table 3.1) were annealed and digested with 
NotI and XbaI and then cloned into the EagI and SpeI sites of the pFrtNeo plasmid. The 
resulting plasmid was digested with PstI and EcoRI and ligated to annealed lox514pm 
oligonucleotides (Table 3.1), which had been digested with NsiI and MfeI. The resulting 
plasmid, plox514Neo, was verified by sequencing and then used as a template for the 
generation of the BAC targeting constructs. pFrtAmp: to generate a plasmid containing 
the Frt-flanked ampicillin gene, we used Famp oligonucleotides (Table 3.1) containing 
Frt sites, sequences complementary to the pUC19AmpR gene and convenient cloning 
sites. Using these primers, the AmpR gene was amplified from pUC19 by PCR, gel-
purified, and digested with BamH1 and EcoR1. This fragment was cloned into the 
BamH1/EcoR1 sites of pIRES2-eGFP vector (Clontech). The fragment was sequenced to 
verify correct generation of the flanking Frt sites. Tn5FlpeTet: a plasmid that 
constitutively expresses Flp recombinase was generated in a manner similar to that 
described by Liu et al. (Liu et al., 2003). 
 
Generation of Targeting Constructs by PCR 
To generate the bacterial targeting constructs, synthetic oligonucleotides were 
used as outlined in previous experiments (Lee et al., 2001). Targeting fragments were 
generated by PCR with ExTaq (Takara), purified from agarose using GenecleanII (Q-
biogene), and digested with DpnI to remove (methylated) template DNA. 100–200 ng of 
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targeting fragment was used in each experiment. To generate single lox sites, the same 
primers (Table 3.1) were used to amplify a targeting fragment containing tandem lox 
sites. After insertion of this fragment into the BAC by homologous recombination, 
induction of cre recombinase resulted in deletion of the intervening selection marker, 
leaving a single loxP site incorporated at the point of selectable marker insertion. 
 
cre Recombinase Induction 
The EL350 strain was used for cre recombinase induction, as previously described 
(Khandekar et al., 2004). Because the frequency of recombination between loxP and 
loxP511 or loxP514 sites is finite, varying the duration of cre induction was used to 
optimize recovery of the desired homologous recombination product. 
 
Modification of Parental BACs 115E9 and 81F7 
To generate the 5’ BAC, homologous recombination was used to insert a loxP514 
site ~13 kbp upstream of the Gata2 translational initiation site. Simultaneously, this 
insertion was designed to delete a loxP site in the pBACe3.6 vector backbone by 
directing the 3’ homologous recombination to position 4862 of the vector sequence 
(Frengen et al., 1999). The primers (-13lox514(f) and bacdellox(r); Table 3.1) and the 
template plasmid plox514Neo were used for PCR to generate a targeting fragment, which 
was then used to modify the 115E9 BAC by homologous recombination. The neomycin 
gene that was used as the positive selection marker was removed by cre induction, 
leaving a single loxP514 site at -13 kbp, and at the same time deleting the loxP site in the 
vector backbone. The resulting BAC was further modified to include an Frt-flanked 
PGK-directed neomycin resistance gene for positive selection. BacNeo primers (Table 
3.1) were used to generate a targeting fragment by PCR using the pFrtNeo plasmid as 
template. The resulting fragment was then inserted into the 115E9lox BAC by 
homologous recombination. 
To generate the 3’ BAC, a loxP514 site was again inserted 13 kbp upstream of the 
Gata2 translational start site, at the same position that was modified in BAC 115E9. The 
-13lox514 forward and reverse primers (Table 3.1) and the ploxP514 plasmid were used 
to generate a fragment that was subsequently inserted into the 81F7 BAC by homologous 
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recombination. The neomycin gene was again removed by cre induction, leaving a single 
loxP514 site at the -13 kbp position. This BAC was further modified to insert an Frt-
flanked ampicillin resistance gene to allow for selection of products that had undergone 
intermolecular recombination. This was achieved by using Famp2977 and Famp4233 
primers (Table 3.1) together with the FrtAmp plasmid to generate a targeting fragment 
that was then inserted into 81F7lox BAC by homologous recombination, and in doing so, 
inserted the FrtAmp cassette between positions 2977 and 4233 of the pBACe3.6 vector 
backbone (Frengen et al., 1999). 
 
cre-mediated BAC Recombination 
To join the two modified BACs, Escherichia coli EL350 bearing the 
115E9loxNeo BAC was grown in overnight culture. After diluting the culture 1:10 and 
allowing it to grow for 10 min, arabinose was added to 1 mg/ml before growing the 
culture for an additional 2 h. The cells were made competent for transformation 
(Khandekar et al., 2004) and then electroporated with the 81F7loxAmp BAC; 
recombinants were selected on Cam/Kan/Amp plates. Homologous recombination was 
verified by HindIII fingerprinting, as well as by P1-SceI digestion and pulsed field gel 
electrophoresis under the conditions: 6 V/cm, linear ramp switch time (10–50 s) 24 h at 
14 °C (Fig. 3.1B). 
 
Verification of Homologous Recombination 
To verify recovery of the correct recombination products by Southern blot 
analyses, three probes from different regions of the recombined BAC were employed. A 
5’ Nco/Spe probe fragment corresponding to -173.9 kbp of the Gata2 locus, which was 
predicted to yield a restriction fragment of 3.9-kbp only from the parental 115E9 BAC 
and the recombinants, was hybridized to HindIII-digested BAC DNAs (Fig. 3.1D). To 
generate a -13 kbp probe, a 600-bp fragment was generated by PCR from the 81F7 BAC 
using the G2–13 primers (Table 3.1). Using this probe and digesting the BACs with PmeI 
and PvuI was predicted to yield a 5-kbp restriction fragment in the case of the 115E9 
parental BAC, or a 10-kbp fragment after appropriate recombination at the loxP514 site 
(Fig. 3.1E). For the 3’ probe, a 900-bp fragment corresponding to a position +200 kbp 
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(relative to the Gata2 translational initiation site) was generated by PCR from the 81F7 
BAC using G2 +200 primers (Table 3.1). Digestion with HindIII followed by 
hybridization with this probe was predicted to yield a 7-kbp band from the 81F7 parental 
BAC as well as the homologous recombinants but not hybridize to the 115E9 BAC (Fig. 
3.1F). 
 
Flp-mediated Removal of the Neomycin Selection Cassette 
Because the neomycin resistance gene carries a eukaryotic promoter, it was 
removed from the linked BAC to avoid possible promoter interference effects. To 
accomplish this, the Tn5FlpeTet plasmid was transformed into bacteria carrying the 
linked BAC (Fig. 3.1A, R), which were then grown on plates containing 
Cam/Kan/Amp/Tet. The Tn5FlpeTet plasmid constitutively expresses Flp recombinase, 
which catalyzed excision of the Neo gene. To subsequently eliminate this plasmid from 
the bacteria bearing the linked BAC, we used nickel ion-based counterselection, because 
bacteria that are tetracycline-resistant are sensitive to nickel death (Podolsky 1996). We 
reasoned that growth in L-broth containing NiSO4 would select for the rare bacteria that 
had lost the Tn5FlpeTet plasmid during cell division. Cam/Kan/Amp/Tet colonies were 
grown in 5 ml of L-broth plus Cam for 3 h, at which time NiSO4 was added to 5 mM. The 
cultures were grown until turbid and then streaked onto Tet/Cam, Kan/Cam/Amp, and 
Cam plates. Cultures that showed slower growth on Tet/Cam and Kan/Cam/Amp plates 
versus Cam plates were replica-spotted onto Cam and Kan/Cam plates to verify loss of 
neomycin resistance. Miniprep DNA from the resulting CamR/KanS clones was verified 
by HindIII restriction digest, pulsed field gel electrophoresis, and Southern blot analyses 
as described above. 
 
Transgenic and Knock-out Mice 
BACs were purified by double banding on CsCl/EtBr gradients and then the 
purified supercoiled DNA was microinjected into oocytes as previously described 
(Khandekar et al., 2004). The Gata2 EII-KI mice have been previously described (Suzuki 




Embryos were harvested and prepared as previously described (Khandekar et al., 
2004). Purified rat anti-chicken GATA-2 monoclonal antibody, RC1.1 (1:10) (Zhou et 
al., 1998), which is cross-reactive with murine GATA-2, was added along with an anti-
green fluorescent protein (anti-GFP) antibody (Molecular Probes, A11122, 1:2000) to the 
embryo sections, which were then incubated overnight at 4°C. The next day the RC1.1 
antibody was detected using a Cy3-conjugated goat anti-rat secondary antibody (Zymed 
Laboratories Inc.), whereas the anti-GFP antibody was detected using Alexa488-
conjugated goat anti-rabbit secondary antibody (Molecular Probes). Both secondary 
antibodies were incubated at 1:200 for 1 h. Finally the sections were treated with 4’,6-
diamidino-2-phenylindole (DAPI) and ProLong Gold antifade reagent (Invitrogen). 






In this strategy, we first identified two overlapping BACs, which together 
encompass the complete structural gene as well as the regulatory domains required for 
Gata2 hematopoietic and urogenital expression (Khandekar et al., 2004; Zhou et al., 
1998), from BAC library RPMI-23. The selected parental BACs, 115E9 (P1) and 81F7 
(P2), bear genomic sequences from -187 to -10 kbp and from -34 to +226 kbp of the 
Gata2 locus, respectively (Fig. 3.1A). To fuse the two BACs precisely in register, we 
employed cre-mediated homologous recombination to exploit the documented differential 
recombination efficiency between homologous versus heterologous loxP sequences 
(Hoess et al., 1986). A single loxP514 site (Fig. 3.1A, yellow arrow), which is distinct 
from the loxP511 sites (Fig. 3.1A, green arrows) in the pBACe3.6 vector backbone 
(Frengen et al., 1999), was inserted at -13 kbp (relative to the Gata2 start codon) of the 
Gata2 locus in both BACs, P1 and P2. Next, Frt-flanked antibiotic resistance markers 
(neomycin or ampicillin) were introduced at the 5’ end of P1 or at the 3’ end of P2, 
respectively, to facilitate drug selection of intermolecular recombinants. The 
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electroporation of P1 into P2-harboring bacteria, in conjunction with cre recombinase 
induction in the E. coli EL350 strain, led to simultaneous loxP514/514 and loxP511/511 
homologous recombination in trans (Fig. 3.1A, gray bars) and the insertion of Gata2 
genomic DNA from P1 into P2, thus generating the 413-kbp (from -187 to +226 kbp of 
the Gata2 locus) recombinant BAC (Fig. 3.1A, R). After Flp-mediated deletion of the Frt-
flanked positive selection markers from this recombinant, the structural integrity of the 
resultant linked BAC (referred to hereafter as G2BAC) was confirmed by pulsed field gel 
electrophoresis (Fig. 3.1B), restriction digest fingerprinting (Fig. 3.1C), and Southern 
blotting analyses using three radiolabeled probes dispersed throughout the Gata2 locus 
(Fig. 3.1A, the positions of the probes are indicated as D, E, and F). Hence, we 













Figure 3.1 - Cre-mediated generation of a 413-kbp linked BAC. (A) A strategy was devised for 
recombining two overlapping parental BACs so that the combination of urogenital and hematopoietic 
enhancers could be examined as a single transgene. The relative positions of the Gata2 structural gene 
(hatched box) and the enhancers known to be critical for hematopoietic (red ovals) or urogenital (purple 
ovals) development are indicated. Site-specific cre-mediated recombination was employed to fuse the two 
parental BACs, 115E9 (P1) and 81F7 (P2), by simultaneous intermolecular homologous recombination 
between loxP514 (yellow arrowheads) and loxP511 (green arrowheads) sites. The strategy was predicted 
to generate a 413-kbp BAC bearing contiguous sequence from -187 to +226 kbp surrounding the Gata2 
gene (G2BAC, right). The neomycin-positive selection marker was subsequently removed by Flp-mediated 
recombination between Frt sites (blue arrowheads). (B) Pulsed-field gel electrophoresis of the two parental 
(P1 and P2) BACs as well as a recombinant-linked BAC (R). The BACs were digested with PI-SceI; 
molecular weight markers (M) are λ DNA concatemers. (C) HindIII restriction digest DNA fingerprinting 
shows that all of the recombinants (R1–R7) contain all of the bands within both parental BACs (P1 and 
P2). Molecular weight markers (M) for panels D-F are a mixture of HindIII- or BstEII-digested λ DNA 
samples. (D-F) Southern blot analysis of the parental (P1 and P2) and linked recombinant (R1–R4) BACs 
display the anticipated sizes. (D) Probe D, located at -174 kbp (see panel A), hybridizes to a 3.9-kbp 
HindIII fragment from P1 (that is not detected in P2) and all recombinant BACs. (E) Hybridization to probe 
E, located at -13 kbp, generates a 5-kbp band in P1 as well as a 10-kbp band in P2 and all of the 
recombinant BACs after digestion with PmeI+PvuII. (F) Probe F, located at approximately +200 kbp, 
hybridizes to a 7-kbp HindIII fragment from P2 and the recombinant BACs, while no hybridization is 




Linked BAC Transgenic Mice 
Due to fragmentation problems encountered when very large linear or nicked 
circular BAC DNAs are used for microinjection (Khandekar and Engel, unpublished 
observations), we injected supercoiled DNA into fertilized mouse ova. Founder animals 
were genotyped using PCR primers (Table 3.1) located at the junction between the BAC 
vector and the most 5’ end of the Gata2 genomic DNA insert at -187 kbp, at the loxP514 
insertion site situated at -13 kbp of the Gata2 locus, and in the chloramphenicol 
acetyltransferase gene. Fourteen founders were verified to be transgenic by Southern blot 
analyses of tail DNA (data not shown). Of these, at least two appeared to contain 
complete transgenes that were transmitted stably to progeny for multiple generations 
(below), so these two lines were investigated further. 
To simultaneously quantify the BAC copy number and roughly assess the 
integrity of the transgenes, we employed a quantitative PCR (Q-PCR) strategy. After 
breeding the lines for several generations to ensure that no further segregation of 
unlinked transgenes occurred, DNA was prepared from the tails of several transgenic 
littermates of each line. Q-PCR was performed on these DNA samples in triplicate using 
Sybr green (Applied Biosystems). PCR primer pairs were designed (Table 3.1) to amplify 
Gata2 genomic sequences at ~50-kbp intervals throughout the length of the linked 
G2BAC. Gata2 genomic sequences lying immediately beyond the boundaries of the 
G2BAC (at approximate positions corresponding to -230 and +270 kbp) as well as the β-
actin gene were used as diploid copy number controls to ensure the validity of the assay. 
As shown in Fig. 3.2, transgenic line 2.2 appears to have incorporated three stably 
integrated transgene copies (three transgenic plus two endogenous = 5 copies), whereas 
line 2.12 appears to bear two. Given the similarity of the quantified results reflected by 
PCR primer pairs spread across the entire locus, we assume that at least one of the 
integrated BAC transgenes is intact in each line, but we performed no additional 













Figure 3.2 - Gata2-linked BAC copy number as determined by Q-PCR. Tail DNA was recovered from 
animals in which the transgenes in two different established lines (called 2.2 and 2.12) were stably 
transmitted to offspring for more than four generations. PCR primers were developed using Primer 
Express, which would detect unique sequences approximately every 50 kbp along the length of the linked 
BAC, as well as at positions outside the boundaries of the BAC (as a diploid copy number control; Table 
3.1). The normalization strategy for each genomic DNA sample involved first standardizing the quantified 
PCR product from Gata2-specific primer pairs to that of the β-actin gene, and then normalizing the values 









Rescue of the Gata2 Null Mutation with a Linked BAC Transgene 
A Gata2 null mutant (EII-KI) mouse in which the green fluorescent protein (GFP) 
was integrated at the translational start site in Gata2 exon II has been previously 
characterized (Suzuki et al., 2006). GFP expression was detected in all of the anticipated 
organs and tissues (Suzuki et al., 2006). We mated the two independent linked BAC 
transgenic (TgG2BAC) lines (2.2 and 2.12) to Gata2 germ line mutant heterozygotes to 
generate Gata2+/-:TgG2BAC compound mutant animals; none of the compound mutant 
offspring exhibited abnormal behavior. The transgenic heterozygotes were backcrossed 
again to Gata2 heterozygotes to generate Gata2 homozygous null mutant transgenic 
mice, which were genotyped by Q-PCR (Fig. 3.3A). The quantitative methodology was 
validated by breeding an F3 Gata2-/-:TgG2BAC (presumptive rescued null mutant) parent to 
wild-type females: all progeny contained one germ line mutant Gata2 allele (Fig. 3.3C), 
thus demonstrating unambiguously that this parent was indeed of Gata2-/-:TgG2BAC 
genotype. 
Because a Gata2 ureteric epithelial enhancer had not been previously identified 
(Khandekar et al., 2004), we speculated that rescue of the Gata2 null mutants with the 
linked BAC might lead to full complementation of the hematopoietic phenotype, as we 
previously observed with a smaller transgenic YAC (Zhou et al., 1998). However, an 
additional expectation was that the BAC-rescued mice might also exhibit perinatal or 
postnatal urogenital deficiencies, given that a ureteric epithelial enhancer was not 
detected among the BACs surveyed in the original BAC-trap screen, and was therefore 
expected to lie somewhere outside the boundaries described by the linked BAC transgene 







Figure 3.3 - BAC-complemented Gata2-/- mice are born in a Mendelian distribution. (A) Q-PCR was 
performed on genomic DNA samples prepared from the tails of sibling pups (S1–S10) from a presumptive 
Gata2+/-:TgG2BAC x Gata2+/- intercross (primer sequences for the EII-KI allele are shown in Table 3.1, Q-
eGFP); β-actin Q-PCR was used as a diploid copy number control. The strategy was designed to detect the 
EII-KI (Gata2-) allele in all GFP+ mice (Table 3.1), and therefore wild-type mice have a ratio (Gata2-/β-
actin) of 0, EII-KI heterozygotes (e.g. both parents) have a ratio of 1, and EII-KI homozygotes (Gata2 null 
mutant mice) have a ratio of 2. (B and C) Representative semi-quantitative PCR results depicting detection 
of the linked BAC transgene allele (B, using BAC5’jxn primers, Table 3.1) or the EII-KI (-) or wild-type 
(+) alleles (C, Table 3.1) from a presumptive Gata2-/-:TgG2BAC X Gata2+/+ intercross. Note that every sibling 
(S1–S9) from this mating carries a (-) germ line allele, whereas only six of nine sibs harbor a BAC allele, 
proving that the genotype of the original transgenic parent (P2) is Gata2-/-:TgG2BAC. Note that the + allele 
can be contributed either through the germ line or from a BAC-derived Gata2 gene. 
 
After crossing the two independent TgG2BAC lines into the Gata2 null mutant 
background, we were able to draw several conclusions. First, all genotypes were 
recovered at the anticipated Mendelian frequency from Gata2+/- x Gata2+/-:TgG2BAC 
intercrosses (actual: 60:127:23; expected: 52:105:26, for Gata2+/+ (both with and without 
the G2BAC), Gata2+/- (again, both with and without the G2BAC), and Gata2-/- (with the 
G2BAC only)) genotypes (Table 3.2), respectively, when performed with either of the 
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G2BAC transgenic lines. Second, BAC-complemented null mutant mice suffer from 
neither hematopoietic nor urogenital defects; neither do they exhibit any adult urological 
deficiency. Furthermore, Gata2-/-:TgG2BAC mice exhibit normal life expectancy, body 
weights, and litter sizes (of expected Mendelian frequencies) compared with wild-type 
controls. 
Given the lack of expression of any of these BAC and YAC transgenes in the 
ureteric epithelium (Khandekar et al., 2004), the observation that adult animals were 
generally normal was somewhat surprising, and therefore we collected, sectioned, and 
stained e14.5 embryos to specifically assess the early development of the ureter and the 
expression of the linked BAC transgenes. Hematoxylin and eosin staining showed that 
the overall morphology of the genitourinary system is unaltered in the Gata2-/-:TgG2BAC 
embryos (Fig. 3.4, A and E). GFP expression (from the Gata2 knock-in allele) localized 
to the same cells in BAC-complemented Gata2-/-:TgG2BAC compound mutant animals as 
in heterozygous mutant (Gata2+/-) controls (Fig. 3.4, B and F). However, much to our 
surprise, GATA-2 protein was expressed in both the urogenital epithelial and 
mesenchymal compartments in the G2BAC-rescued transgenic mice (Fig. 3.4,C and G). 
Although we anticipated that these compound mutant mice might be rescued by the 
linked BAC possibly via non-cell autonomous inductive effects (perhaps as a 
consequence of the mesenchyme inducing ureteric epithelial differentiation), on the basis 
of previous data we did not expect to observe GATA-2 expression in the epithelium 
(Khandekar et al., 2004). The previously characterized lacZ-tagged YAC transgene 
(called d16; Zhou et al., 1998) has boundaries that map to positions -174 to +73 kbp 
according to the revised genome sequence, and an overlapping BAC (333I12, from +60 
to +268 kbp of the Gata2 locus) was also previously examined in the “BAC-trap” lacZ 
reporter assay. These two sequences together encompass sequences represented by both 
the 5’BAC (115E9, -187/-10 kbp of the Gata2 locus) and the 3’BAC (81F7, -34/+226 
kbp) that we examined in this study, and in neither of the former reporter transgenic 
studies were we able to detect GATA-2 activity reflected as reporter staining in the 
ureteric epithelium. Thus the present data indicating that the linked BAC is able to confer 
tissue specificity for epithelial expression that is not observed in the BACs or YAC when 
they are analyzed individually (Khandekar et al., 2004). 
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Figure 3.4 - The G2BAC transgene recapitulates mesenchymal and epithelial Gata2 urogenital 
expression. Transverse cryosections of e14.5 Gata2+/- (A–D) and Gata2-/-:TgG2BAC (E–H) embryos were 
subjected to co-immunostaining using anti-GFP (B and F) and anti-GATA-2 (C and G) antibodies, prior to 
hematoxylin and eosin histological staining (A and E). (B and F) GFP immunofluorescence reflects the 
endogenous GATA-2 expression pattern in the urogenital mesenchymal and epithelial cells of Gata2+/- and 
Gata2-/-:TgG2BAC embryos. (C and G) GATA-2 protein was immunologically detected in the urogenital 
mesenchymal and epithelial compartments of the Gata2+/- embryo (C). In the Gata2-/-:TgG2BAC embryo, 
anti-GATA-2 immunoreactivity was present not only in the urogenital mesenchyme, but also in the ureteric 
epithelium (G). (D and H) Merged images of anti-GFP and anti-GATA-2 immunofluorescence. e, ureteric 




GATA-2 is expressed in multiple tissues during vertebrate development and has 
been shown in several instances to be required for their differentiation. However, there 
are at least an equal number of examples of tissues in which this transcription factor is 
robustly expressed but also for which its in vivo requirement has not yet been completely 
elucidated. Because it is well established that Gata2 null mutants expire from 
hematopoietic failure (Tsai et al., 1994) and that Gata2 YAC-rescued null mutants, after 
surmounting the lethal hematopoietic block, expire from urogenital patterning failures 
(Zhou et al., 1998), it seemed reasonable to ask: if both of these embryonic deficiencies 
were complemented by a transgene bearing activities that would correct both 
deficiencies, would the animals survive? The alternative, which might have been 
expected in this case, is that the animals would probably not survive to reproductive age, 
but expire of a second perinatal lethal urogenital failure (due to the anticipated absence 
from the transgene of any urogenital epithelia-complementing activity), or even from a 
deficiency in some new tissue that was regulated by an enhancer located outside the 
boundaries circumscribed by the linked BAC. 
Through the analyses of two independent transgenic lines, complementation of 
the germ line Gata2 null mutation by the 413-kbp linked BAC appears to be complete: 
Gata2-/-:TgG2BAC mice are born in the anticipated Mendelian ratio, they display no 
obvious physiological deficiencies, and they parent offspring without apparent difficulty. 
The size and general health of all viable progeny derived from Gata2+/- x Gata2+/-
:TgG2BAC intercross is indistinguishable from that of wild-type mice (data not shown, 
Table 3.2).  
One major unexpected consequence resulting from the BAC linking was the 
observation that fusion of the two parental BACs led to Gata2 expression in the 
urogenital epithelium, whereas all of our previous studies examining the expression of 
lacZ-tagged BACs and YACs that fully overlapped this domain gave no indication that a 
reporter gene could be expressed in that specific tissue (Khandekar et al., 2004; Zhou et 
al., 1998; Zhou et al., 2000). The current genetic and histological data support the notion 
that urogenital epithelial expression is conferred by two distinct, delocalized sequences, 
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one contained within each of the two parental BACs (Fig. 3.1), which become a 
functional enhancer element only when the two BACs are joined in cis. This novel 
concept of a delocalized synthetic enhancer has no precedent insofar as we are aware. 
Recent studies have also described the existence of domain boundaries, which is 
established by an array of cis elements (including insulators, boundary elements) that 
serve to delimit an active transcriptional state in a given region of the genome (Blanton et 
al., 2003; Cléard et al., 2006; Saitoh et al., 2000; West et al., 2004). Thus a possible 
scenario is that there is a single Gata2 ureteric epithelial enhancer, which requires the full 
complement of domain boundaries present only in the linked BAC to activate GATA-2 
expression in the ureteric epithelium. Further investigation into the mechanism by which 
the ureteric epithelial enhancer becomes functional promises to reveal novel and 
fundamental insights into transcriptional regulation. 
We conclude from the data shown here that the urogenital deficiency detected in 
the YAC-rescued Gata2-/- mice is indeed the cause of their perinatal lethality (Zhou et al., 
1998). We also conclude that Gata2 enhancers that have been identified lying outside the 
-187/+226 kbp boundaries (Khandekar et al., 2004) encompassed by the G2BAC are 
unnecessary for viability or healthy reproductive status. The possibility that these even 
more distant enhancers control functions for which GATA-2 activity is redundant seems 
likely, but this hypothesis remains to be tested. 
Finally, recombineering-based mutagenesis strategies to link overlapping BACs 
via homologous recombination have been previously described (Kotzamanis and Huxley, 
2004; Sopher and La Spada, 2006; Zhang and Huang, 2003), although none of the earlier 
reports attempted transgenic rescue with the manipulated DNA. Here, we employed a 
somewhat different approach by utilizing cre-mediated homologous recombination to 
exploit the documented differential recombination efficiency between homologous versus 
heterologous loxP sequences to create a fully rescuing BAC transgene. This could 
provide the scientific community with a powerful genetic tool that could be used to 
quickly and efficiently mutate specific sequences in vivo in any rescuing transgene. 
Interrogation of genomic locus activity using these straightforward recombineering 
strategies could provide a much more rapid way of assessing the effects of any mutation 
when compared with the lengthy process involved in the generation of germ line mutants 
 92 
by ES cell targeting, especially if one wishes to examine (e.g.) dozens of different 
mutations in the same genetic locus. Thus this BAC complementation strategy may offer 
several advantages over the creation of conditional germ line mutants for animals in 
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Table 3.1:  Oligonucleotides and primer sequences 
 
Lox514pm 5’ tataacttcgtataatgtacgctatacgaagaagt tatac 3’ 
5’ aattgtataacttcttcgtatagcgtacattatacgaag 
ttatatgca 3’ 
Lox514nx 5’ ggccgtaacttcgtataatgtacgctatacgaag ttatat 3’ 
5’ ctagatataacttcgtatagcgtacattatacgaagt 
tac 3’ 
Famp 5’ cgggatcctgaagttcctatactttctagagaata ggaacttcactaccgttaagggatt 3’ 
5’ cgaattcgaagttcctattctctagaaagtataggaac 
ttcatggttttagacgtcag 3’ 
-13Lox514 5’ cactaggccttggatgtttgtttgtcttcatcttagg tctcaccgcggtggcggccgtaac 3’ 
5’ aaggcacaggcaacttgcagctggtgaccagaaca 
gagagtttaacctcgaatgtataa 3’ 
Bacdellox  5’ gtcgctgtcgacggtgaccctatagtcgagggacct aatagcttgatctcgaatgtataa 3’ 
BacNeo 5’ caagcactactgtcttaggctgtatgtatgtgcac tctttgctaccatggagaagttcctattc 3’ 
5’ gcatcggtcgagcttgacattgtaggactatattgctc 
taagataactgatcagcttgaagttctt 3’ 
Famp2977 5’ ttacgactgcacttctggcaggaggagcgactc aagccttgctcaagcttcgaa 3’ 
 
Famp4233  5’ catgtagcttgtgataaccacattgttgcctttggcttg caggggcggatcctgaagtt 3’ 
G2-13 5’ ggcacgttcagttgtaaaca 3’ 5’ cccatatccactcagtacagag 3’ 
G2+200 5’ accacaggcacttacacctcaa 3’ 5’ gcttctcacatgctagtcagagac 3’ 
BAC5’jxn 5’ atcggtcgagcttgacattgta 3’ 5’ cctttgaggattacagacctcactc 3’ 
BAC-13 5’ atggcaccagcagctctaggt 3’ 5’ cagagaagcttgatctcgaatgtataa 3’ 
CAT 5’ cagtcagttgctcaatgtacc 3’ 5’ actggtgaaactcaccca 3’ 
Q-230 kb 5’ tgttcactgctaaaggaggcc 3’ 5’ tggcaaggtctgtgagtcaca 3’ 
Q-180 kb 5’ ggcagcctattagccacattg 3’  5’ tagccacagcatttcccagc 3’ 
Q-137 kb  5’ ccattctttctttccaccgtg 3’  5’ ttggtggcgacctcacaac 3’ 
Q-87 kb 5’ ctctcacccttcgtccctgtt 3’  5’ cgctggatctcaggatgagc 3’  
Q-37 kb 5’ ttctgcatggccttctcctt 3’ 5’ ccattcccacagacctgctac 3’  
Q+13 kb 5’ tctccagagccaagggttca 3’ 5’ tctccaccaaagcttgccc 3’ 
Q+53 kb 5’ ttttctcgacccctagctgg 3’ 5’ ttctggctctcgtcccaact 3’  
Q+103 kb 5’ tgtaggctccttccttctccc 3’ 5’ ggtaaggctatgctgtgccc 3’ 
Q+153 kb 5’ acaaggatggcactgtgcatt 3’  5’ ctgcacaagctgtgattggc 3’ 
Q+203 kb 5’ gccactaaaagagcccatgc 3’ 5’ gcttagggccaacctgtcac 3’ 
Q+220 kb 5’ tggcagtgatggccacatac 3’ 5’ ttgcccactgagctgtcttg 3’ 
Q+270 kb 5’ ttgaaaaccgacaaccagcc 3’ 5’ ccagcgtccaaggtaagtgc 3’ 
Q β-actin  5’ ccataggcttcacaccttcctg 3’  5’ gcactaacactaccttcctcaaccg 3’ 
Q-eGFP 5’ ctctgttatccagggccgc 3’ 5’ cggtgaacagctcctcgc 3’ 
wt allele 5’ cgccgctgcgagtgtaagtttg 3’ 5’ cgaggctgctcggcgccac 3’ 
GFP allele 5’ agcaagggcgaggagctgttcacc 3’ (same as wt allele) 
 
Table 3.2:  Progeny from F2 Gata2+/- X Gata2+/-: TgG2BAC intercrosses 
 
Line Tg/Total +/+ : +/- : -/- * 
2.2 57/112 35/68/9 
2.12 58/98 25/59/14 
*These numbers include both TgG2BAC-positive and -negative pups. Of the Gata2-/- progeny, only those 
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The “hemangioblast,” hypothesized to exist almost a century ago, is a cell capable 
of differentiating into both hematopoietic and endothelial cells. During primitive 
hematopoiesis, these two distinct cell types arise simultaneously from the blood islands 
of the yolk sac (Murray, 1932; Sabin, 1920). In definitive hematopoiesis, hemangioblasts 
are believed to differentiate from the ventral mesoderm surrounding the floor of the 
dorsal aorta (Garcia-Porrero et al., 1995; Tavian et al., 1996; Tavian et al., 1999), from 
which hematopoietic precursors can be seen budding into the lumen of the dorsal aorta 
from the endothelium. This has been demonstrated in chick (Dieterlen-Lievre, 1975; 
Dieterlen-Lièvre and Le Douarin, 2004; Jaffredo et al., 1998), mice (Cumano et al., 2001; 
Dieterlen-Lievre et al., 1994; Ling and Dzierzak, 2002; Taoudi and Medvinsky, 2007), as 
well as humans (Tavian et al., 2001).  
 Evidence for the existence of hemangioblasts is supported by studies of genes that 
affect both the vasculature and hematopoiesis. Null mutant zebrafish for the gene cloche 
lack an endocardium, and have a reduced number of blood cells (Stainier et al., 1995). 
The receptor tyrosine kinase Flk1 was originally believed to be endothelial specific 
(Millauer et al., 1993); however, Flk1-null mutant mice present a dual phenotype: they 
die between embryonic days 8.5-9.5 from a lack of organized blood vessels along with a 
severely reduced number of hematopoietic progenitors (Shalaby et al., 1995).  
Conversely, the transcription factor SCL was originally shown to be required for 
hematopoietic development in mice (Robb et al., 1995; Shivdasani et al., 1995), but upon 
hematopoietic rescue of Scl-null mutant embryos, SCL was also found to be required for 
remodeling of the yolk sac vasculature (Visvader et al., 1998), and has since been shown 
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to be important for vasculogenesis (Patterson et al., 2005), including endothelial cell 
migration and morphogenesis (Lazrak et al., 2004). 
Most of our information on the possible origin of hemangioblasts has been 
provided through in vitro studies. Embryonic stem cell-derived embryoid bodies, in 
response to vascular endothelial growth factor (the ligand for Flk1), give rise to blast 
colony-forming cells (BL-CFC), which in turn can directly differentiate into 
hematopoietic and endothelial precursors (Choi et al., 1998; Park et al., 2005).  
Furthermore, BL-CFC’s were enriched in a Flk1+SCL+ cell population (Chung et al., 
2002).  Brachyury+Flk-1+ cells isolated from the primitive streak of a developing mouse 
embryo show a similar bipotential differentiation pattern in culture (Huber et al., 2004). 
The only in vivo lineage tracing study to date comes from single-cell-resolution fate maps 
in zebrafish, which show that individually marked cells along the ventral mesoderm can 
contribute to both hematopoietic and endothelial lineages (Vogeli et al., 2006).  
The question remains as to whether definitive hemangioblasts give rise directly to 
hematopoietic and endothelial cells as is seen in vitro and in the blood islands of the yolk 
sac, or whether the hemangioblast first differentiates into a “hemogenic endothelium” 
lining the dorsal aorta, where the endothelium itself has hematopoietic potential (Jaffredo 
et al., 2005; Marshall and Thrasher, 2001). Recent evidence supports the latter 
hypothesis, as blast colony forming cells have recently been found to have an 
intermediate, transiently adherent population that would be consistent with expectations 
from the in vivo hemogenic endothelium model (Lancrin et al., 2009). Direct labeling of 
mesodermal origin cells versus the endothelium in mice has also shown that the budding 
hematopoietic cells arise specifically and uniquely from the endothelial cell population 
(Zovein et al., 2008). 
A number of genes have now been shown to have dual requirements for 
endothelial and hematopoietic development, including Flk1, Scl, and Runx1. The fact that 
a number of these factors are known to interact with the hematopoietic transcription 
factor GATA-2, and that GATA-2 plays a role in vascular development (Chapter 2) 
(Dorfman et al., 1992; Khandekar et al., 2007; Umetani et al., 2001), it seemed 
reasonable to speculate that GATA-2 might play a role in the definitive hemangioblast or 
hemogenic endothelium development as well. 
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Multiple organ systems require GATA-2 expression for proper development. 
GATA-2 is critical for the establishment of primitive hematopoiesis (Tsai et al., 1994), 
proper urogenital patterning (Khandekar et al., 2007), and V2-interneuron development 
(Zhou et al., 2000), among many other developmental contributions. Genetic information 
specified within the 300 kilobase pairs (kbp) surrounding the Gata2 genetic locus 
contains regulatory elements critical for proper embryonic development (Brandt et al., 
2008), with other (presumably less critical) Gata2 regulatory elements known to reside 
outside these boundaries (Khandekar et al., 2004). 
A Gata2 enhancer element was recently described that confers vascular-specific 
expression (Chapter 2) (Khandekar et al., 2007). Interestingly, this same element had 
already been shown to drive GATA-2 expression in erythroid cell lines (Grass et al., 
2006). Enhancer elements having a dual role in hematopoietic and endothelial 
development are not without precedent; for example, the transcription factor Scl contains 
an element with similar specificities (Göttgens et al., 2004). To better understand the role 
of this Gata2 enhancer element, as well as to address the possible developmental roles of 
GATA-2 in hemangioblast and endothelial development, we generated transgenic mice in 
which the Gata2 endothelial enhancer was flanked by insulator elements in a plasmid in 
which the fluorescent reporter protein mCherry and CRE/ERT2 (the cre recombinase 
gene fused in frame to a second generation tamoxifen-sensitive estrogen receptor ligand 
binding domain) were expressed from the Herpes Simplex Virus (HSV) Thymidine 
Kinase promoter. By feeding pregnant dams tamoxifen early in embryogenesis, I 
anticipated that this transgene would specifically mark the hemangioblast population of 
cells – along with progeny hematopoietic and endothelial cells - when crossed to a 
reporter strain of mice.  
These transgenic mice were first used to examine the role of Gata2 specifically in 
vasculogenesis, not only through the hemangioblast, but also potentially through a 
separate angioblast pathway. This alternate pathway is hypothesized because endothelial 
cells lining the dorsal aorta appear to develop normally in Gata2 null mutant mice (Tsai 
et al., 1994), while broadly expressing GFP when knocked-in to the translational start site 
of Gata2 (Suzuki et al., 2006). Given the early embryonic lethality of Gata2 null mutant 
mice, transgenic mice in which the Gata2 vascular enhancer directed cre recombinase 
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expression could be used to conditionally delete Gata2 specifically in the vasculature at 
various stages of embryonic or postnatal development by tamoxifen induction.  The 
results of these experiments should help to elucidate the role played by GATA-2 in 
vasculogenesis, as well as lead to detection of a phenotype associated with hematopoietic 
cells derived from the putative hemangioblast should it exist. 
This work is the first to directly address the role of GATA-2 in hemangioblast and 
vascular development in a mammalian model in vivo. The results of these experiments 
could redefine our knowledge of the earliest phases of blood and vascular development, 
as well as provide new insights into the function of this transcription factor.  Finally, 
given the fact that GATA-2 is known to be vital for cell proliferation (Tsai and Orkin, 
1997), these results could also play a critical role in understanding the propagation of 
certain types of cancer, such as hemangioblastomas. 
In the present experiments we show that a transgenic mouse has been generated in 
which the Gata2 gene can be conditionally ablated in the vasculature; this mouse was 
created in a way that allows simultaneous fluorescent marking of all endothelial cells. 
The data show that GATA-2 plays a significant role in vascular development, 
predominantly through secondary branching of the primary vasculature. These studies 
address the possibility of a common developmental origin for the hematopoietic system 
and the vasculature, and provide evidence of the molecular properties that could 
contribute to defining the hemangioblast, hemogenic endothelium and early definitive 
hematopoietic cells.  This study, though not without its own caveats, adds weight to the 
hypothesis that the definitive hemangioblast exists.  
 
Materials and Methods 
 
Insulated Gata2 Vascular Enhancer Transgene Construction 
Sac1 and HindIII sites from the multiple cloning site of pNEB193 (New England 
Biolabs) were blunted sequentially to augment future cloning steps. Duplicated chicken 
HS4 insulators were then removed from pJC13-1 (Chung et al., 1993) with BamH1 and 
EcoR1 and blunt-end ligated into the Sma1 site of the modified pNEB193 plasmid. A 
second set of chicken HS4 insulators was subsequently blunt-end ligated into the Pme1 
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site of the modified pNEB193 plasmid to generate a general Insulator Vector (IV) 
transgene.  
 To generate the vascular enhancer construct, a previously described transgene 
construct, called pTKSXβ (Khandekar et al., 2007), was generated by adding the Gata2 
vascular enhancer to pTKβ (Clontech). pTKSXβ was digested with Not1, removing the 
LacZ sequence. CreERT2, taken from plasmid pCreERT2 (Feil et al., 1997; Hayashi and 
McMahon, 2002) by digestion with EcoR1, was blunt-end ligated into the Not1 site of 
pTKSXβ, generating the construct Vascular Enhancer – CreERT2 (VEcre). To generate a 
reporter construct, the fluorescent reporter mCherry-N1 (Shaner et al., 2005) was digested 
with BamH1 and Not1 and blunt-end ligated into the same Not1 location of pTKSXβ, 
generating Vascular Enhancer – Cherry (VEcherry).  
 Both the VEcre and VEcherry constructs were then digested with PvuII and Sph1 
and blunt-end ligated into the Pac1 site of IV to generate insulated versions of each 
construct: iVEcre and iVEcherry, respectively. All ligation points were verified by 
sequencing.  
 
Transgenic and Knock-out Mice 
To generate transgenic animals, the iVEcre and iVEcherry expression constructs 
were digested with Fsp1, purified, and microinjected at equal molar ratios into fertilized 
eggs obtained by mating (C57BL/6 x SJL)F1 female mice with (C57BL/6 x SJL)F1 male 
mice. Pronuclear injection was performed as described (Nagy et al., 2003). To identify 
transgenic animals, DNA from yolk sac or tail snip of founder animals was used for 
genotyping by PCR for both Cre and mCherry sequences. Cre primers used are: sense 5'-
ggctgccacgaccaagtgac-3' and anti-sense 5'-cgtgagatatctttaaccctgatc-3'. mCherry primers 
are sense 5'-acggtactcgaggaactgaa-3' and anti-sense 5'-gtgggaggtgatgtccaact-3'. For stable 
lines expressing both iVEcre and iVEcherry (hereafter referred to simply as iVE), F2 and 
subsequent generations of progeny were examined for transgene copy number by 
quantitative real-time PCR as previously described (Brandt et al., 2008). Heterozygous 
and homozygous cre knock-in animals were used for copy number controls. 
 Gata2gfp (Suzuki et al., 2006) and Rosa26RLacZ (Soriano, 1999) mice have been 
previously described. 
 102 
 For collection at embryonic day 10.5 (e10.5), approximately 2.5 mg of tamoxifen 
was administered to the pregnant dam via gavage for four days starting at e6.5. 
Administration of 5 mg per day resulted in almost complete resorption of the embryos by 
e10.5 (data not shown). X-gal staining was performed as previously described 
(Lakshmanan et al., 1999).  
 For the lineage trace, 2.5 mg of tamoxifen was administered to the pregnant dam 
via gavage on embryonic days 6.5, 7.5, and 8.5. The fetal liver and spleen of e17.5 
embryos were then collected and made into a single cell suspension. Beta-galactosidase 
activity in single cells was detected with fluorescein di-β-D-galactopyranoside (FDG, 
Invitrogen).   FDG- loaded cells were incubated with FcBlock (BD Biosciences) and then 
incubated with lineage antibodies for 20 minutes.  The following antibodies were used:  
CD31-APC (clone 390, 0.5ul), B220-APC  (RA3-6B2, 0.6ul), CD3-biotin (145-2C11, 
0.5ul), Gr1-biotin (RB6-8C5, 0.1ul), Mac1-biotin (M1/70, 0.1ul) and TER119-APC 
(TER-119, 0.6ul)  (all concentrations are per 1 million cells; all antibodies are from 
eBiosciences). Biotin-conjugated antibody samples were rinsed and counterstained with 
streptavidin-APC (0.15µl; BD Pharmingen) for another 20 minutes. All cells were 
subsequently counterstained with DAPI for dead cell exclusion.  
 
Immunohistochemistry  
Embryos were harvested at the times indicated in the text and figure legends, and 
processed for immunohistochemistry as previously described (Khandekar et al., 2004). 
Cryosections were stained with rabbit anti-GFP (1:500; Molecular Probes), rat anti-Flk1 
(1:500; BD Pharmingen), rat anti-PECAM-1 (1:500; BD Pharmingen), rat anti-CD144 
(1:500; BD Pharmingen), and rat anti-CD41 (1:500; BD Pharmingen) antibodies 
overnight at 4°C and were subsequently detected using the appropriate fluorochrome-
conjugated secondary antibodies at 1:200 dilution. Digital images were recorded as 








Generation and Characterization of Insulated Gata2 Vascular Enhancer-directed 
Transgenic Mice 
To better address the role of GATA-2 in endothelial - and potentially in 
hemangioblast - development, a conditional knockout strategy for Gata2 inactivation was 
desired in order to circumvent the early hematopoietic deficiency seen in germline Gata2 
null mutant mice (Tsai et al., 1994).  To this end, the Gata2 vascular enhancer (described 
in Chapter 2) was used to generate a tamoxifen inducible, vascular-specific cre construct. 
The HSV thymidine kinase promoter was chosen because it does not have intrinsic 
enhancer activity (Majumder and DePamphilis, 1994), unlike the Gata2 1S and 1G 
promoters (Minegishi et al., 1998).  CreERT2 was chosen to specifically delete Gata2 in 
the vasculature because it is insensitive to endogenous estrogens and is four-fold more 
sensitive to tamoxifen than the original Cre/ER fusion protein (Feil et al., 1997). 
Duplicated chicken HS4 insulator elements (Chung et al., 1993) were placed at either end 
of the insert in an attempt to prevent position of integration effects. An identical construct 
carrying the mCherry reporter gene instead of Cre/ERT2 was also generated, providing a 
convenient marker for transgene expression, along with a vasculature-specific reporter 
(Fig. 4.1, A and B).   
 Pronuclear injection of equal concentrations of both constructs into (C57BL/6 x 
SJL) zygotes resulted in 44 live births. Of these, 13 carried both transgenes, as 
determined by PCR for both Cre and mCherry sequences. Copy number analysis of the 
stably transmitting lines was performed for Cre using quantitative real time PCR (qPCR). 
Based on this assay, the number of insulated vascular enhancer/cre (iVEcre) transgene 
copies integrated into the genome ranged from five (iVE62) to approximately forty-seven 
copies (iVE457) (Fig. 4.1C). Since the iVEcre and iVEcherry transgenes are 
approximately the same length and were co-injected at equal molar ratios, we expected 
that they would be approximately the same copy number; however, we did not determine 
the number of mCherry transgene copies. The iVE56, iVE62, and iVE73 lines showed 
endothelium-specific staining based on whole mount e10.5 embryo mCherry expression 
(data not shown). The iVE62 line expressed mCherry specifically in the vasculature at a 
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level that was approximately four times brighter than the other two lines (Fig. 4.1E). All 
subsequent experiments were carried out using this line of mice, and it will be referred to 
subsequently as TgiVE.  
Given that insulators, by definition, shield genes (or transgenes) from integration 
position effects, it was expected that the copy number of the iVE constructs would 
directly reflect the protein expression level in transgenic mice. However, all high copy 
number lines showed little to no mCherry expression (Fig. 4.1D vs. 4.1E). The negative 
mCherry expression was not due to cellular toxicity, as transgene positive embryos were 
recovered in a normal Mendelian distribution and appeared to be physiologically normal.  
Adult mice were also recovered from high copy number expressing lines and did not 
display any phenotypic abnormalities. Other lines containing a similar low copy number 
to iVE62 did not express mCherry at similar levels (Fig. 4.1E vs. 4.1F). These data 
indicate that the chicken HS4 insulators are ineffective in preventing position of 





Figure 4.1 – Generation and characterization of iVE transgenic mice. (A and B) Transgenes created to 
express Cre/ERT2 (A) or mCherry (B) under the control of the Gata2 vascular enhancer (VE) using the 
Herpes Simplex Virus Thymidine Kinase (TK) promoter. These transgenes are insulated by duplicated 
chicken HS4 insulator elements. The constructs were digested with Fsp1 (f) and co-injected into fertilized 
eggs to generate TgiVE founder animals. (C) Copy number of the Cre transgene was analyzed using 
quantitative real-time PCR from DNA prepared from each of the iVE transgenic lines. (D-F) Whole mount 
mCherry expression in founder embryos. (D) iVE60 has the highest copy number, but displays low 
fluorescent mCherry expression. (E) iVE62 has the lowest copy number, but expresses mCherry the 
strongest of all of the transgenic lines in an endothelial specific manner. (F) Transgenic line iVE473 has a 
similar copy number to iVE62, but does not express mCherry. WT – wild-type. 
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 To confirm our original impression that the iVE transgenes were expressed 
throughout the vasculature, and to compare the vascular patterning profile of a wild-type 
animal to a Gata2 null mutant animal, confocal microscopy analysis was performed. The 
TgiVE:Gata2+/- mouse was crossed with a Gata2gfp/+ animal, which produces eGFP in all 
GATA-2 expressing cells (Suzuki et al., 2006). Confocal analysis of an e10.5 transgenic 
embryo expressing the iVE transgene (red) and eGFP (green) is shown in Figure 4.2. 
Specific staining can be seen in the endothelium throughout the intersomitic vasculature 
of the tail bud (Fig. 4.2A) as well as the head region (Fig. 4.2B) of an e10.5 embryo. 
GATA-2/mCherry and GFP expression overlap in the head vasculature, while GFP 
expression outside the vasculature can be seen in the developing central nervous system 
(Fig. 4.2B).  
The vasculature of the Gata2 null mutant mice showed a significant divergence 
from the heterozygous control animals. Gata2 null mutant animals appear to produce the 
large vessels of the intersomitic vasculature of the tail bud, but fail to undergo vascular 
remodeling or angiogenesis (Fig. 4.2A vs. C). A similar phenotype is observed in the 
head vasculature, where remodeling of the vasculature appears to be normal in 
heterozygous controls; in these mice, large vessels can be seen extending into the furthest 
reaches of the brain and branching into the fine vasculature (Fig. 4.2B). However, the 
vasculature of Gata2 null mutant embryos appears to be aberrant, with the large vessels 
failing to remodel into the fine vasculature  (Fig. 4.2D). This robust phenotype was 
surprising as the effect of GATA-2 on vascular patterning was expected to be subtle at 
best. The caveat to these results is that to date this is the only embryo I have been able to 
examine through this process. More samples will need to be analyzed before the validity 




Figure 4.2 – Vasculature of e10.5 Gata2 heterozygous versus homozygous null mutant embryos. (A 
and C) Confocal microscopy of the intersomitic vasculature in the tail bud of TgiVE:Gata2gfp/+ (A) and 
TgiVE:Gata2gfp/- (C) e10.5 embryos, with the fluorescence of mCherry from the iVE transgene analyzed in 
red and the fluorescence of GFP from the Gata2 knock-in (null) allele in green. (B and D) Confocal 
analysis of the head vasculature of TgiVE:Gata2gfp/+ (B) and TgiVE:Gata2gfp/- (D) e10.5 embryos. GFP 
(green) represents the entire GATA-2 expression profile, while iVE (red) expression reflects GATA-2 
driven from the vascular enhancer. While co-labeling of mCherry and GFP is seen throughout the 
vasculature, independent GFP staining is also visible.  
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Cre Activity in iVE Transgenic Mice 
While mCherry appeared to be expressed specifically in the vasculature, the Cre 
expression pattern required independent validation. To test the efficacy of the iVEcre 
transgene, iVE male mice were mated to Rosa26RlacZ females (Soriano, 1999). e10.5 
embryos were collected and stained with X-gal overnight. The gross expression pattern of 
lacZ clearly mimics that of mCherry (Figure 4.1E vs 4.3A) using the current tamoxifen 
protocol.  Cre/ERT2 is capable of activating β-gal expression in the endothelium of the 
dorsal aorta, as shown by transverse sections of X-gal stained e10.5 dpc embryos. 
Interestingly, it appears that a few hematopoietic cells are also lacZ positive (Figure 
4.3B; arrows). Flow Cytometry analysis was also performed in order to compare the 
expression pattern of mCherry to CD31 (a pan-endothelial marker) in whole e10.5 
embryo single cell suspensions (Fig 4.3C). In this experiment, an average of 68% of 
mCherry positive cells express the endothelial specific marker CD31. The excision 
efficiency of Cre/ERT2 could not be confirmed due to technical issues in this experiment, 
but new experiments circumventing these limitations are currently under investigation.   
 
 
Figure 4.3 – Characterization of Cre activity in iVE transgenic mice. (A) An e10.5 embryo from a 
cross of TgiVE:Gata2+/+ with Rosa26RlacZ treated with 2.5 mg of tamoxifen from e6.5 to e9.5 dpc and 
stained with X-gal solution overnight. (B) Transverse section of the TgiVE:Rosa26RlacZ embryo showing 
lacZ staining in the endothelium of the dorsal aorta. The neural tube is oriented to the top of the image. (C) 
FACS analysis of whole e10.5 embryo single cell suspension shows that 68% of the mCherry positive cells 
express the endothelial-specific marker CD31. 
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Vascular and Hematopoietic cell Staining in the e10.5 Dorsal Aorta 
GATA-2 is predominantly expressed in hematopoietic precursors, including the 
budding hematopoietic clusters of the embryonic dorsal aorta (Khandekar et al., 2007).  A 
number of other transcription factors have also been shown to be critical for 
hemangioblast development, including Flk1 (Shalaby et al., 1995), VE-Cadherin (Breier 
et al., 1996), SCL (Göttgens et al., 2004), and RUNX1 (Lacaud et al., 2002). We 
attempted to localize the presumptive hemangioblast, and hemogenic endothelium, with a 
combination of antibodies that recognize proteins thought to be important for 
hemangioblast development. Based on expression studies in embryonic stem cells, 
GATA-2 expression is elevated upon BMP4 induction, followed temporally by Flk1 and 
SCL (Lugus et al., 2007). There is also some evidence that BMP4 regulates the 
differentiation of hemangioblasts by controlling the level of c-kit (Marshall et al., 2007). 
Unfortunately, an antibody specific for BMP4 in immunohistochemistry is not available. 
GATA-2 expression was analyzed using the previously described Gata2gfp knock-in 
mice. 
 
Flk1 and Gata2 
 Flk1 (fetal liver kinase, also known as Vegfr2) is a receptor tyrosine kinase 
responsive to vascular endothelial growth factor (VEGF) and is expressed primarily on 
proliferating endothelial cells (Millauer et al., 1993), but is also found on hematopoietic 
precursors in vitro (Kabrun et al., 1997). Flk1-null mutant mice die around e8.5 with 
defects in both hematopoietic and vascular development (Shalaby et al., 1995). Flk1 is 
also a direct target of the GATA factors (Kappel et al., 2000). In attempting to delineate 
the role of Flk1 in hemangioblast and hemogenic endothelium development, we analyzed 
Flk1 expression in the dorsal aorta of e10.5 embryos in the presence and absence of 
GATA-2. To do this, the Gata2 GFP knock-in was employed to generate Gata2 
heterozygous and homozygous null mutant mice. Analysis of these mice with respect to 
Flk1 and GATA-2 (GFP) expression revealed three interesting observations. 
 First, the number of endothelial cells, along with the expression level of GFP and 
Flk1, is significantly increased in the absence of GATA-2 (Fig. 4.4ii) when compared to 
Gata2 heterozygous (Fig. 4.4i) mutant mice at e10.5. Second, budding hematopoietic 
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cells do not express Flk1, but robustly express GFP (Fig. 4.4iii). Interestingly, the level of 
Flk1 in the endothelium surrounding the budding hematopoietic cells seems to be reduced 
as well (Fig. 4.4iii vs iv), similar to the expression level of Flk1 in the roof of the dorsal 
aorta (Fig. 4.4i). Third, Flk1 is expressed in cells invading the endothelium of the dorsal 
aorta, while GFP is either not expressed, or is expressed at a lower level, in both Gata2 
heterozygous (Fig. 4.4iv) and homozygous null (Fig. 4.4v) mutant mice. Flk1 expression 
in the endothelium does not appear to be reduced in Gata2 null mutant embryos (Fig. 
4.4iv vs v). No hematopoietic cells can be seen budding from the dorsal aorta in Gata2 
homozygous null mutant animals (Fig. 4.4, data not shown).  
 
Figure 4.4 – Staining of GATA-2 (GFP) and Flk1 in the e10.5 dorsal aorta in Gata2 heterozygous and 
homozygous null mutant mice.  (i and ii) GFP and Flk1 expression are compared in the roof of the dorsal 
aorta of Gata2gfp/+ (i) and Gata2gfp/gfp (ii) embryos. Both antigens are more highly expressed in the Gata2 
null mutant background, and appear to generate a larger number of endothelial cells. (iii) GFP is expressed 
in cells budding into the lumen of the dorsal aorta while Flk1 is restricted to the endothelium. (iv and v) 
Flk1 is expressed in cells invading the endothelium of the dorsal aorta while GFP is either not expressed, or 
only weakly so, in both the Gata2 heterozygous (iv) and homozygous (v) null mutant background. All 
sections are oriented with the neural tube at the top of the image. 
 
VE-cadherin and Gata2 
 VE-Cadherin (vascular endothelial cadherin, also known as CD144) is expressed 
exclusively on endothelial cells, and more specifically at the cell-cell junctions to 
promote cell adhesion, vascular integrity, and to control vascular permeability (Breier et 
al., 1996; Dejana et al., 1999).  Early studies have shown that VE-Cadherin is not 
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expressed in hematopoietic precursors (Lampugnani et al., 1992), but is found in the in 
vitro equivalent of the hemogenic endothelium, which gives rise to hematopoietic 
precursors of the AGM (Fraser et al., 2002; Nishikawa et al., 1998). VE-Cadherin was 
also reported to co-localize with the hematopoietic specific factor CD45 under certain 
conditions (Fraser et al., 2003; Kim et al., 2005; Taoudi et al., 2005), but this was not true 
in vivo in our hands (data not shown).  
 In fact, VE-Cadherin is not expressed on budding hematopoietic cells either, in 
contrast to GFP expression (Fig. 4.5iii). However, VE-Cadherin is still strongly 
expressed in the endothelium around the budding hematopoietic cells, in contrast to Flk1 
(Fig. 4.5iii vs. Fig. 4.4iii). VE-Cadherin is expressed on cells invading into the 
endothelium of the dorsal aorta, where GFP is only weakly expressed, in both Gata2 
heterozygous (Fig. 4.5iv) and homozygous null (Fig. 4.5v) mutant mice. The roof of the 
dorsal aorta in the Gata2 null mutant embryos again contains a larger number of 
endothelial cells than wild type embryos, and expresses GFP and VE-Cadherin at a much 
higher level in Gata2 null mutants (Fig. 4.5ii) than in the heterozygous control (Fig. 4.5i).  
 
Figure 4.5 – Staining of GATA-2 (GFP) and VE-Cadherin in the e10.5 dorsal aorta in Gata2 
heterozygous and homozygous null mutant mice.  (i and ii) GFP and VE-Cadherin expression are 
compared in the roof of the dorsal aorta of Gata2gfp/+ (i) and Gata2gfp/gfp (ii) embryos. Both antigens are 
more highly expressed in the Gata2 null mutant background, and contain more numerous endothelial cells. 
(iii) GFP is expressed in cells budding into the lumen of the dorsal aorta while VE-Cadherin is restricted to 
the endothelium. (iv and v) VE-Cadherin is expressed in cells invading the endothelium of the dorsal aorta 
while GFP is either not expressed, or only weakly so, in both the Gata2 heterozygous (iv) and homozygous 
(v) null mutant background. All sections are oriented with the neural tube at the top of the image. 
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Pecam1 and Gata2 
 PECAM-1 (platelet-endothelial cell adhesion molecule, also known as CD31) is 
expressed on both mature hematopoietic and endothelial cells (Watt et al., 1995). This 
protein functions in cell adhesion (Gumina et al., 1997), promotes cell migration, and 
assists in inflammatory processes associated with wound healing (Watt et al., 1995). 
GATA-2 is required for proper expression of PECAM-1, at least in the megakaryocytic 
lineage (Gumina et al., 1997).  
 Similar to Flk1 and VE-Cadherin, both GFP and PECAM-1 are induced in 
intensity coordinately with an increased number of endothelial cells in the roof of the 
dorsal aorta of Gata2 null mutant embryos (Fig. 4.6ii) when compared to heterozygous 
controls (Fig. 4.6i). PECAM-1 appears to be expressed in budding hematopoietic cells, 
but appears to be reduced coincident with the release of the hematopoietic precursor cell 
into the lumen (Fig. 4.6iii). GFP and PECAM-1 both appear to be expressed in a cell 
invading the dorsal aorta endothelium of a Gata2 null mutant embryo (Fig. 4.6iv). No 
cells were seen invading into the endothelium of the Gata2 heterozygous embryo, but this 
was not uncommon given the rare appearance of such cells.  
 
Figure 4.6 – Staining of GATA-2 (GFP) and PECAM-1 in the e10.5 dorsal aorta of Gata2 
heterozygous and homozygous null mutant mice.  (i and ii) GFP and PECAM-1 expression are 
compared in the roof of the dorsal aorta of Gata2gfp/+ (i) and Gata2gfp/gfp (ii) embryos. Both antigens are 
more abundantly expressed in the Gata2 null mutant background, and contain a greater number of 
endothelial cells. (iii) GFP is expressed in cells budding into the lumen of the dorsal aorta while PECAM-1 
is restricted to the endothelium. (iv) PECAM-1 is expressed in cells invading into the endothelium of the 
dorsal aorta while GFP also appears to be expressed, albeit at a lower level than PECAM-1, in the 
homozygous (v) null mutant background. All sections are oriented with the neural tube at the top of the 
image. 
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CD41 and Gata2 
 CD41 (also known as Itga2b) is one of the developmentally earliest known 
hematopoietic-specific markers (Ferkowicz et al., 2003; Li et al., 2005), and is expressed 
prior to the pan-hematopoietic marker CD45 (Mikkola et al., 2003). CD41 contains two 
subunits, which, in the presence of calcium, act together with CD61 to form a functional 
adhesive receptor protein (Ferkowicz et al., 2003). In later stages of hematopoiesis, CD41 
is expressed in megakaryocytes and platelets (Li et al., 2005). In early development, 
definitive hematopoietic cells appear to require CD41 for differentiation from hemogenic 
endothelium (Li et al., 2005).  
 In accord with expectations from the literature, CD41 is expressed solely in the 
budding hematopoietic cells of the dorsal aorta, while GFP is expressed in the budding 
hematopoietic cells as well as in the underlying endothelium (Fig. 4.7iii). GATA-2 is also 
weakly expressed in cells invading into the endothelium, while CD41 is not (Fig. 4.7iv). 
GATA-2 is expressed more broadly in the roof of the dorsal aorta in Gata2 null mutant 
mice (Fig. 4.7ii) than in the heterozygous control (Fig. 4.7i), whereas CD41 is not 
expressed in either case (the green spot in the CD41 panel of Fig. 4.7ii is artifactual).  
 
Figure 4.7 – Staining of GATA-2 (GFP) and CD41 in the e10.5 dorsal aorta of Gata2 heterozygous 
and homozygous null mutant mice.  (i and ii) GFP and CD41 expression are compared in the roof of the 
dorsal aorta of Gata2gfp/+ (i) and Gata2gfp/gfp (ii) embryos. GFP expression is more highly expressed in the 
Gata2 null mutant background, and contains a greater number of endothelial cells. The green cell in CD41 
(ii) is artifactual. No CD41 expression was found in the roof of the dorsal aorta in either case. (iii) GFP and 
CD41 are expressed in cells budding into the lumen of the dorsal aorta while only GFP is found in the 
endothelium. (iv) CD41 is not found in cells invading into the endothelium of the dorsal aorta while GFP 
appears to be weakly expressed in the heterozygous (iv) background. All sections are oriented with the 
neural tube at the top of the image. 
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 CD45 antibody staining does not show CD45 expression in the endothelium or the 
budding hematopoietic cells of the dorsal aorta; however, it is found on random cells 
throughout the embryo, presumably on monocytes and macrophages (data not shown) as 
previously described (Cuadros et al., 1992; Jaffredo et al., 1998). In Runx1 lacZ-
transgenic mice, LacZ expression is restricted to the floor of the dorsal aorta, along with 
budding hematopoietic cells (Nottingham et al., 2007). Unfortunately, antibody staining 
for RUNX1 has been unsuccessful under all conditions attempted (N. Speck, personal 
communication, and data not shown). Similarly, SCL, a helix-loop-helix transcription 
factor known to be critically important for hemangioblast determination (Lugus et al., 
2007) and differentiation (Lancrin et al., 2009) in vitro, does not display a decipherable 
pattern with currently available SCL antibodies. Elucidation of a genuine hemangioblast 
through experiments like these might be possible if these reagents were generally 
available. Until that time, the iVE transgenic mice that were generated should aid in 
elucidating the role of GATA-2 in early vascular development.   
 
Gata2 iVE in the Hemangioblast 
While the vascular enhancer of Gata2 has already been shown to regulate GATA-
2 expression in the developing vasculature (Khandekar et al., 2007; Wozniak et al., 
2007), it can also robustly activate luciferase expression in erythroid precursor cells 
(Grass et al., 2006), and is also expressed in the budding hematopoietic stem cells of the 
dorsal aorta (Khandekar et al., 2007). These observations indicate that the vascular 
enhancer of Gata2 may direct Gata2 expression in the precursor to these two cells types 
– the hemangioblast.  
Preliminary observations are in accord with this hypothesis, as mCherry is 
robustly expressed in the dorsal aorta of e10.5 mouse embryos (Fig. 4.8A), is expressed in 
budding hematopoietic cells (Fig. 4.8A, arrows), and appears to be expressed in 
circulating hematopoietic cells in the head vasculature (Fig. 4.8B).  By examining a 
confocal microscope z-stack, it became apparent that mCherry was expressed in rounded 
cells lining the floor and ventral walls of the dorsal aorta, while the dorsal walls and roof 
appear to display reduced mCherry expression (Fig. 4.8A), except in the budding 
hematopoietic cells (Fig. 4.8A, arrows).  
 115 
 
Figure 4.8 – Analyzing the Gata2 iVE in the hemangioblast.  (A) Transverse image of a confocal z-stack 
to analyze mCherry expression in the dorsal aorta. Expression is seen in the endothelium of the dorsal aorta 
as well as in budding hematopoietic cells (arrows). The neural tube is oriented at the top of the image. (B) 
A saggital image using a confocal microscopic z-stack to analyze mCherry and GFP expression in the head 
vasculature. Hematopoietic cells appear to express mCherry in the lumen of the blood vessels. (C) Flow 
cytometry analysis of TgiVE:Rosa26RlacZ e17.5 fetal liver and spleen. FDG (lacZ expression) is analyzed on 
the x-axis, and APC-conjugated antibodies to the endothelial and hematopoietic markers listed are assayed 
on the y-axis. Double positive cells can be seen in all lineages in TgiVE:Rosa26RLacZ/+ (left two plots, upper 
right chamber), while no double-positive cells are seen in the Rosa26RLacZ/+ controls (right two plots, upper 
right chamber).  
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 To directly address hemangioblast function in the developing mouse embryo, a 
lineage tracing study was performed. A pregnant dam harboring TgiVE:Rosa26RlacZ 
embryos was fed 2.5 mg of tamoxifen per day via gavage on embryonic days 6.5, 7.5 and 
8.5. This was expected to activate LacZ expression in the putative hemangioblast, but not 
in hematopoietic cells, as definitive hematopoietic precursors are not generated in the 
embryo until approximately e10.5. The fetal liver and spleen were collected on e17.5 and 
co-stained for LacZ along with antibodies for definitive, lineage-restricted hematopoietic 
cells, including B-cell surface marker B220 (Coffman, 1983; Morse et al., 1982), T-cell 
marker CD3 (Leo et al., 1987; Samelson et al., 1987), myeloid marker Gr1 (Hestdal et al., 
1991), the marker Mac1, which is expressed on macrophages, NK cells, granulocytes, 
activated lymphocytes, and mouse B-1 cells (Springer et al., 1979), and the erythroid 
specific marker Ter119 (Kina et al., 2000; Vannucchi et al., 2000), along with the 
endothelial specific marker CD31 (Baldwin et al., 1994). While the overall percentage of 
labeled cells was low, double positive cells containing each of these markers co-stained 
with the LacZ substrate FDG were found in both the fetal liver and spleen when analyzed 
by flow cytometry (Fig. 4.8C), and could explain the population of mCherry positive, 
CD31 negative cells observed in a single cell suspension of a whole e10.5 embryo (Fig. 
4.3C, lower right panel).  This is the first in vivo data in a mammalian model 
demonstrating that precursor cells from the mesoderm give rise to at least a subset of all 
definitive, lineage-restricted hematopoietic cells and the endothelium exists, and that the 




The results of this study indicate that: a transgenic mouse has been generated that 
is capable of specifically labeling, and conditionally ablating, Gata2 in the vasculature; 
GATA-2 indeed plays a significant role in vascular development, primarily through the 
secondary branching of the primary vasculature; and that through further manipulation of 
the iVE/CreERT2 transgenic mice, the in vivo identification and characterization of the 
definitive hemangioblast is almost a reality.  
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Gata2 iVE Transgenic Mice 
The primary constraints in elucidating the vascular phenotype regulated by 
GATA-2 function have been two-fold. First, Gata2 null mutant mice die at embryonic 
day 10.5, only allowing a cursory evaluation of the vasculature at this stage. The second 
is that the vascular phenotype in the Gata2 null mutant background originally appeared to 
be rather subtle. Both of these issues have been addressed by creation of the 
iVE/CreERT2 transgenic mice. The fluorescent protein mCherry provides a very clear 
and robust fluorescent signal specifically localized to the vasculature, providing a useful 
and sensitive reporter. Based on Rosa26RlacZ reporter staining, it appears that the 
CreERT2 transgene specifically ablates Gata2 in the vasculature, allowing normal 
development of the early hematopoietic (Zhou et al., 1998) and urogenital (Khandekar et 
al., 2004) systems that lead to early lethality in complete Gata2 null mutant mice.  
Transgenes succumb to two primary difficulties upon insertion into the genome: 
position of integration effects, in which a transgene is influenced by regulatory elements 
in the DNA surrounding the integration site; and transgene silencing, where the transgene 
over time adopts a closed conformation. Given the small size of the Gata2 vascular 
enhancer, we hypothesized it would be easily influenced by position effects. For this 
reason we attempted to generate transgenes that would be protected from these chromatin 
site of integration effects by including chicken HS4 insulators flanking the expression 
cassette.  These insulators have been shown previously to effectively protect transgenes 
from such position of integration effects in flies and mice (Emery et al., 2000; Sarkar et 
al., 2006). Unfortunately, the insulator elements failed to protect the transgene from its 
surrounding chromatin environment. Through the analysis of future generations of the 
iVE62 line of transgenic mice, we will be able to determine if the insulator elements can 
prevent gene silencing.  
 
The Role of GATA-2 in Vascular Development  
Gata2 null mutant animals carrying the iVE transgene were assessed in an attempt 
to observe a noticeable vascular phenotype using mCherry as a marker of the vasculature. 
Confocal microscopy was used to create optical sagittal sections in e10.5 embryos from 
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Gata2 heterozygous and homozygous null mutant animals to look for altered vascular 
development. The apparent lack of angiogenesis in the Gata2 null mutant embryo 
observed in this study was surprising, as a striking vascular phenotype has not been 
observed in Gata2 null mutant animals. However, I have only been able to analyze one 
embryo to date. A larger number of Gata2 null mutant embryos will need to be examined 
before any definitive conclusions can be drawn about the role of GATA-2 in vascular 
development.  
 As a vascular phenotype for GATA-2 loss or gain of function has been difficult to 
address, the ultimate goal of the iVE transgenic mice is to conditionally ablate GATA-2 
in the vasculature. We plan to mate the iVE transgenic mice to Gata2 conditional 
knockout mice (Gata2f), which contain loxP sites flanking the Gata2 exon 5 zinc finger 
(Charles et al., 2006). Mice of the genotype TgiVE:Gata2f/- should be viable. Tamoxifen 
will be administered to pregnant dams carrying embryos of this genotype, which will then 
be analyzed for vascular defects at various stages of development. Our hypothesis is that 
these mice will display angiogenic deficiencies, but not as severe as those detected in the 
Gata2 null mutant mice in this study (Fig. 4.2).  
 
The Molecular Signature of a Hemangioblast? 
A recent review by Jaffredo et al (Jaffredo et al., 2005) contains a schematic 
representation of a transverse section through the dorsal aorta of a developing mouse 
embryo. This schematic has artificially colored hemangioblasts, differentiating them from 
the mesoderm, hemogenic endothelium, and surrounding non-hemogenic endothelium. 
Our goal was to generate a similar image using mouse confocal sections as the canvas; if 
we could not, this would suggest that the current model of the hemangioblast was 
deficient.  
During this process, I made several interesting discoveries. Historically, 
hematopoietic cells were thought to bud primarily from the ventral walls of the dorsal 
aorta in accord with a model in which the hemangioblast directly generates hematopoietic 
precursor cells. However, in this study hematopoietic cells were always found budding 
from the walls of the dorsal aorta, sometimes ventrally but often laterally as well. Second, 
invading hemangioblast cells were always found ventral to the budding hematopoietic 
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cells in the endothelium. The invading hemangioblast cell and the budding hematopoietic 
cell were never seen in the same location along the dorsal aorta, implying that an 
intermediate state (the hemogenic endothelium) between a common progenitor (the 
hemangioblast) and final product (committed hematopoietic cells) migrates as it 
differentiates. This putative hemogenic endothelium compartment probably responds, 
through either negative or positive regulation, to a global dorsal-ventral patterning signal 
such as Bone Morphogenetic Protein 4 (BMP4) to induce budding of the definitive 
hematopoietic precursors (Fig. 4.9A, Fig. 4i-4.7i). In Gata2 null mutant animals, the data 
shown here suggest that the hemangioblast invades into the endothelium defined by the 
dorsal aorta, but in the absence of GATA-2 protein, the hemogenic endothelium cannot 
respond to the dorsal-ventral patterning signal(s) and therefore cannot differentiate and 
release hematopoietic precursors. As a result, these defective hemangiogenic endothelial 
cells appear to accumulate in the roof of the dorsal aorta (Fig. 4.9B, Fig. 4.4ii-4.7ii).  
The staining pattern of the e10.5 dorsal aorta proved to be informative. Flk1, VE-
Cadherin, and PECAM-1 all appear to be active in the mesenchymal hemangioblast 
precursor, along with low GATA-2 levels. Flk1, VE-Cadherin, PECAM-1, and GATA-2 
are all broadly expressed in the endothelium of the dorsal aorta. In the hemogenic 
endothelium surrounding the budding hematopoietic precursors, Flk1 is down regulated, 
VE-Cadherin is stable, and PECAM-1 appears to be the last to maintain contact with the 
budding hematopoietic cells (among the cell adhesion molecules analyzed here). GATA-
2 is the only protein analyzed in this study that is broadly expressed in both the 
endothelium and budding hematopoietic cells. CD41, the earliest known hematopoietic 
specific marker, begins to express in the budding hematopoietic precursors along with 
continued GATA-2 expression. These results are summarized in Figure 4.9C.   
Other proteins thought to be expressed in both the hemogenic endothelium and 
budding hematopoietic precursors are SCL and RUNX1; however, suitable antibodies for 
immunohistochemistry in mice are not currently available. If the hemangioblast, or 
hemogenic endothelium, cannot be localized using the available protein antibodies, it 
may prove worthwhile to analyze these sections using in situ hybridization probes to SCL  
and/or RUNX1.  
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Figure 4.9 – A model for hemangioblast development and differentiation.  (A) In Gata2 heterozygous 
or wild type animals, hemangioblasts arise from the mesoderm surrounding the floor of the dorsal aorta 
around e10.5 and invade into the endothelium. The endothelium then migrates up the walls of the dorsal 
aorta and differentiates into hematopoietic cells upon recognition of a global patterning protein, such as 
Bone Morphogenetic Protein 4 (BMP4). (B) In Gata2 null mutant animals, hemangioblasts still arise from 
the mesoderm surrounding the floor of the dorsal aorta around e10.5 and invade into the endothelium. The 
endothelium then migrates up the walls of the dorsal aorta, but fails to recognize the global patterning 
protein, resulting in accumulation of the precursor cells in the roof of the dorsal aorta. (C) Description of 
the various cell types represented in (A) and (B), along with the proposed expression pattern of the proteins 




The GATA-2 iVE and the Hemangioblast 
Previous studies have demonstrated that the Gata2 vascular enhancer element 
regulates GATA-2 expression in the endothelium as well as in erythroid cells. It therefore 
seemed reasonable that this enhancer element might be able to direct Gata2 expression in 
the presumptive definitive hemangioblast. Accordingly, mCherry expression has been 
found in the dorsal aorta, budding hematopoietic cells, and possibly even in circulating 
hematopoietic cells (see Fig. 4.3B, arrows). Lineage tracing experiments have now 
confirmed these observations. Tamoxifen was administered to a pregnant Rosa26RlacZ 
dam, after mating to a TgiVE:Gata2+/+ male, from embryonic day 6.5 through 8.5, when 
no definitive hematopoietic precursor cells yet exist. Interestingly, when fetal liver and 
spleen were collected at embryonic day 17.5, a subset of all definitive hematopoietic 
lineage cells, along with endothelial cells, co-express LacZ and the lineage specific 
marker. These data indicate that the CreERT2 transgene excised the floxed stop codon 
preempting LacZ expression in a progenitor cell that gave rise to both endothelial and 
definitive, lineage-restricted hematopoietic cells, providing the first bona fide evidence 
for the existence of the hemangioblast in vivo in mammals. Whether this enhancer 
element is required for all hematopoietic cells is still unclear. Optimization of the 
tamoxifen administration protocol both for concentration and timing may augment the 
number of definitive hematopoietic-restricted cells that co-express the Gata2 iVE 
generated LacZ marker.  
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Summary and Future Directions 
 
 Transcription factors are known to play critical roles in development, but only 
more recently have we realized that the same transcription factor pathways used for 
development are being abused in the generation or elaboration of various disease states. 
For this reason it has become increasingly important to discover the biological 
mechanisms that regulate the development of an organism, and more specifically, to 
discover how specific genes and gene networks are regulated. The results of these studies 
will benefit both the basic science and clinical communities.  
 GATA-2 is a transcription factor that is known to be crucial for a variety of 
developmental processes, including hematopoietic and urogenital development. My work 
has been focused on distinct aspects of mammalian development involving GATA-2, 
including the elucidation of the functional boundaries of the Gata2 locus in addition to 
the initial experiments reported here in which we have attempted to define a role for this 
factor in the generation or maintenance of the hemangioblast, hemogenic endothelium, 
and the vasculature.  
 
A Gata2 Vascular Enhancer 
 Chapter two focused on the regulation of Gata2 in the endothelium of the 
developing mouse embryo. While the original analysis of the Gata2 knockout mouse 
indicated that GATA-2 does not have a functional role in vascular development (Tsai et 
al., 1994), we have shown here that GATA-2 is broadly expressed in endothelial cells of 
an E10.5 days post coitum (dpc) embryo. Using deletion constructs of a YAC spanning 
the Gata2 locus, we identified an endothelial specific enhancer of Gata2 located in intron 
4 of the Gata2 gene.  
 Further analysis of this enhancer allowed us to localize the vascular endothelial 
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regulatory domain to a 322 base pair (bp) enhancer element. A core 167 bp enhancer 
element was able to autonomously confer broad endothelial expression throughout the 
E10.5 dpc embryo, except in the endocardium. The 155 bp immediately 5’ to this 
minimal domain contained a non-autonomous regulatory element necessary for 
endocardial expression of GATA-2. By generating site-specific mutations in the core VE 
element, it was shown that binding sites for multiple Ets factors as well as an e-box 
transcription factor are important for the regulation of this enhancer. I went on to 
determine that the transcription factor SCL+E12 can bind to this e-box in the endothelial 
enhancer element. 
 The Gata2 vascular enhancer element is intriguing for a couple of reasons. First, 
GATA-2 is known to be expressed in endothelial cells (Dorfman et al., 1992; Yamamoto 
et al., 1997), and yet it still has not been reported to have a discernable vascular 
phenotype in mice (De Val and Black, 2009), even though GATA-2 is expressed 
throughout the embryonic vasculature (Chapter 2). Second, this same enhancer was 
originally reported to be required for hematopoietic development (Grass et al., 2006).  
 The transcription factor Scl has a similar developmental profile and physiological 
requirement as Gata2, including embryonic lethality from its germ line loss at E10.5 dpc 
from hematopoietic failure (Robb et al., 1995). To circumvent the early embryonic 
lethality of Scl null mutant mice, in vitro angiogenesis and matrigel implant in vivo 
angiogenesis studies were undertaken, elucidating a role for SCL in the migration, but not 
proliferation, of endothelial cells undergoing angiogenesis (Lazrak et al., 2004). Similar 
experiments for GATA-2 could be performed using adenoviral vectors to introduce 
GATA-2, and/or a dominant negative form of GATA-2, to primary endothelial cells, and 
assess their ability to undergo angiogenesis. Given that GATA-2 and SCL seem to play 
such similar roles in development, and interact to regulate early hematopoietic processes 
(Wozniak et al., 2008), I would expect a similar result to the Scl study in the absence of 
GATA-2. Specifically, one might predict that the GATA-2 dominant negative mutant 
would inhibit the process of angiogenesis in primary endothelial cell and matrigel 
implants. However, unlike the effects due to alteration in SCL expression, I would 
additionally expect the GATA-2 dominant negative protein to abrogate the proliferation 
of primary endothelial cells, as GATA-2 has repeatedly been shown to be important for 
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cell proliferation (Briegel et al., 1993; Kitajima et al., 2002; Tsai and Orkin, 1997). If 
successful, the next step would be to identify the factors that interact with GATA-2 to 
mediate these effects in the vasculature. Candidate factors that have already been 
identified (as discussed above) include SCL, Ets factors, and GATA factor auto- or cross-
regulation, and can be tested using Chromatin Immunoprecipitation (ChIP) analysis. 
Another interesting experiment would be to remove the vascular enhancer of 
GATA-2 by homologous recombination to generate Gata2VE conditional null mutant 
mice. It is expected that these mice would survive beyond the lethality seen at embryonic 
day 10.5 from the gene knockout, as hematopoiesis would proceed normally, and Gata2 
null mutant mice generate initial vascular patterning of the embryo even in the absence of 
GATA-2 protein. I would expect to see vascular remodeling defects similar to that of 
Gata4+/-:Gata6+/- compound heterozygous mutant embryos, which display myocardial 
hypoplasia as well as disorganized patterning of the cranial and intersomitic vessels and 
hemorrhaging. Interestingly, the Gata4/Gata6 compound heterozygous mutant mice 
displayed a 90% reduction in the mRNA level of the myocardial specific factor Mef2c 
(Xin et al., 2006), which is a potential regulator of Gata2 through the MEF2 binding site 
in the endocardial vascular enhancer (Martin et al., 1993). A signaling pathway can be 
envisioned where GATA-4 and GATA-6 regulate the levels of Mef2c, which in turn 
induces GATA-2 expression, resulting in myocardial proliferation. This hypothesis could 
be tested perhaps most easily through gain and loss of function experiments of GATA-4, 
GATA-6, Mef2c, and GATA-2 in a myocardial cell line. 
 The Ets factor family of winged helix proteins, which are known to be important 
for vascular development (De Val et al., 2008; Sumanas and Lin, 2006), are required for 
proper endothelial-specific expression of GATA-2 in founder assays (Chapter 2). All 
three Ets factor binding sites are in close proximity to basic helix-loop-helix (bHLH) 
transcription factor binding sites (two GATA sites, one Scl) in the Gata2 vascular 
enhancer. Mutations of these binding sites reduces GATA-2 expression. To elucidate the 
Ets factors function in the Gata2 vascular enhancer, ChIP experiments could be 
conducted to confirm the in vivo binding of GATA factors and SCL to their respective 
binding sites. Second, co-immunoprecipitation experiments could be performed to 
confirm the interaction of GATA or SCL with Ets proteins, and more specifically which 
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Ets proteins bind these elements. This would begin to define potential combinatorial 
endothelial-specific regulation conferred by Ets factors in collaboration with bHLH 
transcription factors. One candidate Ets factor is Fli1, which appears to act upstream of 
GATA-2 in regulating hemangioblast expression in zebrafish (Liu and Patient, 2008).  
 This same Gata2 intronic enhancer can drive high levels of luciferase expression 
in the erythroid cell line G1E. This expression is critically dependent on the GATA 
binding sites, as mutation of these sites abolishes luciferase activity. This enhancer also 
undergoes a “GATA switch” as shown by quantitative ChIP analysis with GATA-1 
displacing GATA-2 in the vascular enhancer upon GATA-1 induction (Grass et al., 
2006). One possibility is that GATA-2 binds to this region during normal hematopoietic 
development, and then GATA-1 displaces GATA-2 in myeloid (erythroid, 
megakaryocytic, mast and eosinophilic) lineages to promote differentiation.  
 The current data supports a model in which the Gata2 intronic enhancer appears 
to play a dual role in development, regulating GATA-2 expression in both endothelial 
and hematopoietic precursor cells. The question this raises is whether GATA-2 is 
expressed in, or necessary for, hemangioblast (a cell that gives rise to both hematopoietic 
and endothelial cells) development or differentiation. One way to address this question 
would be to conditionally delete the Gata2 intronic enhancer from within the endogenous 
gene through homologous recombination with a construct in which the Gata2 vascular 
enhancer (as discussed above) is flanked by loxP sites, breeding to a vascular-specific cre 
transgene followed by analysis of homozygous Gata2f/f mutant mice. A simpler way to 
address this question was to create a Gata2 transgenic mouse using the intronic vascular 
enhancer to drive Cre recombinase expression. Crossing this mouse into a conditional 
Gata2 knockout line revealed the specific role of this enhancer element in the earliest 
stage of mesodermal/hematopoietic development. Since an inducible form of cre was 
used, the particular role of this enhancer element was addressed by gene ablation from 
the vasculature at various stages of very early embryonic development through to the 





Localizing the Functional Boundaries of the Gata2 Locus 
 Chapter three focused on the rescue of Gata2 null mutant mice using a linked 
bacterial artificial chromosome (BAC) transgene. The goal of this experiment was to 
determine the functional boundaries of the Gata2 locus, or failing that to uncover a 
previously unseen development defect associated with abrogated Gata2 expression. The 
original attempt for this experiment involved rescue of the hematopoietic failure seen in 
Gata2 homozygous null mutant mice by introducing a yeast artifical chromosome (YAC) 
containing the hematopoietic enhancers of Gata2 - located between 40 and 170 kbp 5’ to 
the structural gene - into a Gata2 null mutant environment. These mice showed robust 
hematopoietic expression and survived to birth. However, lethal hydroureternephrosis 
and other genitourinary abnormalities developed, leading to the conclusion that Gata2 
was vitally required for not only embryonic hematopoiesis but for embryonic kidney 
development as well (Zhou et al., 1998). In this manner, a critical secondary requirement 
for GATA-2 in the proper patterning of the ureter-bladder junction was discovered (Zhou 
et al., 1998). Subsequent BAC mapping experiments revealed the existence of three 
separate urogenital enhancers, two in the urogenital mesenchyme located approximately 
100 kbp 3’ to the structural gene, and one in the ureteric epithelium that has not yet been 
specifically localized (Khandekar et al., 2004).  
While elucidation of the regulatory elements required for Gata2 urogenital 
expression was incomplete, a second Gata2 rescue was attempted, but unfortunately 
would not be as simple. Multiple technical issues had come to light involving YACs, and 
the distance between the upstream hematopoietic enhancers and the downstream 
urogenital enhancers was too large to be spanned by a single BAC. To overcome this 
limitation, two overlapping BACs were linked together utilizing the differential 
recombination efficiency of distinct loxP sequences and cre-mediated homologous 
recombination.  
 This linked BAC (containing approximately 150 kbp of 5' sequence information, 
and both known hematopoietic enhancers as well as 220 kbp of the genome 
encompassing the structural gene and the 3' urogenital enhancers, hereafter referred to as 
G2BAC) was used to create transgenic mice and mated into the Gata2 null mutant 
background. There were several scenarios that were envisioned might result from this 
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experiment. First, the rescued mice could manifest a urogenital defect similar to the 
earlier rescue attempt, since the ureteric epithelial enhancer had still not been localized. 
Second, even if the urogenital patterning was normal - presumably due to inductive 
effects from the mesenchyme or compensation by another GATA factor - the mice could 
succumb to a third critical, as yet unknown, developmental role for GATA-2, as this 
transcription factor is known to play a role in various processes in which the enhancers 
have not yet been localized, including the generation of placental trophoblasts, 
adipocytes, the pituitary, and skin development. A third scenario is that the mice would 
be physiologically normal, indicating that the G2BAC transgene is capable of rescuing all 
developmental processes that vitally require GATA-2 expression.  
Upon analysis of the G2BAC-rescued Gata2 null mutant mice, no observable 
behavioral or reproductive anomalies were found. Upon further inspection, we were 
surprised to find that not only was the gross morphology of the ureteric epithelium 
unaltered, GATA-2 protein was expressed at normal levels as well. This expression was 
not seen when analyzing either the original 5' YAC or the 3’ BAC individually (which 
together encompass all of the sequence within the rescuing G2BAC). One potential 
explanation for this discrepancy is that a binary synthetic enhancer could regulate GATA-
2 expression in the ureteric epithelium, with two or more regulatory domains separately 
located in each of the individual BACs that only becomes functional once the BACs are 
linked, as in the normal genomic configuration. Another potential explanation is that a 
single ureteric epithelial enhancer exists, but requires either certain domain boundary 
elements that are present only in the G2BAC for expression, or requires specific spacing 
from the Gata2 promoter, which was abrogated in the BAC-trap study, but is maintained 
in the G2BAC. Discovering the mechanism(s) underlying this discrepancy will be 
informative, as it should elucidate a unique transcriptional regulatory process.  
 The original YAC that rescued Gata2-regulated hematopoiesis spanned from -174 
to +73 kbp relative to the Gata2 translational start site, and one of the original BACs 
(33I12) used for the BAC-trap study spanned +60 to +268 kbp (Khandekar et al., 2004). 
However, when we converted from attempting to use YACs to BACs for gene rescue, the 
5’ BAC (115E9) chosen spanned from -187 to -10 kbp and the 3’ BAC (81F7) employed 
in the linking experiment spanned from -34 to +226 kbp. The original BAC-trap study 
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used a Gata2 promoter sequence that started 4 kbp 5’ to the alternate first exon through 
the translational start site which was fused to a lacZ reporter gene (Khandekar et al., 
2004). While this fragment contained both the Gata2 specific (1S) and general (1G) 
promoters, along with three GATA-motif dependent enhancer elements immediately 5’ to 
this region (Wozniak et al., 2007), it remains possible that regulatory elements lying 
outside these boundaries, or the spatial organization of these elements relative to the 
Gata2 ureteric epithelial enhancer, are necessary for its functionality. The 81F7 BAC, 
which contains sequences from 34 kbp 5' to the translational start site to 100 kbp 3' to the 
most distant known urogenital enhancer, should account for both of these potentialities. 
The original BAC studied (33I12) originated 60 kbp downstream of the translational start 
site, potentially disrupting the spatial orientation of the enhancer and its promoter, along 
with removing 90 kbp of potential regulatory DNA within and surrounding the Gata2 
structural gene. Therefore, the first experiment that should be done is a BAC trap 
experiment similar to those performed previously (Khandekar et al., 2004), this time 
using BAC 81F7 to look for Gata2 ureteric epithelial expression. Since the G2BAC is 
known to confer ureteric epithelial expression to Gata2 in transgenic mice, a subsequent 
experiment would be to delete segments of the G2BAC to localize the necessary 
regulatory elements in a similar manner to the localization of the Gata2 endothelial 
enhancer (Khandekar et al., 2007).  
 Another important experiment that is yet to be performed is characterization of 
the localized urogenital enhancers. Analysis of the sequence for the urogenital enhancers 
UG2 and UG4 should reveal the identity of putative transcription factor binding sites that 
are potentially critical for activation of these enhancers. Once presumptive binding 
factors are discovered, mutation of these sites followed by founder transgenic 
experiments can be performed to reveal their importance in urogenital transcription. 
Since UG2 and UG4 are both a significant distance 3' to the Gata2 gene (at +73 and +113 
kbp, respectively) and yet are spatially and functionally distinct, these experiments could 
help uncover the functional relevance of their unique roles in development. It seems 
likely that the enhancers are responsive to different transcriptional regulatory programs.  
  The final interesting aspect of these experiments is that the G2BAC-rescued 
transgenic Gata2 null mutant mice have a normal phenotypic appearance, even though 
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some enhancer elements have either not been localized (i.e. for giant cell trophoblast, 
pituitary or adipocyte specificity) or are known to lie outside the boundaries of the 
G2BAC (i.e. whisker follicles). For the cell types known to express GATA-2, simple 
analysis of these tissue types in G2BAC transgenic Gata2 null mutant mice for GATA-2 
expression will help to initially refine the position of the various regulatory elements 
(either within or outside the 413 kbp encompassed by the linked BAC). Looking at X-gal 
staining in the BAC-trap mice for these cell types should also help to localize the 
regulatory elements, as the original BAC-trap assays encompassed more than one 
megabase surrounding the Gata2 locus (Khandekar et al., 2004). These experiments may 
reveal a subtle phenotype that was previously overlooked, or may reveal a compensatory 
regulatory mechanism, possibly complemented by other GATA factor family members 
expressed in the same tissue.  
  
GATA-2 in the Vasculature and the Hemangioblast 
 Chapter 4 deals with the possible transcriptional regulatory roles for GATA-2 in 
the vasculature and in an even earlier cell, the hemangioblast. Delineation of a regulatory 
pathway where GATA-2 plays some role in the hemangioblast and/or hemogenic 
endothelium was attempted by comparison of the staining patterns of various 
transcription factors known to be important for hematopoietic and endothelial 
development in the dorsal aorta of E10.5 dpc Gata2 wild type and null mutant embryos. 
A recent review by Jaffredo et al. presented a diagram of the dorsal aorta representing the 
various cell types that might exist or be generated there with distinct colors, including the 
mesenchyme, mesenchyme containing hematopoietic potential (putative hemangioblasts), 
endothelium, hemogenic endothelium, and budding hematopoietic stem cells (Jaffredo et 
al., 2005). I attempted to investigate the validity of this image in vivo in mouse embryo 
sections by following the expression of combinations of marker proteins.  
A number of conclusions can be drawn from these studies. First, Flk1, VE-
Cadherin, and PECAM-1 can all be seen in presumptive hemangioblasts - cells that are 
invading the endothelium of the dorsal aorta. GATA-2 is either not expressed, or only 
weakly so, in this cell population. The endothelium robustly expresses Flk1, VE-
Cadherin, PECAM-1, and GATA-2. Interestingly, Flk1 appears to be diminished in the 
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endothelium surrounding the site of budding hematopoietic cells, while the other markers 
continue to be robustly expressed. GATA-2 and CD41 are the only markers expressed in 
the presumptive budding hematopoietic cells, though remnants of PECAM-1 expression 
can still be seen where the budding hematopoietic cells still attach to the endothelium. 
Unfortunately, antibodies to other known critical players in the development and 
differentiation of the putative hemangioblast, including SCL and RUNX1, are not 
currently available for this assay.  
 GATA-2, Flk1, and SCL are all expressed throughout the endothelium of the 
dorsal aorta, even though the hemogenic endothelium and budding hematopoietic cells 
were previously thought to be restricted to the ventral floor. Given that endothelial 
specificity is known to require a unique combination of multiple transcription factors (De 
Val and Black, 2009), it seems reasonable that these factors are conferring a unique 
identity to the hemogenic endothelium even though their expression appears to be 
uniform throughout the tissue. Lending credence to this hypothesis, analysis of a three 
dimensional image of a transverse section through an E10.5 dpc embryo shows that the 
floor of the dorsal aorta appears to consist of small, rounded cells that strongly express 
the marker protein, while the walls and roof of the dorsal aorta contain cells that are 
elongated and express the marker protein less abundantly, except in the budding 
hematopoietic cells. Thus, while we are not yet at the stage where we can completely 
distinguish between the various cell types (from the mesenchyme through the definitive 
hematopoietic cells) that contribute to this complex early developmental process, the 
stage is set. Complete elucidation may require characterization of factors that have not 
yet been included in the analysis, or an understanding of unique, currently unknown 
molecules that associate with the factors that have been hypothesized to function in the 
hemogenic endothelium. One such factor is RUNX1. This transcription factor is 
expressed most abundantly in the floor of the dorsal aorta, but not in the roof, as assayed 
by in situ hybridization. An antibody for RUNX1 would greatly augment our ability to 
characterize these distinct cell types. Without this reagent, it may still be possible to co-
stain the same section using immunohistochemistry for GATA-2 and in situ hybridization 
for RUNX1.  
GATA-2 is known to bind to an enhancer of Runx1, along with an Ets protein and 
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SCL, to regulate Runx1 expression (Nottingham et al., 2007). We have shown that the 
Gata2 vascular enhancer also relies on Ets factor binding sites for proper expression of 
GATA-2 in the vasculature (Chapter 2). ChIP or EMSA assays analyzing these 
regulatory regions of Runx1 and Gata2 for the Ets factors (potentially Fli1) regulating 
these elements may provide a new target for the immunohistochemistry experiment as 
well.  
While attempting to address the role of GATA-2 in the hemangioblast in a Gata2 
null mutant background has its merits, it also has its limitations. A conditional knockout 
of Gata2 would allow us to analyze the role of GATA-2 specifically in the hemangioblast 
or hemogenic endothelium cell populations without the overriding hematopoietic and 
urogenital deficiencies. To this end, a transgene using the Gata2 intronic endothelial 
enhancer (Chapter 2) was generated to drive a tamoxifen inducible form of cre 
recombinase (Cre-ERT2). Hemangioblast/endothelial specific GATA-2 deficiencies can 
then be directly assessed when crossed to a Gata2 conditional knockout mouse. To test 
the efficacy of this enhancer and generate a robust reporter, an identical construct with 
the fluorescent protein mCherry in the place of the Cre-ERT2 was generated.  To attempt 
to prevent position integration effects, these constructs were also insulated with 
duplicated chicken HS4 insulator elements.  
Equal concentrations of each construct were co-injected into zygotes to create 
transgenic mice. Three lines were found to transmit both transgenes and robustly express 
mCherry in a vasculature specific manner. If the chicken HS4 elements were functioning 
properly, one would expect the copy number of this transgene to directly correlate with 
the expression level of mCherry. However, most transgene positive embryos expressed 
mCherry very weakly, if at all, from mice containing a whole range of transgene copy 
numbers. The lack of expression is not due to cellular toxicity, as the high copy number 
mice can reach adulthood, reproduce, and do not display any obvious phenotypic 
abnormalities. These results indicate that the chicken HS4 insulators are not able to 
prevent position of integration effects. A second effect often seen in transgenic mice is 
reduced expression over time due to chromatin silencing. The ability of the insulators to 
prevent this transgene silencing can be assessed after these transgenic mice have been 
bred for multiple generations.  
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 With an endothelial-specific fluorescent marker at our disposal, mice bearing both 
transgenes were backcrossed into a Gata2 null mutant background to assess the formation 
of the early vasculature. The primary vasculature is properly formed, but the angiogenic 
process appears to be disrupted, though additional studies are required before any firm 
conclusions about how this process is defective can be reached. Since we can now follow 
this phenotype past embryonic day 10.5 in conditional Gata2 knockout mice, we should 
be able to secure informative results. To this end, we also addressed the question of 
whether cre activity would have the same expression profile as mCherry. The iVE 
transgenic mice were crossed to the Rosa26lacZ reporter strain to test the expression 
profile of the iVE/creERT2 transgene. Upon tamoxifen induction, we found that LacZ is 
robustly expressed in a pattern that significantly overlaps that of the mCherry reporter, 
indicating that the tamoxifen administration protocol is working efficiently. Furthermore, 
fluorescence activated cell sorting (FACS) analysis indicated that a significant proportion 
of mCherry-positive cells co-express the endothelial specific marker CD31, indicating 
that they are indeed endothelial specific. However, while LacZ-positive cells were not 
detected that were not also mCherry positive, the percentage of LacZ expressing cells in 
mCherry positive cells was rather low, indicating either that a better protocol for 
tamoxifen administration may still be required or that the lacZ labeling protocol for 
endothelial cells may be less than complete. There were multiple technical issues with the 
way the LacZ flow cytometry experiment was performed, and confirming the excision 
efficiency of Cre is dependent upon accounting for each of these complications. We hope 
to avoid these technical issues altogether by using Rosa26YFP reporter mice in place of 
Rosa26lacZ, so that co-expression of mCherry and YFP fluorescence can be assessed 
directly. 
Another experiment I performed, which is less dependent on the absolute activity 
of the creERT2 fusion protein, is a lineage trace following the activation of LacZ in 
Rosa26lacZ mice. More specifically, tamoxifen was administered to a pregnant dam 
harboring TgiVE:Rosa26lacZ embryos on embryonic days 6.5, 7.5, and 8.5 - well before 
definitive hematopoietic cells begin to emerge in the embryonic AGM at E10.5. The fetal 
liver and spleen of E17.5 embryos was collected and analyzed. The various lineage-
restricted definitive hematopoietic cell types were then characterized by co-expression 
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with LacZ. Interestingly, all of the markers analyzed in this study, including the B-cell 
marker B220, the T-cell marker CD3, the myeloid marker Gr1, the macrophage marker 
Mac1, and the erythroid marker Ter119 contained a small but clear subset of cells that co-
express LacZ. Endothelial cells also contained an infrequent population of cells that 
double stained for CD31 and LacZ. Insofar as I am aware, this is the first study to 
demonstrate that labeling of the mesoderm prior to the existence of definitive 
hematopoietic cells gives rise to all definitive hematopoietic lineages and endothelial 
cells in vivo in mammals, arguing that the definitive hemangioblast indeed exists and is 
functional. It also indicates that the Gata2 vascular enhancer is active in this precursor 
cell population.  
This result raises a number of other interesting questions. For instance, to what 
percentage of hematopoietic and endothelial cells does the definitive hemangioblast 
contribute? In our study, only approximately 1-2% of lineage-marker positive cells 
expressed LacZ; however, as discussed previously, the excision efficiency by cre 
recombinase under the conditions I developed for tamoxifen administration is not yet 
known. Second, if the definitive hemangioblast only contributes to a restricted subset of 
hematopoietic and endothelial cells, do they carry out a unique developmental function? 
Third, what role does GATA-2 play in this process? Conditional ablation of the 
hemangioblast population in TgiVE:Gata2f/- mice will begin to address these questions, 
along with the role GATA-2 plays in hemangioblast, hemogenic endothelium and 
vasculature development.   
 
Conclusions 
The embryonic development of an organism is a complex, intricately organized 
process that sometimes relies on the subtlest of changes to enact broad differentiation 
events. The same transcription factor can be independently utilized to regulate dozens of 
unique developmental processes. To accomplish this specificity, a gene sometimes 
requires regulatory elements up to a megabase away from the structural gene.  
Understanding the molecular mechanisms by which transcription factors can 
affect such a broad array of developmental processes will greatly enhance our ability to 
diagnose, treat, and possibly even prevent a large number of diseases that currently 
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plague humanity. We could enact these changes either through understanding of the 
mechanisms that go awry through DNA damage at various stages of life and how to 
compensate for them, or through understanding of the molecular and cellular pathways 
that regulate development, allowing ex vivo regulation of these processes (i.e. organ 
formation, stem cell transplants, etc) to repair a defective in vivo system.  
In this dissertation, I have attempted to focus on a developmental process 
involving one such broad mediator, the zinc finger transcription factor Gata2. We now 
know where the functional boundaries of the Gata2 locus absolutely required for survival 
reside. We have also identified a previously unknown role for GATA-2 in the 
vasculature, and have developed a new mouse model that should help to clarify one of 
biologies oldest questions regarding the role of the hemangioblast in definitive 
hematopoiesis and vasculogenesis. Given the plethora of tools and information available 
to biologists today, key discoveries are being made at an ever-increasing rate. The next 
major milestone will be to put all of the analysis of individual genes and proteins together 
to understand developmental processes at a systems level, and to define how each of 
these individual proteins interact to generate a particular functional output (e.g. 
generation of a healthy organ). Only then will we be able to truly state that we understand 
how diseases that plague society (such as cancer) are regulated, and that we understand 
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